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1. Introduction 
Angiogenesis or formation of new blood vessels requires the 
binding of signaling molecules, such as vascular endothelial 
growth factor (VEGF), which is one of the most specific and 
important growth factors involved in this process.1,2 VEGF-A165 
mediates its biological effects through receptors located on the 
endothelial cells, i.e. VEGFR-1 (Flt-1) and VEGFR-2 (Flk-
1/KDR). VEGF-A165 is overexpressed by a wide variety of human 
tumors and this overexpression has been correlated with invasion 
and metastasis.3 
Interestingly, Neuropilin-1 (NRP-1), a receptor protein firstly 
described in neuronal guidance,4 is involved in a wide range of 
physiological and pathological processes including angiogenesis.5 
This transmembrane protein was found to be a co-receptor of 
VEGF-A165 acting together with VEGFR-2 via its NRP-1 b1/b2 
domain, resulting in increased affinity of VEGF-A165 for the 
extracellular domain of VEGFR-2.6 VEGF-A165 can also 
contribute to VEGFR-2/NRP-1 complex formation via its binding 
through two different sites for both NRP-1 and VEGFR-2.7 
Moreover, independently of VEGFR-2, NRP-1 alone might 
transduce functional signaling as a result of VEGF binding.8 NRP-
1 is expressed on endothelial cells promoting tumor 
angiogenesis6,9 and on tumor cells and has thus been identified as 
a potential target for anti-angiogenic therapies.10,11 This receptor 
could also be a mediator of choice for cancer imaging. Few 
attempts to use NRP-1 in cancer imaging via a [99mTc]-labelled 
peptide,12 multifunctional nanoparticles engineered with 
gadolinium chelates as MRI contrast agents,13 and fluorescein-
labeled peptides are reported in the literature.14 More recently, 
NRP-1 targeting peptides were conjugated onto the surface of lipid 
microbubbles for molecular imaging of tumor angiogenesis.15 
Targeting NRP-1 with small molecules mimicking VEGF-A165 
is not very advanced, because of difficulty to mimic protein-
protein interactions. Nevertheless, several peptides have been 
reported to modulate VEGF-A165/NRP-1 binding. The first crystal 
structure of the b1 domain of the human NRP-1 was determined 
by Lee et al.16 The role of the loops at b1 domain of human NRP-
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1 as a target binding site for ligand interaction has also been 
highlighted by Vander Kooi et al. with their study of NRP-1 
binding with tuftsin (TKPR), which is very similar to the VEGF-
A165 C-terminus (DKPRR).17 The C-terminal arginine of tuftsin 
contributes to the majority of interactions with NRP-1 and this was 
confirmed by a molecular modeling approach developed by 
Haspel et al.18 The interaction of NRP-1-b1 domain with VEGF-
A165 was recently elucidated by Parker et al.19 Jia et al. have 
discovered a specific bicyclic peptide EG3287 antagonist of 
VEGF-A165 binding to NRP-1.20 Heptapeptide ATWLPPR (A7R), 
selected by screening a phage display library was described as an 
effective antagonist and can be considered as a potent inhibitor of 
tumor angiogenesis.21 NRP-1 targeting photodynamic therapy 
(PDT) using A7R as NRP-1 ligand associated with a porphyrin-
like sensitizer has since been developed.22 New peptides 
structurally related to VEGF-A165 exon-7 and -8 domains were 
recently designed and synthesized.23 
However, peptidic compounds could suffer from poor 
bioavailability and instability24 and the design of new organic 
molecules such as peptidomimetic derivatives seems an attractive 
alternative. In connection with our ongoing program on the design 
of sugar-based peptidomimetics, we described a few years ago the 
design, synthesis and in vitro biological evaluation of sugar-based 
peptidomimetics targeting NRP-1. Interesting compounds were 
obtained and one hit compound was identified (compound 1, Chart 
1a).25 Simultaneously, a paper by Jarvis et al. described compound 
EG00229 as small molecule inhibitor of the NRP-1/VEGF-A165 
binding and this molecule has recently shown in vivo activity 
towards cancer models (Chart 1a).26 More recently, a fully non-
peptidic compound comprising phenylbenzimidazole and 
benzodioxane moieties linked by a stable carboxythiourea spacer 
was identified.27 New antagonists structurally-related to this 
compound were synthesized and evaluated toward VEGF-
A165/NRP-1 binding modulation.28 Several drug-like compounds 
containing a common chlorobenzyloxy alkyloxy halogenobenzyl 
amine scaffold were identified by virtual screening for their 
efficient binding to NRP-1.29 
The objective of the present work was the molecular design and 
synthesis of new NRP-1 ligands inspired by compound 1.25 The 
use of carbohydrates as scaffolds to construct bioactive 
compounds and peptidomimetics is a well-accepted concept since 
the pioneering works related to peptidomimetics of 
somatostatin.30,31,32 We wanted to take advantage of functionalities 
and stereodiversities of sugar derivatives to develop new analogs 
of carbohydrate-based peptidomimetics. Thus, sugar scaffolds 
functionalizable at both ends and offering different spatial 
orientations for residues were investigated according to molecular 
modeling and the in vitro biological properties of the new ligands 
were evaluated. 
2. Results and discussion 
Sugar scaffolds A and B suitable for functionalization at both 
ends could arrange crucial residues in opposite spatial directions 
and were both investigated in this regard (Chart 1b). Firstly, 
compound 1 was modified stepwise, the importance of the two 
guanidine functions was studied and the effect of hydrocarbon 
linker lengths separating the guanidinium groups was explored 
(first series). A second series with an arginine anchored at C1 was 
developed according to docking study. In the meantime, synthetic 
compounds were used to get crystals of NRP-1/ligand complex. 
The binding affinity of new derivatives was performed by ELISA 
and the effects of the most potent ligands were evaluated on 
HUVECs through activation of downstream proteins, viability 
assays and in vitro angiogenic abilities.  
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Chart 1. a) Structure of compound 1 and EG00229. b) Structure of scaffolds 
A and B functionalizable at both ends and structure of starting exo-glycals 2 
and 3. 
2.1. Synthetic Chemistry 
The C-glycosidic scaffold A which was used for compound 1 
synthesis was obtained from the known exo-glycal 2 available in 
excellent yield via a Wittig reaction on the D-gulono-1,4-lactone.33 
In the same way, scaffold B was obtained from exo-glycal 3 
directly available from the corresponding D-ribono-1,4-lactone. 
The first series aimed at synthetizing new peptidomimetic 
compounds close to compound 1 structure. The impact of the 
spatial disposition of both guanidium groups and 2-(indolyl-3-
yl)ethyl residue was evaluated by synthesizing a compound based 
on the sugar scaffold B. Moreover, while maintaining compound 
1 central core (scaffold A) with the 2-(indol-3-yl)ethyl residue at 
C1, the effect of the linker length between both guanidinium 
groups was considered. The replacement of one of the guanidium 
functions by a triazole moiety acting as a stable linker34-36 was 
envisioned.  
The synthetic pathway for the first series required the 
preparation of the key tosylates 8 and 24 (Scheme 1A and 1B). The 
known exo-glycal 2 was converted to C-glycoside 4 by 
stereoselective reduction of the double bond.37 Subsequent 
saponification of 4 followed by coupling with tryptamine led to 
amide 6. Alcohol 7 was prepared by a multistep sequence 
including the selective removal of the exocyclic isopropylidene 
acetal under acidic conditions, NaIO4 mediated oxidative cleavage 
and reduction of the resulting aldehyde. The alcohol 7 was then 
converted in the corresponding tosylate 8 in excellent yield. In the 
same way, exo-glycal 3 was converted in C-glycoside 18. After 
changing acetate protecting group at O7 for a tert-
butyldimethylsilyl ether, subsequent saponification of 20 led to the 
key acid 21 in good yield. Amide 22 was prepared by coupling 
with tryptamine. Removal of the tert-butyldimethylsilyl group was 
achieved by TBAF and the resulting alcohol was converted in 
tosylate 24 in 87% yield.  
Refluxing tosylates 8 and 24 with different commercially 
available monoprotected diaminoalkanes (n = 2, 3 and 4 for 8 and 
n = 1 for 24, Scheme 1C) in a sealed flask led to intermediates 9, 
10, 11 and 25. Free amines obtained in quantitative yields after 
removal of benzyloxycarbonyl group were treated with N,N’-
bis(benzyloxycarbonyl)-S-methylisothiourea38 in DMF. Bis-
guanidinylated derivatives 12, 13, 14 and 26 were obtained in 
modest yields, resulting from the reaction of both primary and 
secondary amines. Finally, removal of protecting groups afforded 
the expected bis-guanidinoglycosides 15, 16, 17 and 27. Attempts 
to remove the 4,5-isopropylidene group under different acidic 
conditions were unsuccessful, the number of nitrogen atoms 
obviously preventing oxygen protonation required for acetal 
deprotection.  
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Scheme 1. Synthetic route to compounds 8 (A), 24 (B) and 15-17 and 27 (C). Reagents and conditions: (a) H2, 15 psi, Pd/C, EtOAc, 25°C, 24h, 4 98%, 18 85 %; 
(b) LiOH, THF/H2O (3/1), 25°C, 18h, 5 98%, 21 65%; (c) tryptamine, EDC, CH2Cl2, 25°C, 18h, 6 80%, 22 80%; (d) i: 1N HCl, MeOH, 0°C to 25°C, 8h; ii: NaIO4, 
MeOH, 25°C, 18h, iii: NaBH4, MeOH, 0°C, 1h, 72% for three steps; (e) TsCl, Et3N, DMAP, CH2Cl2, 25°C, 24h, 8 90%, 24 87%; (f) Na0, MeOH, 0°C, 1h, 97%; 
(g) TBDMSCl, imidazole, DMF, 25°C, 24h, quantitative yield; (h) TBAF, THF, 0°C, 18h, 95%; (i) iPrOH, 100 °C, sealed tube, 48h, 9 72%, 10 70%, 11 80%, 25 
82%; (j) i: H2, 30 psi, Pd/C, MeOH, 18h, quantitative yields, ii: N,N’-bis(benzyloxycarbonyl)-S-methylisothiourea, HgCl2, Et3N, DMF, 25°C, 14h, 12 25%, 13 
25%, 14 35%, 26 30%; (k) H2, 30 psi, Pd/C, MeOH, 18h, 15 90%, 16 85%, 17 94%, 27 90%. 
 
On the basis of structure 1, we next focused our attention on the 
replacement of the guanidine function anchored on the secondary 
amine by a 1,2,3-triazole moiety bearing guanidylated arms 
(Scheme 2). This synthetic approach required the preparation of 
two guanidylated alkynes 28 and 29 obtained by a Mitsunobu 
reaction. The C-glycoside 30 bearing an azido group on C7 was 
obtained by reaction of sodium azide with tosylate 8. The synthesis 
of the 1,4-substituted-1,2,3-triazole moiety was next envisioned 
between azide 30 and alkynes 28 and 29 in a 1/1 H2O/CH2Cl2 
mixture, which was the more appropriate solvent in this case.39,40 
Compounds 31 and 32 were obtained in good yields. Removal of 
benzyloxycarbonyl protecting groups was achieved by 
hydrogenolysis and led to 33 and 34 in nearly quantitative yields. 
Removal of 4,5-isopropylidene protecting group by aqueous 
trifluoroacetic acid was performed and fully deprotected 
derivatives 37 and 38 were then obtained by hydrogenolysis. 
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(d) H2, 30 psi, Pd/C, MeOH, 18h, 33 90%, 34 90%, 37 80%, 38 95%; (e) 
TFA/H2O (1/1), 25°C, 10h, 35 85%, 36 53%. 
 
The synthetic plan for the second series implied the 
introduction of an L-arginine at C1 and the anchoring of a 
hydrophobic residue at C7. The coupling of C-glycosyl compound 
5 with N-nitro-L-arginine methyl ester led to amide 39 (Scheme 
3A). The carboxylic acid and guanidinium function of arginine 
were successively deprotected by classical methods. We next 
investigated the impact of a more rigid system based on C-
glycosylidene derivative obtained from exo-glycal 2 (Scheme 3B). 
To this end, using a method for methyl ester deprotection which 
did not affect the anomeric double bond was mandatory. This was 
achieved by using lithium iodide in pyridine. The resulting vinylic 
acid 41 was then coupled with L-arginine methyl ester without 
protection on its lateral chain. An isomerization of the double bond 
was observed and two isomers E/Z were obtained in an 
approximatively 1/1 ratio. This isomerization could obviously be 
attributed to reversible addition of HOBt on the anomeric carbon 
of activated exo-glycal, prone to 1,4-additions.33 At this point, the 
purification of the isomeric mixture was not possible by normal or 
reverse phase chromatography. This mixture was thus 
subsequently treated by lithium iodide in pyridine and reverse 
phase purification led to isolation of 42, which is the only one 
obtained as pure material.  
Guided by published works25-28 highlighting the favorable 
impact of an hydrophobic group and docking studies pointing out 
the benefit of a supplementary chemical groups such as a phenyl 
(see 2.2), an aromatic residue was linked to C7 via a sulfonamide 
linkage. This required the preparation of the key intermediate 
tosylates 45 and 51 obtained from 44 and 19 (Scheme 3C). The 
selective removal of the exocyclic isopropylidene acetal of 4 under 
acidic conditions led to diol 43 subsequently transformed in 
alcohol 44. Substitution with sodium azide carried out in DMF led 
to azido derivatives 46 and 52 in 84 and 97% yields respectively. 
Catalytic hydrogenation afforded primary amines which were 
treated with benzene sulfonyl chloride in pyridine to give 
phenylsulfonamides 47 and 53 in good yields. We next managed 
the introduction of L-arginine at C1 and compounds 49 and 55 
were obtained in 84% and 71% yields respectively. Finally, fully 
deprotected derivatives 50 and 56 were obtained in good yields 
after methyl ester and arginine side chain protection removal.  
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Scheme 3. Synthetic route to compounds 40 (A), 42 (B) and 50 and 56 (C). Reagents and conditions: (a) H-L-Arg(NO2)-OMe.2HCl, HATU, DIEA, DMF, 0°C 
then 25°C, 24h, 39 50%, 49 84%, 55 71%; (b) i: LiOH, THF/H2O 3/1, 25°C, 18h, ii: H2, 40 psi, Pd/C, MeOH, 18h, 40 70%, 50 82%, 56 70% for two steps; (c) LiI, 
pyridine, 120°C, 24h, 50%; (d) i: L-Arg-OMe.HCl, HATU, DIEA, DMF, 0°C then 25°C, 24h; ii: LiI, pyridine, 120°C, 24h, 33%; (e) 1N HCl, MeOH, 0°C then 
25°C, 6h, 92%; (f) i: NaIO4, MeOH, 25°C, 18h, ii: NaBH4, MeOH, 0°C, 1h, 93% for two steps; (g) TsCl, Et3N, DMAP, CH2Cl2, 25°C, 18h, 45 92%, 51 98%; (h) 
NaN3, DMF, 80°C, 46 84%, 52 97 %; (i) i: H2, 15 psi, Pd/C, MeOH, 8h, quantitative yields, ii: PhSO2Cl, pyridine, 25°C, 18h, 47 80%, 53 83%; (j) LiOH, 3/1 
THF/H2O, 25°C, 18h, 48 90%, 54 96%. 
 
Molecular modeling studies highlighted that presence of a 
negative or positive charge in para position on the aromatic ring 
could led to improved affinity (see 2.2). Taking into account 
preliminary inhibition results (see 2.3), we thus planned to 
functionalize 56 with substituents able to make additional 
hydrogen bonds or salt bridges in the receptor binding site. In this 
regard, an aminomethyl and a hydroxycarboxymethyl groups were 
selected (Scheme 4A and 4B). Starting from azido derivative 52, 
the coupling of the 4-bromomethylphenylsulfonyl chloride in 
dichloromethane led to the bromomethyl derivative 57. Compound 
58 was then obtained in quantitative yield by nucleophilic 
substitution of the bromine with sodium azide in DMF. Coupling 
with L-arginine methyl ester and treatment with lithium hydroxide 
gave acid 60 in 86% yield for two steps. Finally, fully deprotected 
derivative 61 was obtained by catalytic hydrogenation of azido 
group.  
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Schemes 4. Synthetic route to compounds 61 (A), 63 (B) and 69 (C). Reagents and conditions: (a) i: H2, 15 psi, Pd/C, MeOH, 8h, quantitative yield , ii: 4 
bromomethylphenylesulfonyl chloride, CH2Cl2, Et3N, 25°C, 0.5h, 61%; (b) NaN3, DMF, 60°C, 15h, quantitative yield; (c) LiOH, THF/H2O, 25°C, 8h, 59 
quantitative yield, 66 82%; (d) i: L-Arg-OMe.2HCl, HATU, DIEA, DMF, 0°C then 25°C, 18h, ii: LiOH, THF/H2O, 25°C, 8h, 60 86% for two steps, 63 54% for 
two steps, 67 67% for two steps; (e) H2, 15 psi, Pd/C, MeOH, 18h, 87%; (f) i: LiOH, THF/H2O, 25°C, 6h, ii: H2, 15 psi, Pd/C, MeOH, 8h, iii: methyl 2-(4-
chlorosulfonylphenyl)acetate, pyridine, 25°C, 2h, 30% for three steps; (g) i: H2, 15 psi, Pd/C, MeOH, 8h, quantitative yield, ii: 4-iodophenylesulfonyle chloride, 
pyridine, 25°C, 6h, 82%; (h) ethynyltrimethylsilane, CuI, PdCl2(PPh3)2, Et3N, 80°C, 2h, 80%; (i) 68, Cu(OAc)2, sodium ascorbate, tBuOH/H2O, 25°C, 18h, 77%.  
 
The synthesis of compound 63 required a slightly modified pathway, notably the saponification of methyl ester 52 before 
introduction of the sulfonyl chloride. After saponification with lithium hydroxide and catalytic hydrogenolysis of azido 
ester 52 with Pd/C, sulfonamide 62 was obtained by reaction with methyl 2-(4-chlorosulfonylphenyl)acetate. Coupling 
with L-arginine methyl ester and removal of both methyl ester functions led to the diacid 63. In connection with ongoing 
work in our group41 concerning conjugation of biomolecules with sugar derivatives, compound 56 was coupled with the 
2-azidoethyl-6-fluoro--D-glucopyranoside 68. Indeed, 2-azidoethyl-6-fluroglycosides are easily prepared41b and are 
valuable prosthetic groups for fast and easy labelling of peptides or peptidomimetics by copper(I)-catalyzed azide–
alkyne cycloaddition.36 To this end, derivative 64 was obtained by coupling 4-iodobenzenesulfonyle chloride (Scheme 
4C). Sonogashira reaction was then performed with trimethylsilylacetylene. Subsequent removal of methyl ester and 
trimetysilyl protecting groups was performed and led to alkyne 66 in good yield. As described above, L-arginine methyl 
ester was introduced on C1 position. The copper(I)-catalyzed azide–alkyne cycloaddition was performed between alkyne 
67 and azide 68 and led to fluoro derivative 69 in 77% yield. 
 
2.2. Crystallographic study and molecular modeling 
Cocrystallization screenings of NRP-1-b1 fragment were carried out with compound 1 and four others compounds, 
namely compounds 27, 40, 50 and 56 (Chart 2).  
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 Chart 2. Structures of EG00229 and compounds 40, 50, 56 and 
69. 
 
Crystals were obtained in presence of compound 56. They exhibited the same tetragonal crystal packing as those of the 
free protein fragment16 but the resolution of the data was substantially improved (1.45 vs. 1.90 Å, see SI Table S1). The 
structure revealed that the crystallized protein did not form a complex with the synthesized compound. Instead, a bicine 
molecule was found in the VEGF-A165 binding cleft (Figure 1a). The bicine sodium salt was used as pH buffer in the 
crystallization condition. A sodium atom in octahedral geometry was also found, it is interacting with a bicine hydroxyl-
group and five water molecules. The ternary amine and carboxylic group of bicine are hydrogen-bonded to the Tyr353 
and Thr349 side-chains, respectively. The bicine molecule also formed interactions with residues of a symmetry related 
protein molecule (see SI Figures S1, S2). Several methylene hydrogen atoms of bicine form hydrophobic H...Pi and 
H...H interactions with Tyr297 and Trp301. The Asp320 residue, which forms an important salt bridge with an arginine 
in the NRP-1/VEGF-A165 biological complex19 and in the complex with EG0022926a was in the present structure in 
interaction with the Na+ ion through a water bridge. This NRP-1-b1/bicine complex highlighted the conservation of the 
anchoring residues of the VEGF-A165 binding cleft.  
 
Figure 1. (a) Crystal structure of bicine/NRP-1-b1 complex. (b) Docking of compound 56 showing the pi-pi supplementary interaction. 
(c) Docking of compound 56 showing the pi-cation supplementary interaction. (d) Docking of compound 69. 
The crystal structures of NRP-1-b1/ligand complexes provided us additional informations to guide an in silico 
optimization of our synthesized ligands. We undertook optimization of structures by molecular modeling and compound 
40 was chosen as a starting point. It appeared from preliminary docking calculations that all the obtained poses of the 
first docked molecule 40 were anchored within the binding site in the same way as the PDB 3I97 EG00229 ligand (Chart 
2), namely through a strong ionic interaction involving the guanidinium moiety of the ligand and the protein Asp320. It 
should be noted that the best pose obtained for the EG00229 compound itself was exactly similar to the pose found in 
the X-ray structure, therefore validating our docking procedure.26a Depending on poses, several additional favorable H-
bond interactions were detected with residues containing hydroxyl groups such as Tyr353, Tyr297, Thr349 and Ser346. 
It is also noteworthy that these interacting residues are similar to those found in the bicine/NRP1-b1 structure. The best 
docking poses of 40 and EG00229 were next refined using short 10 ns molecular dynamics runs. The analysis of the 
different trajectories confirmed the robustness of the ligand guanidine…Asp320 salt bridge which was observed as stable 
during all simulations (Figure 2a). A supplementary ionic interaction was also established after several ns of the MD 
simulations stabilizing the position of the arginine terminal-carboxyl of the ligands with the ammonium group of Lys351 
(Figure 2b).  
 
 
Figure 2. (a) Molecular dynamics of the protein/40 complex runs confirming the robustness of guanidine…Asp320 side chain salt bridge; 
(b) Molecular dynamics runs confirming the robustness of arginine terminal-carboxyl …Lys351 side chain salt bridge; vertical axis: interatomic 
distances in Å. 
Such an interaction between an exposed Lys side chain with the ligand, while in competition with the solvent, is 
nevertheless observed in many protein/ligand complexes such as the kinases.42 In the case of the X-ray structure complex 
with EG00229, the presence of an intramolecular hydrogen bond involving the arginine terminal-carboxyl of EG00229 
precluded an interaction with Lys351 in the complex. Comparing the behavior of 40 and EG00229 during these MD 
simulations showed that 40 could present additional stabilizing interactions on the condition to add supplementary 
chemical groups such as a phenyl moiety at the C7 position. Furthermore, both C6 stereoisomers were considered 
(scaffolds A and B, Chart 1). Consequently, we checked this hypothesis with both new synthesized compounds 50 
(scaffold A) and 56 (scaffold B) which were submitted to the same docking and short MDs protocols. Comparing the 
interactions found during these MD simulations between 40, 50 and 56 clearly showed that compound 56 should be a 
better compound, this behavior being mostly due to π-π and π-cation additional interactions coming from the added 
phenyl ring with Tyr297 or Lys347 side chains (Figure 1b and 1c). These interactions are observed during most of the 
simulation. According to these simulations, it can also be suggested that expanding the phenyl group with positive or 
negative charged groups (compounds 61 and 63) or with longer chains such as the one found in 69 could give the 
possibility to attract the Lys347 or Glu348 or Glu312 charged side chains (Figure 1d). 
2.3. Biological evaluation  
The binding of new derivatives to recombinant NRP-1 protein was determined using a competition assay initially 
described by Tirand et al.43 Binding of compounds to NRP-1 was assessed using biotinylated VEGF-A165 (bt-VEGF-
A165), in competition, or not, with an excess of compounds or non labelled VEGF-A165. Tuftsin was used as positive 
control (IC50 = 25 µM). A preliminary screening with 100 µM inhibitor concentrations was performed. For the most 
active compounds (inhibition >40% at 100 µM, Table 1), the IC50 value was determined with concentrations ranging 
from 10 µM to 500 µM. VEGF might crosslink VEGF-R2 and NRP-126 and it was recently demonstrated that NRP-1 
could interact directly with VEGF-R2 without VEGF.6b Thus, it was appropriate to compare binding of new derivatives 
with NRP-1 and VEGF-R2. The binding of the four best compounds to VEGF-R2 (KDR) were evaluated using a similar 
competition assay, showing the selectivity for NRP-1 (Table 2). 
 
 
 
  
Table 1. Binding inhibition of bt-VEGF-A165/NRP-1 (%) in the presence of new compounds for a fixed 
concentration of 100 µM and IC50 values. 
Entry Compound Binding inhibition of bt-VEGF-A165 at 100 µM (%) IC50 (µM)a 
1 VEGF-A165 100± 1 - 
2 15 5 ± 2 nd 
3 16 39 ± 2 nd 
4 17 52 ± 1 120  
5 27 26 ± 3 nd 
6 33 5 ± 3 nd 
7 34 18 ± 2 nd 
8 37 37 ± 1 nd 
9 38 4 ± 7 nd 
10 40 43 ± 2 187 ± 19 
11 42 44 ± 1 181± 22 
12 50 55 ± 2 88 ± 8 
13 56 67 ± 1 39 ± 1 
14 61 40 ± 2 134 ± 2  
15 63 18 ± 1 nd 
16 69 57 ± 1 69 ± 2  
a: IC50 values were measured for all compounds showing inhibition >40% at 100 µM; results were obtained from three independent experiments, each performed using triplicate determinations at each concentration of compound and are presented as the mean +/- SEM; R2 values ranged 
from 0.9739 to 0.9927; nd, not determined  
Table 2. Binding inhibition of bt-VEGF-A165/KDR (%) in the presence of compounds 50, 56, 61 and 69 for a 
fixed concentration of 100 µM and IC50 values. 
Entry Compound Binding inhibition of bt-VEGF-A165 for 100 µM (%) IC50 (µM)a 
1 VEGF-A165 96 ± 5 - 
2 50 5 ± 6 > 500 
3 56 15 ± 13 > 500 
4 61 0 ± 13 > 500 
5 69 26 ± 7 306 ± 5 
a: IC50 values were measured for compounds 50, 56, 61 and 69, concentrations ranging from 10 µM to 500 µM; results were obtained from three independent experiments, each performed using triplicate determinations at each concentration of compound and are presented as the 
mean +/- SEM; R2 value for compound 69: 0.9911. 
In order to determine the biological activity of compounds on endothelial cells, human umbilical vein endothelial 
cells (HUVECs) expressing VEGF-R1, VEGF-R2 and NRP-1 were used. It was previously demonstrated that the 
inhibition of VEGF-A165 binding to NRP-1 had effect on VEGF-A165 ability to activate VEGFR-2 (KDR).20 Compounds 
50, 56, 61 and 69, which have the higher affinities for NRP-1 (Table 1) were selected for their biological evaluation on 
HUVECs. Binding of compounds to NRP-1 was evaluated by the activation of PI3K/AKT and MAPK downstream 
signaling pathways, through phosphorylation of AKT, a serine/threonine protein kinase and extracellular signal-
regulated protein kinases 1 and 2 (ERK1/2), respectively. Both are involved in NRP-1/VEGFR-2 signaling pathways. 
The cellular binding of the different compounds to NRP-1 led to a mean of 40% decrease of ERK phosphorylation (ratio 
ranging from 0.61 to 0.68, Figure 3A et 3B) compared to tuftsin (ratio of 0.88), the natural ligand of NRP-1. In contrast, 
an increase of AKT phosphorylation was observed for each ligand as well as for tuftsin. It should be noted that the most 
relevant effect was obtained for compound 56 (ratio 2.52), whereas compound 50 showed a lesser effect (ratio 1.56). 
Effects on HUVECs viability were measured by metabolic assay (WST) (Figure 3C). Modifications observed for 
signaling pathways ERK1/2 and AKT did not lead to detrimental effect on the viability of endothelial cells whatever the 
tested concentration.  
 
Figure 3. A: Effect of the different compounds (c = 50 µM) on the activation of downstream proteins of NRP-1 signaling pathways 
(pERK1/2 and pAKT) evaluated by western blotting. B: Ratio of phosphorylated protein reported to total protein. Optical densities of each 
band have been quantified, the expression ratio have been normalized with value of non-treated cells (nt) as reference. tuf = cells treated with 
tuftsin. C: Effect of the different compounds on HUVECs viability measured by a metabolic test (WST) at different concentrations from 12.5 
µM to 200 µM. No statistically significant difference observed between the different compounds. n =3. 
The anti-angiogenic properties were evaluated through the in vitro ability of HUVECs to form tubules-like capillaries 
on a basement matrix (Figure 4). In vitro angiogenesis assay using HUVEC seeded on Matrigel is a well-established 
assay to screen the angiogenic effect of many substances. Among the tested compounds, 69 demonstrated a wide effect 
on tubules formation. The effects of 69 could be compared to tuftsin and were relatively close to those observed with 
bevacizumab, a humanized anti-VEGF monoclonal antibody used nowadays in clinic for cancer therapy and used here 
as positive control. Inhibition of tubules-like capillaries was also observed to a lesser extent with compound 61.  
HUVECs ability to migrate through a basement membrane matrix was measured via an invasion assay and most of 
tested compounds showed an unexpected slight pro invasive effect (see SI, Figure S3).  
 
 
Figure 4: Effect of the different compounds (c = 50 µM) on HUVECs ability to form capillaries-like structures on basement membrane 
matrix. A: Images were representative of three independent experiments of endothelial cells cultured on Matrigel™ in presence of the different 
compounds. The junctions number. B segments number C as well as the total segments length D were quantified by Angiogenesis Analyser 
for ImageJ. nt, non treated; tuf, tuftsin; beva, bevacizumab. Results are presented as mean ± standard error of the mean of three independent 
experiments and p<0.05 was considered to be statistically significant. 
3. Discussion  
The first series of analogs exhibited a VEGF-A165/NRP-1 inhibition which did not exceed 40%, except for compound 
17. The effect of the linker length of separating both guanidium functions was difficult to evaluate, since compound 15 
inhibited very weakly VEGF-A165/NRP-1 binding (entry 2, Table 1), while a modest activity was observed for 16 and 
17 at 100 µM concentration (entries 3-4). Compound 27, based on sugar scaffold B and functionalized in the same 
manner as compound 1 was less active than this latter, suggesting a non-adapted spatial disposition of crucial residues 
(entry 5). Compounds 34, 33 and the corresponding diols 38 and 37 showed a weak affinity for NRP-1, suggesting that 
triazole moiety could be too rigid linker and deleterious for binding (entries 6-9).  
The second series showed general binding inhibition properties higher than 40% at 100 µM, excepted for compound 
63. Arginine anchored at C1 was beneficial for NRP-1 binding, as shown for compound 50 and 56 (entries 12-13). 
Compound 56 based on scaffold B showed a 67% binding inhibition at 100 µM and an IC50 of 39 µM, this result being 
in agreement with in silico predictions (see 2.2). However, the presence of amino-methyl and hydroxy-carboxymethyl 
groups recommended by molecular modeling was not beneficial for binding (entries 14-15), suggesting that the added 
chains were not long enough. Compound 69 obtained by conjugation with the 6-fluoroglycoside 68 displayed a 70% 
binding inhibition at 100µM and an IC50 of 70 µM, pointing out that the presence of the sugar derivative was not 
deleterious for NRP-1 binding.  
The biological properties of the compounds having the higher affinity were evaluated on HUVECs firstly through the 
downstream signaling pathways of NRP-1. All the compounds induced a similar change of ERK1/2 signaling pathways, 
which did not really impact the viability of endothelial cells even with a high concentration of 200 µM.  Nevertheless, 
some compounds showed a significant effect on angiogenesis network formation. Unexpectedly, while compound 69 
did not have the best affinity (IC50 = 69 µM), this latter demonstrated the most efficient properties toward inhibition of 
tubules formations. On the contrary, compound 56, the most affine compound (IC50 = 39µM), showed a lack of anti-
angiogenic effect, which could be explained by the significant increase of AKT phosphorylation with this compound 
(ratio 2.52). Indeed, AKT signaling pathway is well known to induce cell survival that limit the endothelial cell network 
remodeling during angiogenic process. The complexation of NRP-1 with its two well-known co-receptors, VEGFR and 
plexin (receptor of semaphorins), which have opposite effect on endothelial cell migration and tubulogenesis,46 could 
explain the results obtained with the different compounds. Indeed, the binding domains for semaphorin (a1/a2) are 
relatively close to the VEGF-A165 binding domains (b1/b2) and some compounds could also interact partially with a1/a2 
semaphorin domains. Compounds 50, 56 and 61 which induced a slight invasive effect, could modify the signaling 
pathway involving the plexin/semaphorine/NRP-1 ternary complex. On the contrary, compound 69 seems to be more 
specific of the b1/b2 domains of VEGF due to its similar effect to tuftsin and to a lesser extent to bevacizumab. 
Consequently, despite a good affinity for NRP-1 attested by decrease of MAPK-induced activation, an evaluation of all 
signaling pathways regulated by NRP-147 could allow elucidation of the different cellular effects observed with the tested 
compounds.  
4. Conclusion  
We have synthesized two series of carbohydrate-based peptidomimetics targeting NRP-1. The design of these ligands 
was based on rational modification of compound 1 to enhance binding interaction. Compound 56 inhibited VEGF-
A165/NRP-1 binding with an IC50 = 39 µM, which is in the range of activity described by others working on NRP-1 
inhibitors. Compound 56 demonstrated specificity for NRP-1 over VEGF-R2 binding more than 10-fold. No cytotoxic 
effects on HUVECs proliferation or viability were measured for all tested compounds. Interestingly, compound 69 (IC50 
= 69µM) demonstrated a significant effect on tubules formation which could be compared to tuftsin and to a lesser extent 
to bevacizumab without promoting the endothelial cells migration. In addition to its use as a potential anti-angiogenic 
compound, this compound could be envisaged to target cells overexpressing NRP-1 as cancer cells.  
5. Experimental section  
5.1.  Chemistry 
Reagents, general methods, experimental procedures for synthesis and characterizations of all intermediates are given 
in SI. Compounds 2-6 have been prepared according to literature procedures.25 
N-[2-C-[2,3-O-(1-methylethylidene)-5-benzosulfonylamino--D-galactofuranosyl]carbonymethyl)]-L-
arginine methyl ester 50 
To a solution of 49 (500 mg, 0.85 mmol) in THF (20 mL) and water (3 mL) was added LiOH (65 mg, 2.55 mmol, 3 
eq.) and the mixture was stirred until completion of the reaction monitored by tlc. Amberlite® IR-120 was added until 
pH = 3-4 and the mixture was filtered off. The solvent were evaporated and the obtained carboxylic acid was solubilized 
in MeOH (20 mL) and Pd/C (10%) (40% w/w) was added. After stirring under H2 atmosphere (40 psi) until completion 
of the reaction, the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The crude was 
purified by column chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to provide 50 (367 mg, 82%). White 
solid. Rf; 0.24 (H2O/MeOH: 1/1). HPLC (70/30): tR = 6.049 min. [α]D= +15.0° (c = 0.2, H2O). 1H NMR (400 MHz, 
D2O): δ = 1.22 (s, 3H, C(CH3)2), 1.33 (s, 3H, C(CH3)2), 1.49-1.56 (m, 2H, CH2 arg), 1.64 (m, 1H, CH2 arg), 1.77 (m, 
1H, CH2 arg), 2.53-2.63 (m, 2H, H-2), 3.07-3.11 (m, 3H, H-7, 2 CH2 arg), 3.18 (dd, 1H, Jgem = 13.5, J6,7’ = 4.5 Hz, H-
7’), 3.60 (m, 1H, H-6), 3.85 (td, 1H, J3,4 = 2.5 Hz, H-3), 4.12 (dd, 1H, JH-α,A1 = 8.0 Hz, JH-α,A1’ = 5.0 Hz, H-α), 4.67-4.69 
(m, 2H, H-4, H-5), 7.53-7.57 (m, 2H, H-Ar), 7.64 (m, 1H, H-Ar), 7.79-7.82 (m, 2H, H-Ar). 13C NMR (100 MHz, D2O): 
δ = 23.6 (CH3), 24.4 (CH2 arg), 24.7 (CH3), 28.8 (CH2 arg), 34.7 (C-2), 40.6 (CH2 arg), 41.3 (C-7), 54.8 (C-α), 77.7 (C-
3), 79.1 (C-6), 80.3 (C-5), 81.1 (C-4), 112.8 (C(CH3)2), 126.7 (2 C-Ar), 129.5 (2 C-Ar), 133.6 (C-Ar), 137.9 (C-Ar), 
156.7 (C=N), 171.9 (C=O), 178.4 (C=O). IR (pellets) : 3360, 3180, 2990, 2943, 2876, 1645, 1586. ESI-HRMS: m/z 
calcd for C22H33N5O8SNa [M+Na]+ 550.1942; found 550.1956. 
5.1.1 .  N - [2-C- [2 ,3-O - (1-methylethyl idene)-5-benzosul fonylamino- -D-
r ibofuranosyl ]carbonylmethyl) ] -L-arginine  methyl  ester  56  
Prepared starting from 55 (150 mg, 0.26 mmol) following procedure described for 50 Yield: 70% (94 mg). White 
solid. Rf; 0.22 (H2O/MeOH: 1/1). HPLC (70/30): tR = 5.526 min. [α]D= +17.1° (c = 0.1, H2O). 1H NMR (250 MHz, 
D2O): δ = 1.37 (s, 3H, C(CH3)2), 1.52 (s, 3H, C(CH3)2), 1.59-1.95 (m, 4H, CH2 arg), 2.63 (dd, 1H, Jgem = 14.5, J2,3 = 7.5 
Hz, H-2), 2.72 (dd, 1H, J2,3’ = 6.5 Hz, H-2’), 3.06 (dd, 1H, Jgem = 14.0, J6,7 = 8.0 Hz, H-7), 3.14 (dd, 1H, J6,7’ = 6.0 Hz, 
H-7’), 3.23 (t, 2H, J = 7.0 Hz, CH2 arg), 4.12 (dd, 1H, H-6), 4.20-4.27 (m, 2H, H-3, H-α), 4.74 (d, 1H, J4,5 = 6.0 Hz, H-
5), 4.84 (dd, 1H, J3,4 = 4.0 Hz, H-4), 7.66-7.80 (m, 3H, H-Ar), 7.91-7.95 (m, 2H, H-Ar). 13C NMR (62.9 MHz, D2O): δ 
= 23.6, 24.4, 25.0 (2 CH3, CH2 arg), 28.8 (CH2 arg), 35.2 (C-2), 40.7 (CH2 arg), 41.8 (C-7), 54.6 (C-α), 76.6 (C-3), 80.7, 
82.1, 82.4 (C-4, C-5, C-6), 113.1 (C(CH3)2), 126.6 (2 C-Ar), 129.6 (2 C-Ar), 133.6 (C-Ar), 138.3 (C-Ar), 156.7 (C=N), 
171.7 (C=O), 178.5 (C=O). IR (pellets) : 3331, 3134, 2988, 2928, 2860, 1632, 1575, 1446. ESI-HRMS: m/z calcd for 
C22H33N5O8SNa [M+Na]+ 550.1942; found 550.1957. 
N - [2-C- [2 ,3-O - (1-methylethyl idene)-5- [ ( (4-aminomethyl)benzo)sul fonylamino]- -D-
r ibofuranosyl ]carbonymethyl) ] ] -L-arginine methyl  ester  61  
To a solution of 60 (80 mg, 0.14 mmol) in MeOH (5 mL), was added Pd/C (10%) (8 mg, 10% w/w). After stirring 
under H2 atmosphere (15 psi) until completion of the reaction, the mixture was filtered through a pad of celite and the 
filtrate was concentrated in vacuo. The crude was purified by column chromatography (C-18 silica gel, H2O/MeOH) and 
lyophilized to provide 61 (65 mg, 87%). White solid. Rf; 0.38 (H2O/CH3CN/TFA: 7/3/0.1%). HPLC (70/30): tR = 3.681 
min. [α]D= +6.9° (c = 0.1, H2O). 1H NMR (400 MHz, DMSO-d6): δ = 1.25 (s, 3H, C(CH3)2), 1.38 (s, 3H, C(CH3)2), 1.45-
1.61 (m, 3H, CH2 arg), 1.73 (m, 1H, CH2 arg), 2.47-2.53 (m, 2H, 2 H-2), 2.68 (m, 1H, H-7), 2.82 (m, 1H, H-7’), 3.07-
3.11 (m, 2H, CH2 arg), 3.87 (t, 1H, J6,7 = 7.0 Hz, H-6), 4.10-4.17 (m, 3H, H-3, CH2-NH2), 4.20 (td, 1H, J = 8.0, J = 5.0 
Hz, H-α), 4.63 (d, 1H, J4,5 = 6.0 Hz, H-5), 4.66 (dd, 1H, J3,4 = 3.5 Hz, H-4), 6.99 & 7.20 (br s, 4H, 4 NH), 7.59 (t, 1H, J 
= 5.5 Hz, NH), 7.67 (d, 2H, J = 8.0 Hz, 2 H-Ar), 7.84-7.90 (m, 3H, 2 H-Ar, NH), 8.18 (d, 1H, JNH, = 8.0 Hz, NH), 8.28 
(br s, 3H, CH2-NH3+). 13C NMR (100 MHz, DMSO-d6): δ = 25.2 (CH3), 25.5 (CH2 arg), 26.6 (CH3), 28.8 (CH2 arg), 
35.3 (C-2), 40.7 (CH2 arg), 42.2 (C-7), 42.9 (CH2-NH2), 51.8 (C-α), 77.0 (C-3), 81.3 (C-4), 82.1 (C-6), 83.0 (C-5), 111.8 
(C(CH3)2), 127.3 (2 C-Ar), 130.1 (2 C-Ar), 139.0 (C-Ar), 140.7 (C-Ar), 157.1 (C=N), 158.5 (TFA), 170.0 (C=O amide), 
173.9 (C=O acid). IR (pellets) : 3393, 3189, 2990, 2928, 1676, 1546. ESI-HRMS: m/z calcd for C23H37N6O8S [M+Na]+ 
557.2388; found 557.2399. 
5.1.2 .  Compound 69 
To a solution of alcyne 67 (33 mg, 0.04 mmol, 1 eq.) and azido sugar 68 (15 mg, 0.04 mmol, 1 eq.) in a water/tBuOH 
mixture (0.5 mL/0.5 mL) were added sodium ascorbate (2.4 mg, 0.008 mmol, 0.2 eq.) and Cu(OAc)2 (1.2 mg, 0.004 
mmol, 0.1 eq.). The solution turned progressively pale green and the mixture was stirred at room temperature until 
completion of the reaction (the blue color reappeared). Chelex® resin (100 mg) was then added to the solution and the 
suspension was stirred until the solution became colorless. The resin was filtered off and the solvent were removed under 
reduced pressure. The crude was purified by column chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to 
provide 69 (37 mg, 77%).White solid. Rf; 0.29 (H2O/MeOH: 1/1). HPLC (70/30): tR = 4.180 min. [α]D= -6.7° (c = 0.1, 
H2O). 1H NMR (400 MHz, D2O): δ = 1.31 (s, 3H, C(CH3)2), 1.46 (s, 3H, C(CH3)2), 1.53-1.61 (m, 2H, CH2 arg), 1.69 
(m, 1H, CH2 arg), 1.84 (m, 1H, CH2 arg), 2.59 (dd, 1H, Jgem = 15.0, J2,3 = 8.0 Hz, H-2), 2.66 (dd, 1H, J2’,3 = 6.5 Hz, H-
2’), 3.04 (dd, 1H, Jgem = 13.5, J6,7 = 8.5 Hz, H-7), 3.08-3.17 (m, 3H, CH2 arg, H-7’), 3.26 (m, 1H, H-11), 3.42- 3.59 (m, 
3H, H-12, H-13, H-14), 4.08 (dd, 1H, J6,7 = 8.5, J6,7’ = 6.5 Hz, H-6), 4.14-4.25 (m, 3H, H-3, H-α, H-9), 4.33 (m, 1H, H-
9’), 4.47 (d, 1H, J10,11 = 8.0 Hz, H-10), 4.61 (dd, 2H, JH,F = 47.5, J14,15 = 2.0 Hz, H-15), 4.68 (d, 1H, J4,5 = 6.0 Hz, H-5), 
4.73-4.77 (m, 3H, H-4, 2 H-8), 7.94 (d app., 2H, J = 8.0 Hz, H-Ar), 7.99 (d app., 2H, H-Ar), 8.49 (H-triazole). 13C NMR 
(62.9 MHz, D2O): δ = 23.9 (CH3), 24.6 (CH2 arg), 25.3 (CH3), 29.1 (CH2 arg), 35.6 (C-2), 40.9 (CH2 arg), 42.2 (C-7), 
50.9 (C-8), 54.8 (C-α), 68.5 (d, JC,F = 7.0 Hz, C-13), 68.7 (C-9), 73.1 (C-11), 74.5 (d, JC,F = 18.0 Hz, C-14), 75.7 (C-12), 
77.0 (C-3), 81.0, 82.4, 82.7 (C-4, C-5, C-6), 82.1 (d, JC,F = 168.0 Hz, C-15), 102.9 (C-10), 113.3 (C(CH3)2), 124.4 (C-
Ar), 126.7 (2 C-Ar), 127.8 (2 C-Ar), 134.7 (C-triazole), 138.5 (C-Ar), 146.0 (C-triazole), 156.9 (C=N), 172.0 (C=O), 
178.7 (C=O) 19F NMR (235.2 MHz, D2O): δ = -235.16 (td, JH,F = 47.0, JH,F = 27.0 Hz). IR (ATR) : 3346, 3236, 1655, 
1505, 1150. ESI-HRMS: m/z calcd for C32H47FN8O13SNa [M+Na]+ 825.2860; found 825.2845. 
5.2. Molecular modeling 
The structures of the investigated compounds were prepared according to the CORINA48 (for the 3D conformers) and 
MOPAC49 softwares (for the atomic charges). The chemicals were firstly docked using the GOLD software (see SI for 
details).50 The protein target was the 3D structure of the b1 domain of NRP-1 as solved by X-ray when bound with the 
small molecule EG0022926 (pdb code 3I97). 
5.3. Biocrystallography 
A crystallization screening of NRP-1-b1 fragment including a 6-His tag at the N-terminus was carried out in presence 
of compounds 27, 40, 50 and 56 (see SI for details). The crystal structure has been deposited at the Protein Data Bank51 
with code 5C7G. 
 
 
5.4. Biological Assay 
General procedure for receptor binding assays: The binding of new derivatives to recombinant NRP-1 protein was 
determined using a competition assay initially described by Tirand et al. (see details in SI).43 
General procedure for HUVECs culture and treatments: HUVECs were collected from umbilical cords as previously 
described by Jaffe et al. (see details in SI).52 
General procedure for NRP1 signaling pathways: For analysis of pAKT and pERK1/2 expression, western blotting 
was realized as previously described (see details in SI).53 
General procedure for cell viability assays: Roche’s WST-1 cell proliferation reagent is a simple, colorimetric assay 
designed to measure the relative proliferation rates of cells in culture (see details in SI).  
Angiogenesis assay: HUVECs were plated (90,000 cells/cm2) onto 24-well plate ibidi precoated with Matrigel™ 
Basement Membrane Matrix (BD Biosciences, France, see details in SI).  
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Experimental procedures for synthesis and characterizations of all intermediates and copies of 1H and 13C NMR spectra, 
crystallographic summary of NRP-1/bicine structure, protein production and purification, biological assays and 
experimental procedures for molecular modeling and biocrystallography. This material is available free of charge via 
the Internet at  
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MRI, magnetic resonance imaging; AKT, serine/threonine protein kinase; ERK1/2, extracellular signal-regulated 
protein kinases 1 and 2.  
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Experimental procedures and characterizations of all compounds  
 
Reagents and general methods  
DMF was dried by distillation from calcium hydride. Other solvents and reagents were 
purchased from commercial sources and used without further purification. TLC analyses were 
performed using standard procedures on Kieselgel 60 F254 plates (Merck). Compounds were 
visualized using UV light (254 nm) and 30% methanolic H2SO4/heat as developing agent. 
Column chromatography was performed on silica gel SI 60 (63-200 m) or Lichroprep RP-18 
(40-63m) (Merck). FTIR spectra were recorded on a Perkin-Elmer spectrum 1000 on NaCl 
windows (film) or KBr pellets (cm-1). Melting points were determined with a Tottoli apparatus 
and are uncorrected. Optical rotations were measured on an Anton Paar MC300 polarimeter. 
1H and 13C NMR spectra were recorded on a Bruker spectrometer DPX250 (250 MHz and 62.9 
MHz, respectively) and DRX400 (400 MHz and 100.6 MHz, respectively). For complete 
assignment of 1H and 13C signals, two-dimensional 1H,1H COSY and 1H,13C correlation spectra 
were recorded. Mass spectra (MS) were recorded on a ESI/QqTOF Bruker spectrometer. Purity 
of the compounds for biological assays was confirmed to be greater than 95% by high-
performance liquid chromatography. HPLC analyses were run on a Waters system (2695 
ebpump, auto sampler injector, 2998 PDA detector and 2424 ELSD detector) controlled by the 
Empower software. Analyses were performed on a Platinium C18 (5 µm, 250x4.6 mm) from 
Grace with a AcCN/H2O/0.2%TFA mixture (proportions given in brackets) at 1 mL/min. 
 
3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-hydroxy-
L-galacto-heptonamide 7 
To a stirred solution of 6 (3.73 g, 8.40 mmol) in methanol (180 mL) at 0°C was added 
dropwise an aqueous solution of 1N HCl (60 mL). After stirring at room temperature until 
completion of the reaction, sat. aq. NaHCO3 was added until pH = 7. Half of the solvent was 
removed under vacuum and the product was extracted with CH2Cl2 (3 x 100 mL). The organic 
layer was dried over MgSO4, filtered and the solvent was evaporated. To a stirred solution of 
this diol in methanol (180 mL) was added NaIO4 (3.59 g, 16.8 mmol, 2 eq.) under argon. After 
stirring at room temperature until completion of the reaction, the solvent was removed by half 
in vacuo. The mixture was diluted with CH2Cl2 (200 mL). The organic layer was washed with 
water (3 x 75 mL), dried over MgSO4, filtered and the solvent was removed under reduced 
pressure. The product was used without further purification.To a stirred solution of the obtained 
aldehyde in MeOH (190 mL) was added NaBH4 (320 mg, 8.40 mmol, 1 eq.) at 0°C. After 1 h 
at room temperature, the solvent was removed under reduced pressure. The residue was diluted 
in CH2Cl2 (100 mL) and the organic layer was washed with a solution of 1N HCl (30 mL) and 
with water until pH = 7. The organic layer was dried over MgSO4, filtrered and evaporated 
under reduced pressure. The crude product 7 (2.26 g, 72%) was used without further 
purification. Yellow powder. Rf; 0.38 (CH2Cl2/MeOH 9/1). [α]D= +3.0 (c = 1.50, CHCl3). Mp. 
= 94°C. 1H NMR (250 MHz, CDCl3): δ = 1.29 (s, 3H, C(CH3)2), 1.45 (s, 3H, C(CH3)2), 2.53-
2.68 (m, 3H, 2 H-2, OH), 3.00 (t, 2H, Jα,β = 6.5 Hz, 2 H-β), 3.51-3.71 (m, 3H, H-6, 2 H-α), 3.83-
3.89 (m, 3H, H-3, 2 H-7), 4.60 (dd, 1H, J4,5 = 6.0, J5,6 = 3.5 Hz, H-5), 4.70 (dd, 1H, J3,4 = 3.5 
Hz, H-4), 6.22 (br s, 1H, NHamide), 7.09-7.26 (m, 3H, 3 H-Ar), 7.41 (d, 1H, J = 8.0, H-Ar), 
7.63 (d, 1H, J = 8.0, H-Ar), 8.55 (br s, 1H, NHindole). 13C NMR (62.9 MHz, CDCl3): δ = 23.4 
(CH3), 23.9 (CH3), 24.7 (C-β), 35.1 (C-2), 38.6 (C-α), 59.8 (C-7), 76.9 (C-3), 80.1, 80.2, 80.5 
(C-4, C-5, C-6), 110.2, 111.4, 111.6 (2 C-Ar, C(CH3)2), 117.6 (C-Ar), 118.3 (C-Ar), 120.9 (C-
Ar), 121.4 (C-Ar), 126.3 (C-Ar), 135.3 (C-Ar), 169.5 (C=O). IR (film) : 3327, 1645. ESI-
HRMS: m/z calcd for C20H27N2O5 [M+H]+ 375.1914; found 375.1898. 
 
3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-(4-
methylbenzenesulfonate)-L-galacto-heptonamide 8 
To a solution of 7 (1.94 g, 5.2 mmol) in CH2Cl2 (50 mL) were added Et3N (1.8 mL, 13 mmol, 
2.5 eq.), DMAP (61 mg, 0.5 mmol, 0.1 eq.) and tosyl chloride (2 g, 10.4 mmol, 2 eq.) and the 
mixture was stirred for 24 h at room temperature. The solution was washed with 1N HCl (20 
mL), sat. aq. NaHCO3 (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, 
filtered and the solvent was evaporated in vacuo. The compound was purified by flash 
chromatography (silica gel, cyH/EA) to provide 8 (2.47 g, 90%). White solid. Rf; 0.49 
(CH2Cl2/MeOH 9/1). [α]D= +6.0 (c = 1.0, CHCl3). Mp = 64°C. 1H NMR (400 MHz, CDCl3): δ 
= 1.21 (s, 3H, CH3), 1.30 (s, 3H, CH3), 2.44 (s, 3H, Ph-CH3), 2.49-2.51 (m, 2H, H-2), 2.98 (t, 
2H, Jα,β = 6.5 Hz, H-β), 3.49 (m, 1H, H-α), 3.62 (m, 1H, H-6), 3.68-3.77 (m, 2H, Hα, H-3), 4.12 
(dd, 1H, J6,7 = 7.5, J7,7’ = 11.0 Hz, H-7), 4.25 (dd, 1H, J6,7’ = 4.0 Hz, H-7’), 4.54 (dd, 1H, J3,4 = 
3.5, J4,5 = 6.0 Hz, H-4), 4.59 (dd, 1H, J5,6 = 4.0 Hz, H-5), 6.13 (t, 1H, J = 5.5 Hz, CONH), 7.08-
7.12 (m, 2H, H-Ar), 7.19 (m, 1H, H-Ar), 7.33 (d, 2H, J = 8.0, H-Ar), 7.41(d, 1H, J = 8.0, H-
Ar), 7.59 (d, 1H, J = 8.0, H-Ar), 7.79 (d, 2H, J = 8.5 Hz, H-Ar), 8.58 (s, 1H, NH-Ar). 13C NMR 
(100 MHz, CDCl3): δ = 21.7 (CH3-Ph), 24.6 (CH3), 24.9 (C-β), 25.7 (CH3), 36.4 (C-2), 39.6 
(C-α), 68.2 (C-7), 78.5 (C-3), 79.9 (C-6), 80.4 (C-5), 81.4 (C-4), 111.4 (C-Ar), 112.6 (C(CH3)2), 
112.8 (C-Ar), 118.6 (C-Ar), 119.2 (C-Ar), 122.0 (C-Ar), 122.5 (C-Ar), 127.4 (C-Ar), 128.0 (2 
C-Ar), 129.9 (2 C-Ar), 132.5 (C-Ar), 136.5 (C-Ar), 145.2 (C-Ar), 170.3 (C=O). IR (film) : 
1654, 1535. ESI-HRMS: m/z calcd for C27H32N2O7SNa [M+Na]+ 551.1822; found 551.1852. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[3-
[[(phenylmethoxy)carbonyl]amino]propyl]amino]-L-galacto-heptonamide 9 
A solution of 8 (422 mg, 0.8 mmol, 1 eq.) and amine (0.8 mmol, 4 eq.) in isopropanol (4 mL) 
was heated at 100°C for 48h in a sealed tube. The solvent was removed under reduced pressure 
and the residue was diluted with EtOAc (10 mL) and washed with sat. aq. NaHCO3 (2x5 mL). 
The organic layer was dried over MgSO4, filtered and the solvent was evaporated under reduced 
pressure. The compound was purified by flash chromatography (silica gel, cyH/EA) to provide 
9 (324 mg, 72%). Colorless gum. Rf; 0.33 (CH2Cl2/MeOH 9/1). [α]D= +10.3 (c = 0.5, CHCl3). 
1H NMR (250 MHz, CDCl3): δ = 1.27 (s, 3H, CH3), 1.42 (s, 3H, CH3), 1.59-1.76 (m, 2H, H-9), 
2.55-2.59 (m, 2H, H-2), 2.69-2.74 (m, 2H, H-10), 2.77-2.92 (m, 2H, H-7), 2.99 (t, 2H, Jα,β = 
7.5 Hz, H-β), 3.13-3.23 (m, 2H, H-8), 3.44-3.79 (m, 4H, H-3, H-6, H-α), 4.55 (dd, 1H, J4,5 = 
6.0, J5,6 = 3.5 Hz, H-5), 4.60 (dd, 1H, J3,4 = 3.5 Hz, H-4), 5.12 (s, 2H, CH2-Ph), 5.50 (br s, 1H, 
NH), 6.29 (br s, 1H, NH), 7.05-7.23 (m, 3H, H-Ar), 7.32-7.42 (m, 6H, H-Ar), 7.61 (d, 1H, J = 
8.0 Hz, H-Ar), 8.81 (br s, 1H, NH). 13C NMR (62.9 MHz, CDCl3): δ = 24.7 (CH3), 25.1 (C-β), 
25.8 (CH3), 29.2 (C-9), 36.4 (C-2), 39.5 (C-α), 39.7 (C-8), 47.6 (C-7), 47.9 (C-10), 66.7 (CH2-
Ph), 78.1 (C-3), 80.4 (C-6), 81.0 (C-4), 81.5 (C-5), 111.4 (C-Ar), 112.3 (C(CH3)2), 112.9 (C-
Ar), 118.7 (C-Ar), 119.3 (C-Ar), 122.0 (C-Ar), 122.2 (C-Ar), 127.5 (C-Ar), 128.1 (2 C-Ar), 
128.5 (3 C-Ar), 136.4 (C-Ar), 136.6 (C-Ar), 156.8 (OCONH), 170.5 (CONH). IR (film) : 
3312, 1714, 1645. ESI-HRMS: m/z calcd for C31H40N4O6Na [M+Na]+ 587.2840; found 
587.2866. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[4-
[[(phenylmethoxy)carbonyl]amino]butyl]amino]-L-galacto-heptonamide 10 
Prepared starting from 8 (422 mg, 0.8 mmol) following procedure described for 9. Yield: 
70% (323 mg). Colorless gum. Rf; 0.29 (CH2Cl2/MeOH 9/1). [α]D= +9.1 (c = 1.0, CHCl3). 1H 
NMR (400 MHz, CDCl3): δ = 1.26 (s, 3H, CH3), 1.41 (s, 3H, CH3), 1.50-1.56 (m, 4H, H-9, H-
10), 2.55 (dd, 2H, Jgem= 6.5 Hz, J2,3 = 4.0 Hz, J2’,3 = 2.0 Hz, H-2), 2.61-2.65 (m, 2H, H-11), 2.81 
(dd, 1H, Jgem = 12.5 Hz, J6,7 = 7.5 Hz, H-7), 2.88 (dd, 1H, J6,7’ = 4.5 Hz, H-7’), 2.98 (t, 2H, Jα,β 
= 6.5 Hz, H-β), 3.17-3.21 (m, 2H, H-8), 3.52-3.61 (m, 2H, H-α, H-6), 3.65 (m, 1H, H-α), 3.74 
(m, 1H, H-3), 4.49-4.55 (m, 2H, H-4, H-5), 5.10 (s, 2H, CH2-Ph), 5.47 (br s, 1H, NH), 6.26 (t, 
1H, J = 5.5 Hz, NH), 7.05 (s, 1H, H-Ar), 7.12 (m, 1H, H-Ar), 7.20 (m, 1H, H-Ar), 7.31-7.40 
(m, 6H, H-Ar), 7.61 (d, 1H, J = 8.0 Hz, H-Ar), 8.72 (br s, 1H, NH). 13C NMR (100 MHz, 
CDCl3): δ = 24.7 (CH3), 25.1 (C-β), 25.8 (CH3), 26.6, 27.7 (C-9, C-10), 36.3 (C-2), 39.7 (C-α), 
40.8 (C-8), 47.9 (C-7), 49.4 (C-11), 66.6 (CH2-Ph), 78.0 (C-3), 80.2 (C-6), 81.0, 81.5 (C-4, C-
5), 111.4 (C-Ar), 112.3 (C(CH3)2), 112.8 (C-Ar), 118.7 (C-Ar), 119.3 (C-Ar), 122.0 (C-Ar), 
122.3 (C-Ar), 127.4 (C-Ar), 128.2 (2 C-Ar), 128.5 (3 C-Ar), 136.4 (C-Ar), 136.7 (C-Ar), 156.6 
(OCONH), 170.5 (CONH). IR (film) : 3312, 1716, 1648. ESI-HRMS: m/z calcd for 
C32H42N4O6Na [M+Na]+ 601.2997; found 601.3002. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[5-
[[(phenylmethoxy)carbonyl]amino]pentyl]amino]-L-galacto-heptonamide 11 
Prepared starting from 8 (422 mg, 0.8 mmol) following procedure described for 9. Yield: 
80% (378 mg). Colorless gum. Rf; 0.37 (CH2Cl2/MeOH 9/1). [α]D= +5.5 (c = 1.0, CHCl3). 1H 
NMR (250 MHz, CDCl3): δ = 1.27 (s, 3H, CH3), 1.43 (s, 3H, CH3), 1.29-1.53 (m, 6H, H-9, H-
10, H-11), 2.57 (d, 2H, J2,3 = 6.5 Hz, H-2), 2.62 (t, 2H, J11,12 = 7.0 Hz, H-12), 2.82-2.92 (m, 2H, 
H-7), 2.98 (t, 2H, Jα,β = 7.5 Hz, H-β), 3.16-3.21 (m, 2H, H-8), 3.54-3.65 (m, 3H, H-6, H-α), 
3.81 (m, 1H, H-3), 4.56 (dd, 1H, J4,5 = 6.0, J5,6 = 3.5 Hz, H-5), 4.61 (dd, 1H, J3,4 = 3.5 Hz, H-
4), 4.92 (br s, 1H, NH), 5.11 (s, 2H, CH2-Ph), 6.16 (t, 1H, J = 5.5 Hz, NH), 7.05 (s, 1H, H-Ar), 
7.12 (m, 1H, H-Ar), 7.20 (m, 1H, H-Ar), 7.31-7.39 (m, 6H, H-Ar), 7.62 (d, 1H, J = 8.0 Hz, H-
Ar), 8.78 (br s, 1H, NH). 13C NMR (62.9 MHz, CDCl3): δ = 24.2 (C-10), 24.7 (CH3), 25.2 (C-
β), 25.9 (CH3), 29.2, 29.7 (C-9, C-11), 36.3 (C-2), 39.7 (C-α), 40.9 (C-8), 48.0 (C-7), 49.7 (C-
12), 66.6 (CH2-Ph), 78.0 (C-3), 80.5 (C-6), 81.1 (C-4), 81.5 (C-5), 111.3 (C-Ar), 112.3 
(C(CH3)2), 112.8 (C-Ar), 118.7 (C-Ar), 119.3 (C-Ar), 122.0 (C-Ar), 122.3 (C-Ar), 127.4 (C-
Ar), 128.1 (2 C-Ar), 128.5 (3 C-Ar), 136.4 (C-Ar), 136.7 (C-Ar), 156.5 (OCONH), 170.4 
(CONH). IR (film) : 3312, 1704, 1652. ESI-HRMS: m/z calcd for C33H44N4O6Na [M+Na]+ 
615.3153; found 615.3137. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[N-
[bis[(phenylmethoxy)carbonyl]]aminoiminomethyl]-N-[3-
[bis[(phenylmethoxy)carbonyl]]guanidinopropyl]amino]-L-galacto-heptonamide 12 
To a solution of 9 (282 mg, 0.5 mmol) in MeOH (10 mL) was added Pd/C (10%) (30 mg, 
10% w/w). After stirring under H2 atmosphere (30 psi) until completion of the reaction, the 
mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The 
crude was solubilized in DMF (3 mL) and N,N’-bis(dibenzyloxycarbonyl)-S-methylisothiourea 
(1.0 mmol, 2eq.), HgCl2 (134 mg, 0.5 mmol, 1 eq.) and Et3N (153 mg, 1.5 mmol, 3 eq.) were 
added under argon atmosphere. After stirring 14 h at room temperature, the solvent was 
removed in vacuo and the residue was dissolved in EtOAc (40 mL). The organic layer was 
washed with water (5 mL), brine (5 mL), dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. The compound was purified by column chromatography 
(silica gel, cyH/EA) to provide 12 (131 mg, 25%).White solid. Rf; 0.52 (EA). [α]D= +5.1 (c = 
0.2, CHCl3). Mp = 65°C. 1H NMR (250 MHz, MeOH d4): δ = 1.21 (s, 3H, CH3), 1.31 (s, 3H, 
CH3), 1.80-1.92 (m, 2H, H-9), 2.46-2.49 (m, 2H, H-2), 2.91 (t, 2H, Jα,β = 7.0 Hz, H-β), 3.36-
3.68 (m, 8H, H-7, H-8, H-10, H-α), 3.76-3.84 (m, 2H, H-3, H-6), 4.55 (dd, 1H, J4,5 = 6.0, J3,4 = 
3.5 Hz, H-4), 4.62 (dd, 1H, J5,6 = 4.0 Hz, H-5), 4.96-5.03 (m, 4H, CH2-Ph), 5.07 (s, 2H, CH2-
Ph), 5.12 (s, 2H, CH2-Ph), 6.94-7.09 (m, 3H, H-Ar), 7.22-7.37 (m, 21H, H-Ar), 7.55 (d, 1H, J 
= 8.0 Hz, H-Ar). 13C NMR (62.9 MHz, MeOH d4): δ = 25.0 (CH3), 26.1 (C-β), 26.3 (CH3), 27.8 
(C-9), 36.7 (C-2), 39.4 (C-10), 41.3 (C-α), 41.5 (C-8), 48.9 (C-7), 68.4 (CH2-Ph), 68.7 (2 CH2-
Ph), 69.2 (CH2-Ph), 79.7 (C-3), 80.1 (C-6), 82.1 (C-4), 83.0 (C-5), 112.3 (C-Ar), 113.3 (C-Ar), 
113.7 (C(CH3)2), 119.4 (C-Ar), 119.7 (C-Ar), 122.4 (C-Ar), 123.5 (C-Ar), 128.8 (C-Ar), 128.9 
(C-Ar), 129.0 (2 C-Ar), 129.1 (C-Ar), 129.2 (2 C-Ar), 129.3 (C-Ar), 129.5 (8 C-Ar), 129.6 (C-
Ar), 129.7 (4 C-Ar), 136.5 (2 C-Ar), 138.1 (C-Ar), 138.2 (2 C-Ar), 154.6 (2 C=N), 157.4 (2 
NHCOO), 164.8 (2 NHCOO), 172.7 (CONH). IR (film) : 1754, 1730, 1640. ESI-HRMS: m/z 
calcd for C57H62N8O12Na [M+Na]+ 1073.4379; found 1073.4374. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[N-
[bis[(phenylmethoxy)carbonyl]]aminoiminomethyl]-N-[4-
[bis[(phenylmethoxy)carbonyl]]guanidinobutyl]amino]-L-galacto-heptonamide 13 
Prepared starting from 10 (289 mg, 0.5 mmol) following procedure described for 12. Yield: 
25% (133 mg). White solid. Rf; 0.59 (EA). [α]D= +10.3 (c = 0.2, CHCl3). Mp = 68°C. 1H NMR 
(250 MHz, MeOH d4): δ = 1.25 (s, 3H, CH3), 1.35 (s, 3H, CH3), 1.42-1.69 (m, 4H, H-9, H-10), 
2.50-2.59 (m, 2H, H-2), 2.94 (t, 2H, Jα,β = 7.0 Hz, H-β), 3.37-3.54 (m, 6H, H-8, H-11, H-α), 
3.61-3.71 (m, 2H, H-7), 3.76-3.84 (m, 2H, H-3, H-6), 4.59-4.68 (m, 2H, H-4, H-5), 5.04-5.06 
(m, 4H, CH2-Ph), 5.11 (s, 2H, CH2-Ph), 5.20 (s, 2H, CH2-Ph), 6.98-7.12 (m, 3H, H-Ar), 7.25-
7.43 (m, 21H, H-Ar), 7.58 (d, 1H, J = 8.0 Hz, H-Ar). 13C NMR (62.9 MHz, MeOH d4): δ = 25.1 
(CH3), 26.3 (CH3), 26.4, 27.2, 28.2 (C-β, C-9, C-10), 36.9 (C-2), 41.5 (C-α), 41.7 (C-8), 50.0 
(C-7, C-12), 68.5 (CH2-Ph), 68.9 (2 CH2-Ph), 69.4 (CH2-Ph), 79.8 (C-3), 80.4 (C-6), 82.3 (C-
4), 83.1 (C-5), 112.4 (C-Ar), 113.4 (C-Ar), 113.9 (C(CH3)2), 119.5 (C-Ar), 119.8 (C-Ar), 122.5 
(C-Ar), 123.6 (C-Ar), 128.9 (C-Ar), 128.9 (2 C-Ar), 129.0 (2 C-Ar), 129.1 (C-Ar), 129.2 (2 C-
Ar), 129.4 (C-Ar), 129.6 (8 C-Ar), 129.7 (C-Ar), 129.9 (4 C-Ar), 136.7 (2 C-Ar), 138.3 (2 C-
Ar), 138.4 (C-Ar), 154.8 (C=N), 154.9 (C=N), 157.5 (2 NHCOO), 165.0 (2 NHCOO), 172.9 
(CONH). IR (film) : 1728, 1638, 1622. ESI-HRMS: m/z calcd for C58H64N8O12Na [M+Na]+ 
1087.4536; found 1087.4492. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[N-
[bis[(phenylmethoxy)carbonyl]]aminoiminomethyl]-N-[5-
[bis[(phenylmethoxy)carbonyl]]guanidinopentyl]amino]- L-galacto-heptonamide 14 
Prepared starting from 11 (296 mg, 0.5 mmol) following procedure described for 12. Yield: 
35% (188 mg). White solid. Rf; 0.63 (EA). [α]D= +12.3° (c = 0.5, CHCl3). Mp = 70°C. 1H NMR 
(400 MHz, MeOH d4): δ = 1.24 (s, 3H, CH3), 1.26-1.33 (m, 2H, H-10), 1.35 (s, 3H, CH3), 1.50-
1.64 (m, 4H, H-9, H-11), 2.50-2.52 (m, 2H, H-2), 2.93 (t, 2H, Jα,β = 7.5 Hz, H-β), 3.30-3.51 (m, 
6H, H-8, H-12, H-α), 3.58-3.68 (m, 2H, H-7), 3.74 (m, 1H, H-6), 3.84 (m, 1H, H-3), 4.59-4.64 
(m, 2H, H-4, H-5), 5.03 (s, 4H, CH2-Ph), 5.10 (s, 2H, CH2-Ph), 5.19 (s, 2H, CH2-Ph), 6.98-7.09 
(m, 3H, H-Ar), 7.25-7.40 (m, 21H, H-Ar), 7.57 (d, 1H, J = 8.0 Hz, H-Ar). 13C NMR (100 MHz, 
MeOH d4): δ = 24.7 (C-10), 24.9 (CH3), 26.1 (C-β), 26.3 (CH3) 27.6, 29.4, 30.7 (C-9, C-11), 
36.7 (C-2), 41.4 (C-α), 41.8 (C-8), 49.1 (C-7), 50.1 (C-12), 68.4 (CH2-Ph), 68.7 (2 CH2-Ph), 
69.3 (CH2-Ph), 79.6 (C-3), 80.2 (C-6), 82.1 (C-4), 83.0 (C-5), 112.3 (C-Ar), 113.3 (C-Ar), 113.7 
(C(CH3)2), 119.4 (C-Ar), 119.6 (C-Ar), 122.3 (C-Ar), 123.5 (C-Ar), 128.9 (C-Ar), 129.0 (4 C-
Ar), 129.1 (4 C-Ar), 129.5 (8 C-Ar), 129.7 (4 C-Ar), 136.5 (2 C-Ar), 138.1 (C-Ar), 138.3 (2 C-
Ar), 154.8 (2 C=N), 157.3 (2 NHCOO), 164.8 (2 NHCOO), 172.8 (CONH). IR (film) : 1759, 
1728, 1643. ESI-HRMS: m/z calcd for C59H66N8O12Na [M+Na]+ 1101.4692; found 1101.4706. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[N-
(aminoiminomethyl)-N-(3-guanidinopropyl)amino]-L-galacto-heptonamide 15 
To a solution of 12 (110 mg, 0.1 mmol) in MeOH (10 mL) was added Pd/C (10%) (10% 
w/w). After stirring under H2 atmosphere (30 psi) until completion of the reaction, the mixture 
was filtered through a pad of celite and the filtrate was concentrated in vacuo. The crude was 
purified by column chromatography (C-18 silica gel, H2O/CAN/0.1%TFA) and lyophilized to 
provide 15 (46 mg, 90%). White solid. Rf; 0.27 (H2O/MeCN/TFA: 6/4/0.1%). HPLC (60/40): 
tR = 4.920 min. [α]D= +11.2° (c = 0.1, MeOH). 1H NMR (250 MHz, MeOH d4): δ = 1.30 (s, 
3H, CH3), 1.45 (s, 3H, CH3), 1.88-1.94 (m, 2H, H-9), 2.58 (d, 2H, Jgem = 7.0 Hz, H-2), 2.95 (t, 
2H, Jα,β = 7.0 Hz, H-β), 3.18 (t, 2H, J9,10 = 7.0 Hz, H-10), 3.40-3.78 (m, 7H, H-6, H-7, H-8, H-
α), 3.91 (m,1H, H-3), 4.67 (dd, 1H, J4,5= 6.0, J3,4 = 3.5 Hz, H-4), 4.77 (m, 1H, H-5), 6.96-7.11 
(m, 3H, H-Ar), 7.33 (d, 1H, J = 8.0 Hz, H-Ar), 7.56 (d, 1H, J = 8.0 Hz, H-Ar). 13C NMR (62.9 
MHz, MeOH d4): δ = 23.5 (CH3), 25.0, 25.1 (C-β, CH3), 25.8 (C-9), 35.3 (C-2), 38.6 (C-7), 
40.4 (C-α), 45.0 (C-8), 48.7 (C-10), 78.8 (C-3), 79.0 (C-6), 81.1 (C-4), 81.6 (C-5), 111.1 (C-
Ar), 112.1 (C-Ar), 112.6 (C(CH3)2), 118.1 (C-Ar), 118.4 (C-Ar), 121.2 (C-Ar), 122.3 (C-Ar), 
127.7 (C-Ar), 137.0 (C-Ar), 157.6 (C=N), 157.7 (C=N), 171.7 (CONH). IR (film) : 3351, 
1651, 1607. ESI-HRMS: m/z calcd for C25H38N8O4Na [M+Na]+ 537.2908; found 537.2930. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[N-
(aminoiminomethyl)-N-(4-guanidinobutyl)amino]-L-galacto-heptonamide 16 
Prepared starting from 13 (110 mg, 0.1 mmol) following procedure described for the 
synthesis of 15. Yield: 85% (45 mg). White solid. Rf; 0.23 (H2O/MeCN/TFA: 6/4/0.1%). HPLC 
(60/40): tR = 5.138 min. [α]D= +5.0° (c = 0.1, MeOH). 1H NMR (250 MHz, MeOH d4): δ = 1.30 
(s, 3H, CH3), 1.46 (s, 3H, CH3), 1.59-1.71 (m, 4H, H-9, H-10), 2.57-2.61 (m, 2H, H-2), 2.95 (t, 
2H, Jα,β = 7.0 Hz, H-β), 3.20 (t, 2H, H-11), 3.38-3.69 (m, 6H, H-7, H-8, H-α), 3.78 (m, 1H, H-
6), 3.94 (m, 1H, H-3), 4.68 (dd, 1H, J4,5 = 6.0, J3,4 = 3.0 Hz, H-4), 4.83 (m, 1H, H-5), 6.97-7.11 
(m, 3H, H-Ar), 7.34 (d, 1H, J = 8.0 Hz, H-Ar), 7.56 (d, 1H, J = 8.0 Hz, H-Ar). 13C NMR (62.9 
MHz, MeOH d4): δ = 24.7 (CH3), 25.3 (CH3), 26.2, 26.3, 26.8 (C-β, C-9, C-10), 36.4 (C-2), 
41.6 (C-α), 42.2 (C-7), 49.9 (C-8), 50.4 (C-11), 79.9 (C-3), 80.2 (C-6), 82.3 (C-4), 82.8 (C-5), 
112.3 (C-Ar), 113.2 (C-Ar), 113.7 (C(CH3)2), 119.3 (C-Ar), 119.6 (C-Ar), 122.3 (C-Ar), 123.5 
(C-Ar), 128.8 (C-Ar), 138.1 (C-Ar), 158.6 (C=N), 158.8 (C=N), 172.9 (CONH). IR (film) : 
3379, 1681. ESI-HRMS: m/z calcd for C26H40N8O4Na [M+Na]+ 551.3065; found 551.3039. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[N-
(aminoiminomethyl)-N-(5-guanidinopentyl)amino]-L-galacto-heptonamide 17 
Prepared starting from 14 (160 mg, 0.15 mmol) following procedure described for the 
synthesis of 15. Yield: 94% (76 mg). White solid. Rf; 0.20 (H2O/MeCN/TFA: 6/4/0.1%). HPLC 
(60/40): tR = 5.404 min. [α]D= +6.9° (c = 0.2, MeOH). 1H NMR (250 MHz, MeOH d4): δ = 1.30 
(s, 3H, CH3), 1.46 (s, 3H, CH3), 1.30-1.42 (m, 2H, H-10), 1.56-1.70 (m, 4H, H-9, H-11), 2.59 
(d, 2H, J2,3 = 6.5 Hz, H-2), 2.94 (t, 2H, Jα,β = 7.5 Hz, H-β), 3.17 (t, 2H, J11,12 = 7.0 Hz, H-12), 
3.36-3.67 (m, 6H, H-α, H-8, H-7), 3.76 (m, 1H, H-6), 3.94 (m, 1H, H-3), 4.68 (dd, 1H, J4,5 = 
6.0, J5,6 = 3.5 Hz, H-5), 4.77 (dd, 1H, J3,4 = 3.5 Hz, H-4), 6.97-7.12 (m, 3H, H-Ar), 7.33 (d, 1H, 
J = 8.0 Hz, H-Ar), 7.57 (d, 1H, J = 8.0 Hz, H-Ar). 13C NMR (62.9 MHz, MeOH d4): δ = 24.6 
(CH3), 24.7 (CH3), 26.2, 26.3 (C-β, C-10), 27.6, 29.6 (C-9, C-11), 36.5 (C-2), 41.6 (C-7), 42.3 
(C-α), 49.7 (C-8), 50.7 (C-12), 79.9 (C-3), 80.2 (C-6), 82.3 (C-4), 82.8 (C-5), 112.3 (C-Ar), 
113.3 (C(CH3)2), 113.7 (C-Ar), 119.3 (C-Ar), 119.6 (C-Ar), 122.3 (C-Ar), 123.4 (C-Ar), 128.8 
(C-Ar), 138.2 (C-Ar), 158.7 (C=N), 158.8 (C=N), 172.8 (CONH). IR (film) : 3327, 1657, 
1617. ESI-HRMS: m/z calcd for C27H42N8O4Na [M+Na]+ 565.3221; found 565.3200. 
 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-7-O-acetyl-D-altro-heptoanic acid 
methyl ester 18 
To a stirred solution of 3 (2.5 g, 8.7 mmol) in EtOAc (20 mL) was added Pd/C (10%) (1 g, 
40% w/w). The mixture was stirred under H2 atmosphere (30 psi) for 18h. The reaction mixture 
was then filtered through a pad of celite and the solvent was removed in vacuo. The compound 
was purified by column chromatography (silica gel, cyH/EA) to provide 18 (2.1 g, 85%). 
Colorless gum. Rf; 0.38 (cH/EA: 2/1). [α]D= -13.3° (c = 0.27, CHCl3). 1H NMR (250 MHz, 
CDCl3): δ = 1.34 (s, 3H, CH3), 1.49 (s, 3H, CH3), 2.09 (s, 3H, OCH3), 2.72 (dd, 1H, Jgem = 16.0, 
J2,3 = 5.0 Hz, H-2), 2.81 (dd, 1H, J2’,3 = 6.0 Hz, H-2’), 3.71 (s, 3H, COOCH3), 4.05 (dd, 1H, 
Jgem = 11.0, J6,7 = 4.5 Hz, H-7), 4.13-4.28 (m, 2H, H-7’, H-6), 4.36 (m, 1H, H-3), 4.67 (d, 1H, 
J4,5 = 6.0 Hz, H-5), 4.80 (dd, 1H, H-4). 13C NMR (62.9 MHz, CDCl3): δ = 20.7 (CH3COO), 
24.8, 26.0 (C(CH3)2), 34.0 (C-2), 51.5 (CH3OCO), 63.3 (C-7), 77.3, 81.1, 81.4, 82.7 (C-3, C-4, 
C-5, C-6), 112.6 (C(CH3)2), 170.3, 171.2 (2 C=O). IR (film) : 2990, 2943, 1742. ESI-HRMS: 
m/z calcd for C13H20O7Na [M+Na]+ 311.1101; found 311.1119. 
 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-D-altro-heptonic acid methyl ester 19 
To a stirred solution of 18 (2.0 g, 6.9 mmol) in methanol (50 mL) was added a catalytic 
amount of sodium at 0°C under argon atmosphere. After completion of the reaction (approx. 
1h), acidic resin Amberlite IR-120 was added until pH = 4. After filtration, the solvent was 
removed under reduced pressure to provide 19 (1.65 g, 97%). Colorless gum. Rf; 0.10 (cH/EA: 
2/1). [α]D= +5.4° (c = 0.52, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 1.33 (s, 3H, C(CH3)2), 
1.49 (s, 3H, C(CH3)2), 1.91 (br s, 1H, OH), 2.72 (dd, 1H, Jgem = 16.5, J2,3 = 7.0 Hz, H-2), 2.80 
(dd, 1H, J2’,3 = 7.0, H-2’), 3.60-3.66 (m, 2H, H-7, H-7’), 3.71 (s, 3H, OCH3), 4.14 (td, 1H, J6,7 
= 7.0, J5,6 = 1.0 Hz, H-6), 4.39 (td, 1H, J3,4 = 4.0 Hz, H-3), 4.66 (dd, 1H, J4,5 = 6.0 Hz, H-5), 
4.78 (dd, 1H, H-4). 13C NMR (62.9 MHz, CDCl3): δ = 25.2 (CH3), 26.4 (CH3), 34.5 (C-2), 51.9 
(OCH3), 62.1 (C-7), 77.2 (C-3), 81.5, 82.6, 84.3 (C-4, C-5, C-6), 113.0 (C(CH3)2), 171.8 (C=O). 
IR (film) : 3464, 2990, 2943, 1737. ESI-HRMS: m/z calcd for C11H18O6Na [M+Na]+ 
269.0996; found 269.1005. 
 
3,6-Anhydro-2-deoxy-7-O-[(tert-butyldimethyl)silyl]-4,5-O-(1-methylethylidene)-D-
altro-heptonic acid methyl ester 20 
To a solution of 19 (1.5 g, 6.1 mmol, 1 eq.) in DMF (12 mL), were added tert-
butyldimethylsilyl chloride (1.1g, 6.71 mmol, 1.1 eq.) and imidazole (1.04 g, 15.25 mmol, 2.5 
eq.) and the mixture was stirred at room temperature until completion of the reaction. The 
reaction was quenched by addition of EtOH and the solvent were removed in vacuo. The residue 
was diluted in EtOAc (40 mL) and washed with water (20 mL) and brine (20 mL). The organic 
layer was dried over MgSO4, filtered and concentrated in vacuo. The compound was purified 
by column chromatography (silica gel, cyH/EA) to provide 20 in quantitative yield (2.2 g). 
Colorless gum. Rf; 0.76 (cH/EA: 2/1). [α]D= -12.7° (c = 0.45, CHCl3). 1H NMR (250 MHz, 
CDCl3): δ = 0.06 (s, 6H, CH3), 0.89 (s, 9H, C(CH3)3), 1.34 (s, 3H, CH3), 1.48 (s, 3H, CH3), 2.67 
(dd, 1H, Jgem = 16.0, J2,3 = 4.5 Hz, H-2), 2.75 (dd, 1H, J2’,3 = 4.0, H-2’), 3.69 (s, 3H, COOCH3), 
3.64-3.75 (m, 2H, H-7, H-7’), 4.07 (t, 1H, J6,7 = 3.5 Hz, H-6), 4.50 (m, 1H, H-3), 4.75 (m, 1H, 
H-5), 4.82 (d, 1H, J4,5 = 6.0 Hz, H-4). 13C NMR (62.9 MHz, CDCl3): δ = -5.5 (Si(CH3)2), 18.2 
(C(CH3)3), 25.1 (C(CH3)2), 25.9 (C(CH3)3), 26.3 (C(CH3)2), 34.9 (C-2), 51.7 (CH3OCO), 64.9 
(C-7), 78.6, 81.9, 83.3, 84.3 (C-3, C-4, C-5, C-6), 112.3 (C(CH3)2), 171.8 (C=O). IR (film) : 
2976, 2957, 2933, 2853, 1742. ESI-HRMS: m/z calcd for C17H32O6SiNa [M+Na]+ 383.1860; 
found 383.1864. 
 
 
3,6-Anhydro-7-O-[(tert-butyldimethyl)silyl]-2-deoxy-4,5-O-(1-methylethylidene)-D-
altro-heptonic acid 21 
To a solution of 20 (500 mg, 1.39 mmol) in THF (15 mL) and water (5 mL) was added LiOH 
(100 mg, 4.17 mmol, 3 eq.) and the mixture was stirred until completion of the reaction 
monitored by tlc. THF was removed under reduced pressure, CH2Cl2 (20 mL) was added and 
the pH was adjusted to 2-3 with 1N HCl. The organic layer was washed with brine and dried 
over MgSO4, filtered and concentrated to provide 21 (312 mg, 65%). Colorless gum. Rf; 0.56 
(cH/EA: 2/1). [α]D= -21.1° (c = 0.1, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 0.06 (s, 6H, 
CH3), 0.89 (s, 9H, C(CH3)3), 1.35 (s, 3H, CH3), 1.50 (s, 3H, CH3), 2.71 (dd, 1H, Jgem = 16.0, 
J2,3 = 4.5 Hz, H-2), 2.80 (dd, 1H, J2’,3 = 4.0, H-2’), 3.69 (dd, 1H, Jgem = 11.0, J6,7 = 3.5 Hz, H-
7), 3.76 (dd, 1H, J6,7’ = 3.5 Hz, H-7’), 4.13 (t, 1H, H-6), 4.51 (m, 1H, H-3), 4.76 (m, 1H, H-5), 
4.84 (d, 1H, J4,5 = 6.0 Hz, H-4). 13C NMR (62.9 MHz, CDCl3): δ = -5.5 (SiCH3), -5.4 (SiCH3), 
18.3 (C(CH3)3), 25.0 (C(CH3)2), 26.0 (C(CH3)3), 26.2 (C(CH3)2), 34.9 (C-2), 65.0 (C-7), 78.5, 
81.9, 83.3, 84.4 (C-3, C-4, C-5, C-6), 112.6 (C(CH3)2), 176.3 (C=O). IR (film) : 2933, 2853, 
2251, 1714. ESI-HRMS: m/z calcd for C16H30O6SiNa [M+Na]+ 369.1704; found 369.1701. 
 
3,6-anhydro-7-O-[(tert-butyldimethyl)silyl]-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-
(1-methylethylidene)-D-altro-heptonamide 22 
To a stirred solution of 21 (260 mg, 0.75 mmol, 1 eq.) in CH2Cl2 (10 mL) were added 
tryptamine (132 mg, 0.83 mmol, 1.1 eq.) and EDC (159 mg, 0.83 mmol, 1.1 eq.) at 0°C under 
argon atmosphere. After stirring overnight at room temperature, the solvent was evaporated 
under reduced pressure. The residue was diluted with CH2Cl2 (20 mL) and the organic layer 
was washed with a saturated aqueous solution of NaHCO3 (10 mL), dried over MgSO4, filtered 
and the solvent was removed in vacuo. The product was purified by column chromatography 
(silica gel, cyH/EA) to provide 22 (292 mg, 80%). Colorless gum. Rf; 0.75 (CH2Cl2/MeOH 
9/1). [α]D= -0.1 (c = 0.34, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 0.04 (s, 6H, CH3), 0.88 (s, 
9H, C(CH3)3), 1.30 (s, 3H, CH3), 1.45 (s, 3H, CH3), 2.53 (d, 2H, J2,3 = 6.5 Hz, H-2, H-2’), 2.98 
(t, 2H, J = 7.0 Hz, H-β), 3.53-3.69 (m, 4H, H-7, H-7’, H-α), 4.03 (t, 1H, J6,7 = 4.0 Hz, H-6), 
4.38 (m, 1H, H-3), 4.63 (m, 1H, H-5), 4.77 (d, 1H, J4,5 = 6.0 Hz, H-4), 6.24 (t, 1H, J = 5.0 Hz, 
CONH), 7.06-7.24 (m, 3H, H-Ar), 7.37 (d, 1H, H-Ar), 7.62 (d, 1H, H-Ar), 8.03 (br s, 1H, NH). 
13C NMR (62.9 MHz, CDCl3): δ = -5.5 (SiCH3), -5.4 (SiCH3), 18.3 (C(CH3)3), 24.9 (C(CH3)2), 
25.4 (C-β), 26.0 (C(CH3)3), 26.3 (C(CH3)2), 37.6 (C-2), 39.9 (C-α), 64.4 (C-7), 79.0, 82.1, 83.1, 
84.5 (C-3, C-4, C-5, C-6), 111.3 (C(CH3)2), 112.3, 113.2, 118.9, 119.5, 122.1, 122.2, 127.5, 
136.5 (8 C-Ar), 170.9(C=O). IR (film) : 3327, 2947, 2933, 2862, 1650. ESI-HRMS: m/z calcd 
for C26H40N2O5SiNa [M+Na]+ 551.2599; found 551.2549. 
 
3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-D-altro-
heptonamide 23 
To a solution of 22 (248 mg, 0.51 mmol, 1 eq.) in dry THF (3 mL) was added dropwise TBAF 
(1M in THF) (0.77 mL, 0.77 mmol, 1.5 eq.) at 0°C and the reaction mixture was stirred 
overnight under argon atmosphere. Water (5 mL) was added and the aqueous layer was 
extracted with EtOAc (2x15 mL). The combined organic layers were washed with brine (10 
mL), dried over MgSO4, filtered and the solvent was removed in vacuo. The product was 
purified by flash chromatography (silica gel, cyH/EA) to provide 23 (181 mg, 95%). Colorless 
gum. Rf; 0.61 (CH2Cl2/MeOH 9/1). [α]D= -6.3 (c = 0.09, CHCl3). 1H NMR (250 MHz, CDCl3): 
δ = 1.27 (s, 3H, CH3), 1.44 (s, 3H, CH3), 2.40 (br s, 1H, OH), 2.53 (d, 2H, J2,3 = 6.5 Hz, H-2, 
H-2’), 2.97 (t, 2H, J = 6.5 Hz, H-β), 3.51 (d, 2H, J6,7 = 5.5 Hz, H-7, H-7’), 3.56-3.66 (m, 2H, 
H-α), 4.06 (t, 1H, H-6), 4.30 (m, 1H, H-3), 4.55-4.63 (m, 2H, H-5, H-4), 6.19 (t, 1H, J = 5.0 
Hz, CONH), 7.04-7.23 (m, 3H, H-Ar), 7.37 (d, 1H, H-Ar), 7.60 (d, 1H, H-Ar), 8.36 (br s, 1H, 
NH). 13C NMR (62.9 MHz, CDCl3): δ = 24.9 (C(CH3)2), 25.2 (C-β), 26.3 (C(CH3)2), 37.1 (C-
2), 39.9 (C-α), 62.3 (C-7), 77.7, 81.8, 82.6, 84.7 (C-3, C-4, C-5, C-6), 111.4 (C(CH3)2), 112.6, 
112.9, 118.8, 119.5, 122.2, 122.4, 127.5, 136.5 (8 C-Ar), 171.1(C=O). IR (film) : 3336, 2985, 
2943, 2876, 1650. ESI-HRMS: m/z calcd for C20H26N2O5Na [M+Na]+ 397.1734; found 
397.1731. 
 
3,6-Anhydro-2-deoxy-N-[2-(1H-indol-3-yl)ethyl]-7-(4-methylbenzenesulfonate)-4,5-O-
(1-methylethylidene)-D-altro-heptonamide 24 
Prepared starting from 23 (160 mg, 0.43 mmol) following procedure described for 8. Yield: 
87% (197 mg). White solid. Rf; 0.67 (EA). [α]D= +10.7 (c = 1.0, CHCl3). Mp = 64°C. 1H NMR 
(250 MHz, CDCl3): δ = 1.22 (s, 3H, CH3), 1.42 (s, 3H, CH3), 2.48 (s, 3H, Ph-CH3), 2.46-2.52 
(m, 2H, H-2), 3.02 (t, 2H, Jα,β = 6.5 Hz, H-β), 3.60-3.68 (m, 2H, H-α), 3.92 (dd, 1H, J6,7 = 4.5, 
Jgem = 11.0 Hz, H-7), 4.03 (dd, 1H, J6,7’ = 5.0 Hz, H-7’), 4.13-4.23 (m, 2H, H-6, H-3), 4.45 (dd, 
1H, J4,5 = 6.0, J5,6 = 4.0 Hz, H-5), 4.60 (d, 1H, H-4), 6.11 (t, 1H, J = 5.5 Hz, CONH), 7.09-7.44 
(m, 6H, H-Ar), 7.63 (d, 1H, J = 8.0 Hz, H-Ar), 7.81 (d, 2H, J = 8.5 Hz, H-Ar), 8.33 (s, 1H, NH-
Ar). 13C NMR (62.9 MHz, CDCl3): δ = 21.7 (CH3-Ph), 24.7 (CH3), 25.0 (CH3), 26.1 (C-β), 37.2 
(C-2), 39.5 (C-α), 69.5 (C-7), 78.8 (C-3), 81.4 (C-6, C-4), 82.3 (C-5), 111.3 (C(CH3)2), 112.8 
(C-Ar), 112.9 (C-Ar), 118.7 (C-Ar), 119.4 (C-Ar), 122.1 (C-Ar), 122.3 (C-Ar), 127.4 (C-Ar), 
127.9 (2 C-Ar), 130.1 (2 C-Ar), 132.2 (C-Ar), 136.4 (C-Ar), 145.4 (C-Ar), 170.1 (C=O). IR 
(film) : 3407, 3308, 1652. ESI-HRMS: m/z calcd for C27H32N2O7SNa [M+Na]+ 551.1822; 
found 551.1853. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[2-
[[(phenylmethoxy)carbonyl]amino]ethyl]amino]-D-altro-heptonamide 25 
Prepared starting from 24 (170 mg, 0.32 mmol) following procedure described for 9. Yield: 
82% (144 mg). Colorless gum. Rf; 0.35 (CH2Cl2/MeOH 9/1). [α]D= +3.5 (c = 0.5, CHCl3). 1H 
NMR (400 MHz, CDCl3): δ = 1.28 (s, 3H, C(CH3)2), 1.45 (s, 3H, C(CH3)2), 2.07 (br s, 1H, 
NH), 2.47 (dd, 1H, Jgem = 12.5, J6,7 = 5.0 Hz, H-7), 2.53-2.59 (m, 3H, 2 H-2, H-7), 2.71 (t, 2H, 
J8,9 = 6.0 Hz, H-8), 2.97 (t, 2H, Jα,β = 6.5 Hz, H-β), 3.23-3.27 (m, 2H, H-9), 3.58-3.64 (m, 2H, 
H-α), 4.09 (m, 1H, H-6), 4.14 (m, 1H, H-3), 4.47 (d, 1H, J4,5 = 6.0 Hz, H-5), 4.56 (dd, 1H, J3,4 
= 4.0 Hz, H-4), 5.12 (s, 2H, CH2-Ph), 5.39 (t, 1H, J = 5.0 Hz, CONH), 6.12 (t, 1H, J = 5.0 Hz, 
CONH), 7.05 (d, 1H, J = 2.0 Hz, H-Ar), 7.13 (m, 1H, H-Ar), 7.21 (m, 1H, H-Ar), 7.32-7.39 (m, 
6H, H-Ar), 7.61 (d, 1H, J = 8.0 Hz, H-Ar), 8.52 (br s, 1H, NH). 13C NMR (100 MHz, CDCl3): 
δ = 24.9 (C(CH3)2), 25.1 (C-β), 26.2 (C(CH3)2), 36.6 (C-2), 39.7 (C-α), 40.3 (C-9), 48.3 (C-7), 
48.6 (C-8), 66.7 (CH2-Ph), 76.5 (C-3), 81.3 (C-4), 82.9 (C-6), 83.7 (C-5), 111.3 (C-Ar), 112.6 
(C(CH3)2), 112.9 (C-Ar), 118.7 (C-Ar), 119.4 (C-Ar), 122.1 (C-Ar), 122.2 (C-Ar), 127.4 (C-
Ar), 128.1 (C-Ar), 128.2 (2 C-Ar), 128.5 (2 C-Ar), 136.4 (C-Ar), 136.6 (C-Ar), 156.7 
(OCONH), 170.5 (CONH). IR (film) : 3327, 1709, 1650. ESI-HRMS: m/z calcd for 
C30H38N4O6Na [M+Na]+ 573.2684; found 573.2707. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[[N-
[bis[(phenylmethoxy)carbonyl]]aminoiminomethyl]-N-[2-
[bis[(phenylmethoxy)carbonyl]]guanidinoethyl]amino]-D-altro-heptonamide 26  
Prepared starting from 25 (120 mg, 0.22 mmol) following procedure described for 12. Yield: 
30% (68 mg). White solid. Rf; 0.50 (EA). [α]D= +11.4 (c = 0.5, CHCl3). Mp = 70°C. 1H NMR 
(400 MHz, MeOH-d4): δ = 1.23 (s, 3H, C(CH3)2), 1.39 (s, 3H, C(CH3)2), 2.47 (dd, 1H, Jgem = 
15.5, J2,3 = 5.5 Hz, H-2), 2.56 (dd, 1H, J2’,3 = 8.0 Hz, H-2’), 2.90 (t, 2H, Jα,β = 6.5 Hz, H-β), 
3.44-3.72 (m, 8H, 2 H-α, 2 H-7, 2 H-8, 2 H-9), 4.25-4.29 (m, 2H, H-6, H-3), 4.43 (d, 1H, J4,5 = 
6.0 Hz, H-5), 4.51 (dd, 1H, J3,4 = 3.5 Hz, H-4), 5.00-5.01 (m, 6H, CH2-Ph), 5.08 (s, 2H, CH2-
Ph), 6.96-7.08 (m, 3H, H-Ar), 7.19-7.36 (m, 21H, H-Ar), 7.54 (d, 1H, J = 8.0 Hz, H-Ar). 13C 
NMR (100 MHz, MeOH-d4): δ = 25.1 (C(CH3)2), 26.1 (C-β), 26.6 (C(CH3)2), 36.9 (C-2), 39.7 
(C-7), 41.3 (C-α), 48.8 (C-8), 68.3 (CH2-Ph), 68.8 (CH2-Ph), 69.2 (2 CH2-Ph), 78.0 (C-3, C-6), 
82.6 (C-4), 84.5 (C-5), 112.3 (C-Ar), 113.3 (C-Ar), 113.6 (C(CH3)2), 119.4 (C-Ar), 119.6 (C-
Ar), 122.3 (C-Ar), 123.5 (C-Ar), 128.8 (C-Ar), 129.0 (2 C-Ar), 129.2 (8 C-Ar), 129.4 (4 C-Ar), 
129.5 (4 C-Ar), 129.6 (4 C-Ar), 136.4 (C-Ar), 138.1 (2 C-Ar), 154.4 (2 C-gua), 157.7 (2 
OCONH), 164.7 (2 OCONH), 172.8 (CONH). IR (film) : 3327, 1742, 1636, 1619. ESI-
HRMS: m/z calcd for C56H60N8O12Na [M+Na]+ 1059.4223; found 1059.4244. 
 
3,6-anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[N-
(aminoiminomethyl)-N-(2-guanidinoethyl)amino]-D-altro-heptonamide 27  
Prepared starting from 26 (50 mg, 0.05 mmol) following procedure described for the 
synthesis of 15. Yield: 90% (20 mg). White solid. Rf; 0.29 (H2O/MeCN/TFA: 6/4/0.1%). HPLC 
(60/40): tR = 4.740 min. [α]D= +23.0 (c = 0.2, MeOH). 1H NMR (250 MHz, MeOH-d4): δ = 
1.33 (s, 3H, C(CH3)2), 1.48 (s, 3H, C(CH3)2), 2.52-2.66 (m, 2H, H-2), 2.97 (t, 2H, Jα,β = 7.0 Hz, 
H-β), 3.38-3.62 (m, 8H, H-α, H-7, H-8, H-9), 4.24 (m, 1H, H-6), 4.39 (m, 1H, H-3), 4.60 (d, 
1H, J4,5 = 6.0 Hz, H-5), 4.72 (dd, 1H, J3,4 = 4.0 Hz, H-4), 6.99-7.14 (m, 3H, H-Ar), 7.36 (d, 1H, 
J = 8.0 Hz, H-Ar), 7.59 (d, 1H, J = 8.0 Hz, H-Ar). 13C NMR (62.9 MHz, MeOH-d4): δ = 25.1 
(C(CH3)2), 26.2 (C-β), 26.6 (C(CH3)2), 36.7 (C-2), 40.2 (C-α), 41.6 (C-7), 49.7, 49.8 (C-8, C-
9), 78.0 (C-3), 82.7, 84.0, 84.5 (C-4, C-5, C-6), 112.3 (C-Ar), 113.3 (C(CH3)2), 113.9 (C-Ar), 
119.3 (C-Ar), 119.6 (C-Ar), 122.3 (C-Ar), 123.5 (C-Ar), 128.8 (C-Ar), 138.1 (C-Ar), 159.2, 
159.7 (2 C=N), 172.9 (CONH). IR (film) : 3374, 3189, 1674, 1607. ESI-HRMS: m/z calcd for 
C24H36N8O4Na [M+Na]+ 523.2752; found 523.2762. 
 
N,N’-[Bis(phenylmethoxy)carbonyl]-N’’-(but-3-ynyl)-guanidine 28 
To a cooled solution of butyn-4-ol (151 µL, 2.0 mmol, 1 eq.), N,N’-
bis(benzyloxycarbonyl)guanidine (650 mg, 2.0 mmol, 1 eq.) and PPh3 (630 mg, 2.4 mmol, 1.2 
eq.) in dry toluene (10 mL), was added dropwise over 5 minutes a solution of 
diethylazodicarboxylate (DEAD, 378 µL, 2.4 mmol, 1.2 eq.) in toluene (5 mL) under argon 
atmosphere. The mixture was stirred at room temperature for 4h and the solvent was removed 
in vacuo. The crude was purified by flash chromatography (silica gel, cyH/EA) to provide 28 
(700 mg, 92%). Colorless oil. Rf; 0.68 (cH/EA: 8/2). 1H NMR (250 MHz, CDCl3): δ = 1.92 (t, 
1H, J = 2.0 Hz, C≡C-H), 2.57 (td, 2H, J = 7.0 Hz, CH2), 4.22 (t, 2H, CH2), 5.18 (s, 2H, CH2-
Ph), 5.28 (s, 2H, CH2-Ph), 7.32-7.45 (m, 10H, 10 H-Ar), 9.29 (br s, 1H, NH), 9.47 (br s, 1H, 
NH). 13C NMR (62.9 MHz, CDCl3): δ = 17.5 (CH2), 41.8 (CH2), 66.0 (C≡C-H), 67.9, 69.0 (2 
CH2-Ph), 79.7 (C≡C-H), 126.8 (C-Ar), 126.9 (2 C-Ar), 127.3 (4 C-Ar), 127.7 (3 C-Ar), 133.5 
(C-Ar), 135.9 (C-Ar), 154.7 (C=N), 159.1 (C=O), 162.7 (C=O). IR (film) : 3388, 3289, 3033, 
2947, 1718, 1645, 1610, 1508. ESI-HRMS: m/z calcd for C21H22N3O4 [M+H]+ 380.1616; found 
380.1594. 
 
N,N’-[Bis(phenylmethoxy)carbonyl]-N’’-(pent-4-ynyl)-guanidine 29 
Prepared starting from pentyn-5-ol (185 µL, 2.0 mmol) following procedure described for 
28. Yield: 89% (700 mg). Colorless oil. Rf; 0.75 (cH/EA: 8/2). 1H NMR (250 MHz, CDCl3): δ 
= 1.78-1.90 (m, 3H, CH2, C≡C-H), 2.19 (td, 2H, J = 7.0, J = 7.0 Hz, CH2), 4.10 (t, 2H, CH2), 
5.16 (s, 2H, CH2-Ph), 5.25 (s, 2H, CH2-Ph), 7.28-7.42 (m, 10H, 10 H-Ar), 9.28 (br s, 1H, NH), 
9.44 (br s, 1H, NH). 13C NMR (62.9 MHz, CDCl3): δ = 14.9 (CH2), 26.4 (CH2), 43.0 (CH2), 
66.0 (C≡C-H), 67.5, 67.9 (2 CH2-Ph), 82.4 (C≡C-H), 126.7 (C-Ar), 126.8 (2 C-Ar), 127.3 (4 
C-Ar), 127.6 (2 C-Ar), 127.7 (C-Ar), 133.6 (C-Ar), 135.9 (C-Ar), 154.8 (C=N), 159.5 (C=O), 
162.8 (C=O). IR (film) : 3393, 3289, 3033, 2952, 1716, 1645, 1610, 1511. ESI-HRMS: m/z 
calcd for C22H24N3O4 [M+H]+ 394.1777; found 394.1776. 
 
3,6-Anhydro-7-azido-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-
methylethylidene)-L-galacto-heptonamide 30  
To a solution of 8 (1.0 g, 1.9 mmol) in DMF (10 mL) was added sodium azide (1.0 g, 15.2 
mmol, 8 eq.) and the mixture was stirred for 2 days at 80°C. The solvent was removed in vacuo 
and the residue was diluted with EtOAc (50 mL) and washed with H2O (20 mL) and brine (20 
mL). The organic layer was dried over MgSO4, filtered and the solvent was evaporated under 
reduced pressure. The compound was purified by flash chromatography (silica gel, cyH/EA) to 
provide 30 (667 mg, 88%). Colorless gum. Rf; 0.49 (CH2Cl2/MeOH: 9/1). [α]D= +9.7° (c = 0.4, 
CHCl3). 1H NMR (250 MHz, CDCl3): δ = 1.27 (s, 3H, C(CH3)), 1.42 (s, 3H, C(CH3)), 2.57 (d, 
2H, J2,3 = 6.5 Hz, H-2), 2.99 (t, 2H, Jα,β = 6.5 Hz, H-β), 3.44 (dd, 2H, Jgem = 7.5, J6,7 = 3.0 Hz, 
H-7), 3.52-3.70 (m, 3H, H-6, H-α), 3.86 (td, 1H, J3,4= 2.5 Hz, H-3), 4.59-4.66 (m, 2H, H-4, H-
5), 6.04 (t, 1H, J = 5.0 Hz, CONH), 7.05-7.24 (m, 3H, H-Ar), 7.38 (d, 1H, J = 8.0, H-Ar), 7.62 
(d, 1H, J = 8.0 Hz, H-Ar), 8.11 (s, 1H, NH-Ar). 13C NMR (62.9 MHz, CDCl3): δ = 24.7 (CH3), 
25.2 (CH3), 25.9 (C-β), 36.3 (C-2), 40.0 (C-α), 49.6 (C-7), 78.4 (C-3), 80.0 (C-6), 80.7 (C-4), 
81.5 (C-5), 111.4 (C(CH3)2), 112.8 (C-Ar), 113.0 (C-Ar), 118.8 (C-Ar), 119.5 (C-Ar), 122.2 
(C-Ar), 122.3 (C-Ar), 127.6 (C-Ar), 136.5 (C-Ar), 170.4 (C=O). IR (film) : 2099, 1655. ESI-
HRMS: m/z calcd for C20H25N5O4Na [M+Na]+ 422.1799; found 422.1821. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-
[2-[N-[bis(phenylmethoxy)carbonyl]]guanidinoethyl]-1H-1,2,3-triazol-1-yl]-L-galacto-
heptonamide 31 
To a solution of 30 (300 mg, 0.75 mmol, 1 eq.) and 28 (284 mg, 0.75 mmol, 1 eq.) in CH2Cl2 
(4 mL) were added H2O (4 mL), CuSO4,5H2O (8 mg, 0.04 mmol, 0.05 eq.) and sodium 
ascorbate (15 mg, 0.075 mmol, 0.1 eq.). After completion of the reaction, the solution mixture 
was diluted with water and CH2Cl2 (20 mL) and the layers were separated. The aqueous layer 
was washed with CH2Cl2 (2x20 mL) and the combined organic layers were dried over MgSO4, 
filtered and the solvent was removed under reduced pressure. The compound was purified by 
column chromatography (silica gel, cyH/EA) to provide 31 (466 mg, 80%). White solid. Rf; 
0.46 (EA). [α]D= -3.5° (c = 0.2, CHCl3). Mp = 72°C. 1H NMR (250 MHz, MeOH d4): δ = 1.29 
(s, 3H, C(CH3)), 1.47 (s, 3H, C(CH3)), 2.53-2.58 (m, 2H, H-2), 2.86-2.93 (m, 2H, H-8), 2.89 (t, 
2H, Jα,β = 7.5 Hz, H-β), 3.38-3.50 (m, 2H, H-α), 3.78 (m, 1H, H-6), 3.85 (m, 1H, H-3), 4.11-
4.19 (m, 2H, H-10), 4.39 (dd, 1H, Jgem = 14.0, J6,7 = 8.0 Hz, H-7), 4.57 (dd, 1H, J6,7’ = 4.0 
Hz, H-7’), 4.61-4.69 (m, 2H, H-4, H-5), 5.10 (s, 2H, CH2-Ph), 5.11 (s, 2H, CH2-Ph), 6.94-7.08 
(m, 3H, H-Ar), 7.23-7.39 (m, 11H, H-Ar), 7.53 (d, 1H, J = 8.0 Hz, H-Ar), 7.59 (s, 1H, H-
triazole). 13C NMR (62.9 MHz, MeOH d4): δ = 24.9 (CH3), 25.8 (C-8), 26.2, 26.3 (CH3, C-β), 
36.6 (C-2), 41.5 (C-α), 45.4 (C-9), 50.5 (C-7), 68.3 (CH2-Ph), 69.9 (CH2-Ph), 79.7 (C-3), 80.7 
(C-6), 82.2, 82.9 (C-4, C-5), 112.3 (C-Ar), 113.2 (C-Ar), 113.8 (C(CH3)2), 119.3 (C-Ar), 119.6 
(C-Ar), 122.3 (C-Ar), 123.5 (C-Ar), 128.8 (C-Ar), 128.9 (4 C-Ar), 129.5 (5 C-Ar), 129.6 (C-
Ar), 129.7 (2 C-Ar), 136.5 (C-Ar), 138.1 (C-Ar), 138.5 (C-Ar), 156.7 (NHCOO), 161.7 (C=N), 
164.9 (NHCOO), 172.9 (C=O). IR (film) : 1721, 1648, 1612. ESI-HRMS: m/z calcd for 
C41H46N8O8Na [M+Na]+ 801.3331; found 801.3316. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-
[3-[N-[bis(phenylmethoxy)carbonyl]]guanidinopropyl]-1H-1,2,3-triazol-1-yl]-L-galacto-
heptonamide 32 
Prepared starting from 30 (300 mg, 0.75 mmol) following procedure described for 31. Yield: 
70% (415 mg). White solid. Rf; 0.43 (EA). [α]D= -5.5° (c = 0.2, CHCl3). Mp = 62°C. 1H NMR 
(400 MHz, MeOH d4): δ = 1.28 (s, 3H, C(CH3)), 1.46 (s, 3H, C(CH3)), 1.83-1.90 (m, 2H, H-9), 
2.51 (dd, 1H, Jgem = 15.0, J2,3 = 5.5 Hz, H-2), 2.51-2.61 (m, 3H, H-8, H-2’), 2.87 (t, 2H, Jα,β = 
7.0 Hz, H-β), 3.35-3.49 (m, 2H, H-α), 3.77-3.85 (m, 2H, H-3, H-6), 3.88-3.92 (m, 2H, H-10), 
4.38 (dd, 1H, Jgem = 14.5 , J6,7 = 8.5 Hz, H-7), 4.53 (dd, 1H, J6,7’ = 4.0 Hz, H-7’), 4.60-4.64 (m, 
2H, H-4, H-5), 5.08 (d, 1H, J = 12.0 Hz, CH2-Ph), 5.09 (d, 1H, CH2-Ph), 5.17 (s, 2H, CH2-Ph), 
6.95-7.08 (m, 3H, H-Ar), 7.24-7.37 (m, 11H, H-Ar), 7.53 (d, 1H, J = 8.0 Hz, H-Ar), 7.69 (s, 
1H, H-triazole). 13C NMR (100 MHz, MeOH d4): δ = 23.4 (C-8), 24.8 (CH3), 26.2 (CH3, C-β), 
28.9 (C-9), 36.6 (C-2), 41.5 (C-α), 45.4 (C-10), 50.4 (C-7), 68.2 (CH2-Ph), 69.9 (CH2-Ph), 79.7 
(C-3), 80.7 (C-6), 82.2, 82.9 (C-4, C-5), 112.3 (C-Ar), 113.2 (C-Ar), 113.8 (C(CH3)2), 119.3 
(C-Ar), 119.6 (C-Ar), 122.3 (C-Ar), 123.5 (C-Ar), 124.0 (C-Ar), 128.8 (C-Ar), 128.9 (3 C-Ar), 
129.4 (2 C-Ar), 129.5 (2 C-Ar), 129.7 (3 C-Ar), 136.5 (C-Ar), 138.1 (C-Ar), 138.5 (C-Ar), 
148.2 (C-Ar), 156.8 (NHCOO), 161.9 (C=N), 165.0 (NHCOO), 172.9 (C=O). IR (film) : 3388, 
3279, 1723, 1648, 1610. ESI-HRMS: m/z calcd for C42H48N8O8Na [M+Na]+ 815.3487; found 
815.3480. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-
(2-guanidinoethyl)-1H-1,2,3-triazol-1-yl]-L-galacto-heptonamide 33 
Prepared starting from 31 (150 mg, 0.19 mmol) following procedure described for 15. Yield: 
90% (87 mg). White solid. Rf; 0.0 (EA). HPLC (60/40): tR = 5.401 min. [α]D= -11.9° (c = 0.2, 
MeOH). Mp = 138°C. 1H NMR (400 MHz, MeOH-d4): δ = 1.32 (s, 3H, C(CH3)), 1.50 (s, 3H, 
C(CH3)), 2.55-2.65 (m, 2H, H-2), 2.89-2.94 (m, 4H, H-8, H-β), 3.41-3.49 (m, 4H, H-9, H-α), 
3.87-3.93 (m, 2H, H-3, H-6), 4.53 (dd, 1H, Jgem = 14.0, J6,7 = 8.5 Hz, H-7), 4.66-4.77 (m, 3H, 
H-7’, H-4, H-5), 6.99-7.11 (m, 3H, H-Ar), 7.35 (d, 1H, J = 8.0 Hz, H-Ar), 7.57 (d, 1H, J = 8.0 
Hz, H-Ar), 7.80 (s, 1H, H-triazole). 13C NMR (100 MHz, MeOH-d4): δ = 24.9 (CH3), 26.1 (C-
8), 26.2 (CH3, C-β), 36.5 (C-2), 41.5 (C-α), 41.9 (C-9), 50.6 (C-7), 79.7 (C-3), 80.7 (C-6), 82.2, 
82.9 (C-4, C-5), 112.3 (C-Ar), 113.2 (C-Ar), 113.8 (C(CH3)2), 119.3 (C-Ar), 119.6 (C-Ar), 
122.3 (C-Ar), 123.5 (C-Ar), 124.8 (C-Ar), 128.8 (C-Ar), 138.1 (C-Ar), 145.3 (C-Ar), 158.9 
(C=N), 172.9 (C=O). IR (pellets) : 3327, 1652. ESI-HRMS: m/z calcd for C25H34N8O4Na 
[M+Na]+ 533.2595; found 533.2597. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-4,5-O-(1-methylethylidene)-7-[4-
(3-guanidinopropyl)-1H-1,2,3-triazol-1-yl]-L-galacto-heptonamide 34 
Prepared starting from 32 (150 mg, 0.19 mmol) following procedure described for 15. Yield: 
90% (90 mg). White solid. Rf; 0.0 (EA). HPLC (60/40): tR = 5.587 min. [α]D= -11.6° (c = 0.2, 
MeOH). Mp = 132°C. 1H NMR (250 MHz, MeOH-d4): δ = 1.32 (s, 3H, C(CH3)), 1.49 (s, 3H, 
C(CH3)), 1.83-1.89 (m, 2H, H-9), 2.56-2.61 (m, 2H, H-2), 2.68 (t, 2H, J8,9 = 8.0 Hz, H-8), 2.91 
(t, 2H, Jα,β = 7.5 Hz, H-β), 3.11 (t, 2H, J9,10 = 7.0 Hz, H-10), 3.43-3.49 (m, 2H, H-α), 3.86-3.95 
(m, 2H, H-3, H-6), 4.51 (dd, 1H, Jgem = 14.5 , J6,7 = 8.5 Hz, H-7), 4.68 (m, 1H, H-7’), 4.73-4.80 
(m, 2H, H-4, H-5), 6.96-7.11 (m, 3H, H-Ar), 7.33 (d, 1H, J = 8.0 Hz, H-Ar), 7.55 (d, 1H, J = 
8.0 Hz, H-Ar), 7.73 (s, 1H, H-triazole). 13C NMR (62.9 MHz, MeOH-d4): δ = 23.2 (C-8), 24.9 
(CH3), 26.2 (CH3, C-β), 29.6 (C-9), 36.6 (C-2), 41.5 (C-α), 41.7 (C-10), 50.6 (C-7), 79.8 (C-3), 
80.8 (C-6), 82.3, 83.0 (C-4, C-5), 112.3 (C-Ar), 113.3 (C-Ar), 113.9 (C(CH3)2), 119.3 (C-Ar), 
119.7 (C-Ar), 122.4 (C-Ar), 123.6 (C-Ar), 124.2 (C-Ar), 128.8 (C-Ar), 138.2 (C-Ar), 147.8 (C-
Ar), 159.0 (C=N), 173.0 (C=O). IR (pellets) : 3355, 1650. ESI-HRMS: m/z calcd for 
C26H36N8O4Na [M+Na]+ 547.2752; found 547.2752. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-7-[4-[2-[N-
[bis(phenylmethoxy)carbonyl]]guanidinoethyl]-1H-1,2,3-triazol-1-yl]-L-galacto-
heptonamide 35 
To a stirred solution of 31 (250 mg, 0.32 mmol) in H2O (2 ml) at 0°C was added trifluoroacetic 
acid (2 ml). After completion of the reaction (tlc monitoring), the solution mixture was diluted 
with EtOAc (50 mL) and NaHCO3 sat. aq. was added until pH 5-6. The product was extracted 
with EtOAc (2x15 ml) and the combined organic layers were dried over MgSO4, filtered and 
the solvent was removed under reduced pressure. The compound was purified by column 
chromatography (silica gel, EA/MeOH) to provide 35 (200 mg, 85%). Colorless gum. Rf; 0.23 
(EA/MeOH: 9/1). [α]D= -5.8° (c = 0.1, MeOH). 1H NMR (250 MHz, MeOH-d4): δ = 2.46-2.58 
(m, 2H, H-2), 2.89 (t, 4H, H-8, H-β), 3.46 (t, 2H, Jα,β = 7.0 Hz, H-α), 4.01-4.18 (m, 5H, H-4, 
H-5, H-6, H-9), 4.30 (t, 1H, J2,3 = 5.5 Hz, H-3), 4.41 (dd, 1H, Jgem = 14.5, J6,7 = 9.0 Hz, H-7), 
4.56 (dd, 1H, J6,7’ = 3.5 Hz, H-7’), 5.08 (s, 3H, CH2-Ph), 5.11 (s, 3H, CH2-Ph), 6.92-7.08 (m, 
3H, H-Ar), 7.25-7.37 (m, 11H, H-Ar), 7.52 (d, 1H, J = 8.0 Hz, H-Ar), 7.58 (s, 1H, H-triazole). 
13C NMR (62.9 MHz, MeOH-d4): δ = 25.8, 26.3 (C-8, C-β), 38.4 (C-2), 41.5 (C-α), 45.4 (C-9), 
52.7 (C-7), 68.4, 69.9 (CH2-Ph), 73.3 (C-4, C-5), 79.0 (C-3), 79.9 (C-6), 112.3 (C-Ar), 113.2 
(C-Ar), 119.3 (C-Ar), 119.6 (C-Ar), 122.3 (C-Ar), 123.4 (C-Ar), 124.6 (C-Ar), 128.9 (4 C-Ar), 
129.4 (4 C-Ar), 129.7 (4 C-Ar), 136.4 (C-Ar), 138.1 (C-Ar), 138.5 (C-Ar), 156.7 (C=N), 161.7 
(2 NHCOO), 162.9, 163.2 (TFA), 173.9 (C=O). IR (pellets) : 3325, 1665, 1632. ESI-HRMS: 
m/z calcd for C38H42N8O8Na [M+Na]+ 761.3018; found 761.3011. 
 
3,6-Anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-7-[4-[3-[N-
[bis(phenylmethoxy)carbonyl]]guanidinopropyl]-1H-1,2,3-triazol-1-yl]-L-galacto-
heptonamide 36 
Prepared starting from 32 (250 mg, 0.32 mmol) following procedure described for 35. Yield: 
53% (127 mg). Colorless gum. Rf; 0.34 (EA/MeOH: 9/1). [α]D= -2.0° (c = 0.2, MeOH). 1H 
NMR (250 MHz, MeOH-d4): δ = 1.82-1.93 (m, 2H, H-9), 2.47-2.61 (m, 4H, H-2, H-8), 2.85-
2.90 (m, 2H, H-β), 3.44 (t, 2H, Jα,β = 7.0 Hz, H-α), 3.89 (t, 2H, J9,10 = 7.5 Hz, H-10), 4.04-4.15 
(m, 3H, H-4, H-5, H-6), 4.29 (t, 1H, J2,3 = 5.5 Hz, H-3), 4.42 (dd, 1H, Jgem = 14.5, J6,7 = 9.0 
Hz, H-7), 4.54 (dd, 1H, J6,7’ = 3.5 Hz, H-7’), 5.11 (s, 2H, CH2-Ph), 5.18 (s, 2H, CH2-Ph), 6.92-
7.07 (m, 3H, H-Ar), 7.25-7.38 (m, 11H, H-Ar), 7.52 (d, 1H, J = 8.0 Hz, H-Ar), 7.69 (s, 1H, H-
triazole). 13C NMR (62.9 MHz, MeOH-d4): δ = 23.3 (C-9), 26.3, 28.7 (C-8, C-β), 38.5 (C-2), 
41.5 (C-α), 45.8 (C-10), 52.7 (C-7), 68.5, 70.1 (CH2-Ph), 73.3 (C-4, C-5), 79.0 (C-3), 79.9 (C-
6), 112.2 (C-Ar), 113.2 (C-Ar), 119.3 (C-Ar), 119.6 (C-Ar), 122.3 (C-Ar), 123.5 (C-Ar), 124.2 
(C-Ar), 128.7 (C-Ar), 129.0 (3 C-Ar), 129.4 (2 C-Ar), 129.5 (2 C-Ar), 129.7 (4 C-Ar), 136.4 
(C-Ar), 138.1 (C-Ar), 138.2 (C-Ar), 156.5 (C=N), 161.4 (2 NHCOO), 163.0 (TFA), 173.9 
(C=O). IR (pellets) : 3368, 1668, 1645. ESI-HRMS: m/z calcd for C39H44N8O8Na [M+Na]+ 
775.3174; found 775.3172. 
 
3,6-anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-7-[4-(3-guanidinoethyl)-1H-1,2,3-
triazol-1-yl]-L-galacto-heptonamide 37 
Prepared starting from 35 (150 mg, 0.2 mmol) following procedure described for 15. Yield: 
80% (75 mg). Colorless gum. Rf; 0.58 (H2O/MeCN/TFA: 4/6/0.1%). HPLC (60/40): tR = 3.678 
min. [α]D= -9.0° (c = 0.1, MeOH). 1H NMR (250 MHz, MeOH-d4): δ = 2.56-2.61 (m, 2H, H-
2), 2.85-2.96 (m, 4H, H-8, H-β), 3.40-3.51 (m, 4H, H-α, H-9), 4.11-4.19 (m, 3H, H-4, H-5, H-
6), 4.37 (t, 1H, J2,3 = 5.5 Hz, H-3), 4.52 (dd, 1H, Jgem = 14.0, J6,7 = 9.0 Hz, H-7), 4.65 (dd, 1H, 
J6,7’ = 3.0 Hz, H-7’), 6.96-7.11 (m, 3H, H-Ar), 7.32 (d, 1H, J = 8.0 Hz, H-Ar), 7.55 (d, 1H, J = 
8.0 Hz, H-Ar), 7.77 (s, 1H, H-triazole). 13C NMR (62.9 MHz, MeOH-d4): δ = 24.9, 25.1 (C-8, 
C-β), 37.3 (C-2), 40.4 (C-α), 40.7 (C-9), 51.7 (C-7), 72.2 (C-4, C-5), 78.0 (C-3), 78.8 (C-6), 
111.1 (C-Ar), 112.1 (C-Ar), 118.1 (C-Ar), 118.4 (C-Ar), 121.2 (C-Ar), 122.3 (2 C-Ar), 123.9 
(C-Ar), 127.6 (C-Ar), 137.0 (C-Ar), 157.5 (C=N), 172.7 (C=O). IR (pellets) : 3339, 3210, 
2657, 2922, 1665, 1649. ESI-HRMS: m/z calcd for C22H30N8O4Na [M+Na]+ 493.2282; found 
493.2274. 
 
3,6-anhydro-2,7-dideoxy-N-[2-(1H-indol-3-yl)ethyl]-7-[4-(3-guanidinopropyl)-1H-
1,2,3-triazol-1-yl]-L-galacto-heptonamide 38 
Prepared starting from 36 (100 mg, 0.13 mmol) following procedure described for 15. Yield: 
95% (60 mg). Colorless gum. Rf; 0.34 (H2O/MeCN/TFA: 6/4/0.1%). HPLC (60/40): tR = 3.692 
min. [α]D= -6.5° (c = 0.2, MeOH). 1H NMR (250 MHz, D2O): δ = 1.63-1.75 (m, 2H, H-9), 2.38-
2.59 (m, 4H, H-2, H-8), 2.81-2.94 (m, 4H, H-10, H-β), 3.33-3.51 (m, 2H, H-α), 4.01-4.21 (m, 
3H, H-4, H-5, H-6), 4.33-4.45 (m, 2H, H-3, H-7), 4.54 (dd, 1H, Jgem = 14.5, J6,7’ = 3.0 Hz, H-
7’), 6.98-7.18 (m, 3H, H-Ar), 7.39 (d, 1H, J = 8.0 Hz, H-Ar), 7.54-7.57 (m, 2H, H-Ar, H-
triazole). 13C NMR (62.9 MHz, D2O): δ = 21.7 (C-9), 24.2, 27.4 (C-8, C-β), 37.0 (C-2), 40.3 
(C-α, C-10), 51.3 (C-7), 71.6, 71.8 (C-4, C-5), 77.2 (C-3), 77.9 (C-6), 111.7 (C-Ar), 111.8 (C-
Ar), 118.4 (C-Ar), 119.1 (C-Ar), 121.8 (C-Ar), 123.3 (2 C-Ar), 123.7 (C-Ar), 126.9 (C-Ar), 
136.1 (C-Ar), 156.5 (C=N), 173.5 (C=O). IR (pellets) : 3279, 1622, 1549. ESI-HRMS: m/z 
calcd for C23H32N8O4Na [M+Na]+ 507.2439; found 507.2445. 
 
N-[2-C-[2,3:5,6-Bis-O-(1-methylethylidene)--D-gulofuranosyl]carboxymethyl)]-L-
nitro-arginine methyl ester 39 
To a solution of N-NO2-L-arg-OMe (296 mg, 1.1 mmol, 1.1 eq.) and 5 (300 mg, 1 mmol, 1 
eq.) in DMF (10 mL) were added HATU (570 mg, 1.5 mmol, 1.5 eq.) and DIEA (363 µL, 2.1 
mmol, 2.1 eq.) at 0°C under argon atmosphere. After stirring at room temperature for 24h, the 
solvent was evaporated. The residue was dissolved in ethyl acetate (10 mL), washed with 1N 
HCl (5 mL), NaHCO3 sat. aq. (5 mL) and brine (5 mL). The organic layer was dried over 
MgSO4, filtered and concentrated. The product was purified by column chromatography (silica 
gel, cyclohexane/AcOEt) to provide 39 (258 mg, 50%). Colorless oil. Rf; 0.36 (CH2Cl2/MeOH: 
9/1). [α]D= -22.2° (c = 0.2, CHCl3). 1H NMR (250 MHz, DMSO-d6): δ = 1.20 (s, 3H, C(CH3)2), 
1.25 (s, 3H, C(CH3)2), 1.30 (s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2), 1.45-1.73 (m, 4H, CH2 
arg), 2.49-2.54 (m, 2H, H-2), 3.10-3.17 (m, 2H, CH2 arg), 3.41 (dd, 1H, J6,7 = 8.5, J5,6 = 3.5 
Hz, H-6), 3.62 (s, 3H, OCH3), 3.66 (t, 1H, J7,8 = 7.5 Hz, H-8), 3.85 (td, 1H, J2,3 = 6.5, J3,4 = 3.0 
Hz, H-3), 4.01 & 4.01 (2m, 2H, H-7, H-8’), 4.26 (m, 1H, H-α), 4.60 (dd, 1H, J4,5 = 6.0 Hz, H-
4), 4.66 (dd, 1H, H-5), 7.91 (br s, 2H, NH), 8.32 (d, 1H, J = 7.5 Hz, NH), 8.46 (br s, 1H, NH). 
13C NMR (62.9 MHz, DMSO-d6): δ = 24.7 (CH3, CH2 arg), 25.3 (CH3), 25.8 (CH3), 26.5 (CH3), 
28.2 (CH2 arg), 34.3 (C-2), 40.1 (CH2 arg), 51.5 (C-α), 51.8 (OCH3), 65.2 (C-8), 75.2 (C-7), 
77.4 (C-3), 80.6 (C-5), 81.1 (C-4), 82.4 (C-6), 108.6 (C(CH3)2), 111.3 (C(CH3)2), 159.3 (C=N), 
169.7 (C=O), 172.5 (C=O). IR (film) : 3317, 2985, 2928, 2862, 1742, 1650, 1629, 1598, 1539. 
ESI-HRMS: m/z calcd for C21H35N5O10Na [M+Na]+ 540.2276; found 540.2294. 
 
N-[2-C-[2,3:5,6-Bis-O-(1-methylethylidene)--D-gulofuranosyl]carboxymethyl)]-L-
arginine 40 
To a solution of 39 (200 mg, 0.39 mmol) in THF (9 mL) and water (3 mL) was added LiOH 
(30 mg, 1.17 mmol, 3 eq.) and the mixture was stirred until completion of the reaction 
monitored by tlc. Amberlite® IR-120 was added until pH = 3-4 and the mixture was filtered off. 
The solvent were evaporated and the obtained carboxylic acid was solubilized in MeOH (10 
mL) and Pd/C (10%) (80 mg, 40% w/w) was added. After stirring under H2 atmosphere (40 psi) 
until completion of the reaction, the mixture was filtered through a pad of celite and the filtrate 
was concentrated in vacuo. The crude was purified by column chromatography (C-18 silica gel, 
H2O/MeOH) and lyophilized to provide 40 (125 mg, 70%). White foam. Rf; 0.32 (H2O/MeOH: 
1/1). HPLC (70/30): tR = 4.436 min. [α]D= -1.0° (c = 0.2, H2O). 1H NMR (400 MHz, D2O): δ = 
1.26 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 1.38 (s, 3H, C(CH3)2), 1.42 (s, 3H, C(CH3)2), 
1.51-1.60 (m, 2H, CH2 arg, 1.66 (m, 1H, CH2 arg), 1.77 (m, 1H, CH2 arg), 2.70 (d, 2H, J2,3 = 
7.0 Hz, H-2), 3.12 (t, 2H, J = 7.0 Hz, CH2 arg), 3.64 (dd, 1H, J6,7 = 8.5, J5,6 = 3.5 Hz, H-6), 
3.80 (dd, 1H, Jgem = 9.0, J7,8 = 6.5 Hz, H-8), 3.99 (td, 1H, J3,4 = 3.5 Hz, H-3), 4.12 (dd, 1H, J = 
8.0, J = 5.0 Hz, H-α), 4.17 (dd, 1H, J7,8’ = 7.0 Hz, H-8’), 4.33 (m, 1H, H-7), 4.77 (dd, 1H, J4,5 
= 6.0 Hz, H-4), 4.81 (dd, 1H, H-5). 13C NMR (100 MHz, D2O): δ = 23.6 (CH3), 24.1 (CH3), 
24.4 (CH2 arg), 24.7 (CH3), 25.5 (CH3), 28.7(CH2 arg), 34.6 (C-2), 40.6 (CH2 arg), 54.6 (C-
α), 65.2 (C-8), 74.6 (C-7), 78.0 (C-3), 80.4 (C-5), 81.1 (C-4), 82.6 (C-6), 110.4 (C(CH3)2), 113.1 
(C(CH3)2), 156.7 (C=N), 171.8 (C=O), 178.6 (C=O). IR (pellets) : 3364, 2985, 2938, 2867, 
1652, 1579. ESI-HRMS: m/z calcd for C20H34N4O8Na [M+Na]+ 481.2269; found 481.2275. 
 
(E)-3,6-Anhydro-2-deoxy-4,5:7,8-bis-O-(1-methylethylidene)-D-gulo-Oct-2-enonic acid 
methyl 41 
To a solution of 2 (630 mg, 2 mmol, 1 eq.) in pyridine (15 mL) was added LiI (2.6 g, 20 
mmol, 10 eq.) and the mixture was stirred at 120 °C until completion of the reaction monitored 
by tlc. The solvent was removed under reduced pressure, CH2Cl2 (20 mL) was added and the 
pH was adjusted to 2-3 with 1N HCl. The layers were separated and the organic layer was 
washed with brine and dried over MgSO4, filtered and concentrated. The crude residue was 
purified by column chromatography (silica gel, cyH/EA) to provide 41 (300 mg, 50%). White 
solid. Rf; 0.21 (cH/EA: 1/1). [α]D= -36.5° (c = 1.0, CHCl3). Mp = 201°C. 1H NMR (250 MHz, 
CDCl3): δ = 1.37 (s, 3H, CH3), 1.39 (s, 3H, CH3), 1.43 (s, 3H, CH3), 1.46 (s, 3H, CH3), 3.77 
(dd, 1H, Jgem = 9.0, J7,8 = 7.0 Hz, H-8), 4.18-4.26 (m, 2H, H-6, H-8), 4.42 (m, 1H, H-7), 4.75 
(dd, 1H, J4,5 = 6.0, J5,6 = 4.0 Hz, H-5), 5.51 (s, 1H, H-2), 5.76 (d, 1H, H-4), 10.66 (br s, 1H, 
COOH). 13C NMR (62.9 MHz, CDCl3): δ = 25.2 (CH3), 25.6 (CH3), 26.4 (CH3), 26.7 (CH3), 
65.7 (C-8), 75.5, 77.5, 79.9, 86.5 (C-4, C-5, C-6, C-7), 94.9 (C-2), 110.3, 113.7 (2 C(CH3)2), 
172.0 (C-3), 173.1 (C=O). IR (film) : 3061, 2985, 2933, 2563, 1685, 1655. ESI-HRMS: m/z 
calcd for C14H20O7Na [M+Na]+ 323.1101; found 323.1102. 
 
Compound 42 
To a solution of HCl.H-L-arg-OMe (191 mg, 0.73 mmol, 1.1 eq.) and 41 (200 mg, 0.67 mmol, 
1 eq.) in DMF (10 mL) were added HATU (380 mg, 1.0 mmol, 1.5 eq.) and DIEA (243 µL, 
1.41 mmol, 2.1 eq.) at 0°C under argon atmosphere. After stirring at room temperature for 24h, 
the solvent was evaporated. The crude product was solubilized in pyridine (15 mL), LiI (871 
mg, 6.7 mmol, 10 eq.) was added and the mixture was stirred at 120 °C until completion of the 
reaction monitored by tlc. The solvent was removed under reduced pressure and the crude was 
purified by column chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to provide 
42 (96 mg, 33%). White solid. Rf; 0.41 (H2O/MeOH: 1/1). HPLC (70/30): tR = 4.782 min. [α]D= 
-44.6° (c = 0.08, H2O). 1H NMR (250 MHz, D2O): δ = 1.47 (s, 3H, CH3), 1.48 (s, 3H, CH3), 
1.53 (s, 3H, CH3), 1.54 (s, 3H, CH3), 1.63-1.75 (m, 2H, CH2 arg), 1.79-1.99 (m, 2H, CH2 arg), 
3.26 (t, 2H, J = 7.0 Hz, CH2 arg), 4.08 (dd, 1H, Jgem = 9.0, J7,8 = 6.0 Hz, H-8), 4.32-4.39 (m, 
2H, H-6, H-8’), 4.62 (m, 1H, H-7), 4.73 (m, 1H, H-α), 5.07 (dd, 1H, J4,5 = 6.0, J5,6 = 4.0 Hz, H-
5), 5.22 (d, 1H, J2,4 = 1.0 Hz, H-2), 5.49 (dd, 1H, H-4). 13C NMR (62.9 MHz, D2O): δ = 24.6 
(CH3, CH2 arg), 25.0 (CH3), 25.9 (CH3), 26.0 (CH3), 29.4 (CH2 arg), 41.0 (CH2 arg), 54.6 (C-
α), 65.6 (C-8), 74.9 (C-7), 77.2 (C-5), 81.6 (C-4), 87.0 (C-6), 96.0 (C-2), 111.0 (C(CH3)2), 115.2 
(C(CH3)2), 157.0 (C=N), 165.5 (C-3), 167.3 (C=O), 178.9 (C=O). IR (pellets) : 3132, 3165, 
2981, 2937, 2725, 2860, 1672, 1583. ESI-HRMS: m/z calcd for C20H33N4O8 [M+H]+ 457.2293; 
found 457.2278. 
 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-D-glycero-L-galacto-octonic acid 
methyl ester 43 
To a stirred solution of 4 (3.16 g, 10.0 mmol) in methanol (200 mL) at 0°C was added an 
aqueous solution of 1N HCl (70 mL). After stirring at room temperature until completion of the 
reaction, sat. aq. NaHCO3 was added until pH = 7. Half of the solvent was removed under vacuo 
and the product was extracted with CH2Cl2 (3 x 100 mL). The organic layer was dried over 
MgSO4, filtered and the solvent was evaporated. The crude residue was purified by column 
chromatography (silica gel, cyH/EA) to provide 43 (2.54 g, 92%). White solid. Rf; 0.29 (EA). 
[α]D= -5.6° (c = 1, CHCl3). Mp = 50°C. 1H NMR (250 MHz, CDCl3): δ = 1.31 (s, 3H, C(CH3)2), 
1.47 (s, 3H, C(CH3)2), 2.78 (dd, 1H, Jgem = 17.0, J2,3 = 7.0 Hz, H-2), 2.86 (dd, 1H, J2’,3 = 7.0 
Hz, H-2’), 3.57 (dd, 1H, J6,7 = 6.5, J5,6 = 3.0 Hz, H-6), 3.72 (s, 3H, O-CH3), 3.74 (dd, 1H, Jgem 
= 11.5, J7,8 = 5.0 Hz, H-8), 3.81 (dd, 1H, J7,8’ = 4.0 Hz, H-8’), 3.95 (td, 1H, J3,4 = 3.5 Hz, H-3), 
4.09 (m, 1H, H-7), 4.75 (dd, 1H, J4,5 = 6.0 Hz, H-4), 4.79 (dd, 1H, H-5). 13C NMR (62.9 MHz, 
CDCl3): δ = 24.6 (CH3), 25.7 (CH3), 33.3 (C-2), 51.8 (OCH3), 63.4 (C-7), 70.7 (C-8), 77.3 (C-
3), 81.0, 81.3 (C-4, C-5, C-6), 112.6 (C(CH3)2), 171.5 (C=O). IR (film) : 3440, 2990, 2938, 
2876, 1735. ESI-HRMS: m/z calcd for C12H20O7K [M+K]+ 315.0841; found 315.0858. 
 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-L-galacto-heptonic acid methyl ester 
44 
To a stirred solution of 43 (2.2 g, 7.97 mmol) in methanol (180 mL) was added NaIO4 (3.42 
g, 16.0 mmol, 2 eq.) under argon. After stirring at room temperature until completion of the 
reaction, the solvent was removed by half in vacuo. The mixture was diluted with CH2Cl2 (200 
mL). The organic layer was washed with water (3 x 75 mL), dried over MgSO4, filtered and the 
solvent was removed under reduced pressure. The product was used without further 
purification.To a stirred solution of the obtained aldehyde in MeOH (190 mL) was added 
NaBH4 (305 mg, 7.97 mmol, 1 eq.) at 0°C. After 1 h at room temperature, the solvent was 
removed under reduced pressure. The residue was diluted in CH2Cl2 (100 mL) and the organic 
layer was washed with a solution of 1N HCl (30 mL) and with water until pH = 7. The organic 
layer was dried over MgSO4, filtrered and evaporated under reduced pressure. The crude 
product 44 was used without further purification. Yield: 93% (1.82 g). Colorless oil. Rf; 0.47 
(EA). [α]D= -1.4° (c = 0.2, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 1.32 (s, 3H, C(CH3)2), 
1.47 (s, 3H, C(CH3)2), 1.94 (br s, 1H, OH), 2.77 (dd, 1H, Jgem = 17.0, J2,3 = 7.0 Hz, H-2), 2.85 
(dd, 1H, J2’,3 = 7.0 Hz, H-2’), 3.66 (m, 1H, H-6), 3.71 (s, 3H, CH3), 3.89 (dd, 1H, Jgem = 11.0, 
J6,7 = 5.0 Hz, H-7), 3.96 (dd, 1H, J6,7’ =4.0 Hz, H-7’), 3.97 (m, 1H, H-3), 4.75 (dd, 1H, J4,5 = 
6.0 Hz, H-4), 4.79 (dd, 1H, H-5). 13C NMR (62.9 MHz, CDCl3): δ = 24.7 (CH3), 25.8 (CH3), 
33.3 (C-2), 51.8 (OCH3), 61.0 (C-7), 77.4 (C-3), 80.9, 81.3, 81.4 (C-4, C-5, C-6), 112.7 
(C(CH3)2), 171.4 (C=O). IR (film) : 3459, 2985, 2928, 2862, 1737. ESI-HRMS: m/z calcd for 
C11H18O6Na [M+Na]+ 269.0996; found 269.1030. 
 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-7-(4-methylbenzenesulfonate)-L-
galacto-heptonic acid methyl ester 45 
Prepared starting from 44 (1.50 g, 6.1 mmol) following procedure described for 8. Yield: 
92% (2.24 g). Colorless oil. Rf; 0.75 (EA). [α]D= + 4.5° (c = 0.2, CHCl3). 1H NMR (250 MHz, 
CDCl3): δ = 1.26 (s, 3H, C(CH3)2), 1.34 (s, 3H, C(CH3)2), 2.45 (s, 3H, Ph-CH3), 2.68 (dd, 1H, 
Jgem = 16.0, J2,3 = 7.0 Hz, H-2), 2.78 (dd, 1H, J2’,3 = 7.0 Hz, H-2’), 3.70 (s, 3H, OCH3), 3.76 
(m, 1H, H-6), 3.91 (td, 1H, J3,4 = 3.5 Hz, H-3), 4.17 (dd, 1H, Jgem = 10.5, J6,7 = 7.0 Hz, H-7), 
4.31 (dd, 1H, J6,7’ = 5.0 Hz, H-7’), 4.67 (dd, 1H, J4,5 = 6.0 Hz, H-4), 4.73 (dd, 1H, J5,6 = 3.5 Hz, 
H-5), 7.34 (d, 2H, J = 8.0 Hz, H-Ar), 7.81 (d, 2H, J = 8.0 Hz, H-Ar). 13C NMR (62.9 MHz, 
CDCl3): δ = 21.6 (Ph-CH3), 24.8 (CH3), 25.7 (CH3), 33.2 (C-2), 51.8 (OCH3), 67.5 (C-7), 77.7 
(C-3), 78.5 (C-6), 80.5, 80.9 (C-4, C-5), 112.8 (C(CH3)2), 128.1 (2 C-Ar), 129.7 (2 C-Ar), 132.8 
(C-Ar), 144.8 (C-Ar), 171.2 (C=O). IR (film) : 2981, 2928, 2853, 1735, 1596. ESI-HRMS: 
m/z calcd for C18H24O8SNa [M+Na]+ 423.1084; found 423.1116. 
3,6-Anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-azido-L-galacto-heptonic acid 
methyl ester 46 
Prepared starting from 45 (2.0 g, 5.0 mmol) following procedure described for 30. Yield: 
84% (1.14 g). Colorless oil. Rf; 0.51 (cH/EA: 1/1). [α]D= + 6.0° (c = 0.1, CHCl3). 1H NMR (250 
MHz, CDCl3): δ = 1.32 (s, 3H, C(CH3)2), 1.46 (s, 3H, C(CH3)2), 2.76 (dd, 1H, Jgem = 17.0, J2,3 
= 7.0 Hz, H-2), 2.84 (dd, 1H, J2’,3 = 7.0 Hz, H-2’), 3.51 (dd, 1H, Jgem = 12.5, J6,7 = 6.5 Hz, H-
7), 3.57 (dd, 1H, J6,7’ = 6.5 Hz, H-7’), 3.67 (m, 1H, H-6), 3.71 (s, 3H, OCH3), 3.96 (td, 1H, J3,4 
= 3.5 Hz, H-3), 4.70 (dd, 1H, J4,5 = 6.0 Hz, H-4), 4.78 (dd, 1H, J5,6 = 3.5 Hz, H-5). 13C NMR 
(62.9 MHz, CDCl3): δ = 25.1 (CH3), 26.0 (CH3), 33.5 (C-2), 49.8 (C-7), 52.0 (OCH3), 77.9 (C-
3), 79.9 (C-6), 81.0, 81.3 (C-4, C-5), 113.0 (C(CH3)2), 171.5 (C=O). IR (film) : 2985, 2943, 
2867, 2099, 1742. ESI-HRMS: m/z calcd for C11H17N3O5Na [M+Na]+ 294.1060; found 
294.1065. 
 
3,6-anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-benzosulfonylamino-L-galacto-
heptonic acid methyl ester 47 
To a solution of 46 (500 mg, 1.84 mmol, 1 eq.) in MeOH (10 mL) was added Pd/C (10%) (50 
mg, 10% w/w). After stirring under H2 atmosphere (15 psi) until completion of the reaction, the 
mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The 
crude amine was solubilized in pyridine (3 mL) and this solution was added dropwise under 
argon atmosphere to a stirred solution of benzylsulfonyl chloride (282 µL, 2.21 mmol, 1.2 eq.) 
in pyridine (6 mL). After stirring at room temperature until completion of the reaction, the 
solvent was removed under reduced pressure. The residue was diluted with EtOAc (15 mL) and 
washed with H2O (2x5 mL). The organic layer was dried over MgSO4, filtered and the solvent 
was evaporated under reduced pressure. The compound was purified by flash chromatography 
(silica gel, cyH/EA) to provide 47 (566 mg, 80%). Colorless oil. Rf; 0.22 (cH/EA: 7/3). [α]D= 
+12.2° (c = 0.5, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 1.27 (s, 3H, C(CH3)2), 1.36 (s, 3H, 
C(CH3)2), 2.64 (dd, 1H, Jgem = 16.5, J2,3 = 6.5 Hz, H-2), 2.73 (dd, 1H, J2’,3 = 6.5 Hz, H-2’), 3.27 
(t, 2H, J7,NH = 6.5, J6,7 = 6.5 Hz, H-7), 3.63 (td, 1H, J5,6 = 3.5 Hz, H-6), 3.70 (s, 3H, OCH3), 
3.88 (td, 1H, J3,4 = 3.5 Hz, H-3), 4.63 (dd, 1H, J4,5 = 6.0 Hz, H-4), 4.71 (dd, 1H, H-5), 4.88 (t, 
1H, NH), 7.48-7.61 (m, 3H, H-Ar), 7.85-7.89 (m, 2H, H-Ar). 13C NMR (62.9 MHz, CDCl3): δ 
= 24.7 (CH3), 25.7 (CH3), 33.3 (C-2), 42.1 (C-7), 51.8 (OCH3), 77.5 (C-3), 79.1 (C-6), 80.8, 
81.2 (C-4, C-5), 112.7 (C(CH3)2), 127.1 (2 C-Ar), 129.1 (2 C-Ar), 132.6 (C-Ar), 140.0 (C-Ar), 
171.2 (C=O). IR (film) : 3284, 2985, 2938, 2872, 1737. ESI-HRMS: m/z calcd for 
C17H23NO7SNa [M+Na]+ 408.1087; found 408.1122. 
 
3,6-anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-benzosulfonylamino-L-galacto-
heptonic acid 48 
Prepared starting from 47 (500 mg, 1.30 mmol) following procedure described for 21. Yield: 
90% (434 mg). Colorless gum. Rf; 0.10 (cH/EA: 1/2). [α]D= +11.3° (c = 0.08, CHCl3). 1H NMR 
(250 MHz, CDCl3): δ = 1.28 (s, 3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2), 2.69 (dd, 1H, Jgem = 17.0, 
J2,3 = 6.5 Hz, H-2), 2.79 (dd, 1H, J2’,3 = 6.5 Hz, H-2’), 3.28 (t, 2H, J7,NH = 6.5, J6,7 = 6.5 Hz, H-
7), 3.66 (td, 1H, J5,6 = 3.5 Hz, H-6), 3.88 (td, 1H, J3,4 = 3.5 Hz, H-3), 4.65 (dd, 1H, J4,5 = 6.0 
Hz, H-4), 4.71 (dd, 1H, H-5), 5.02 (t, 1H, NH), 7.48-7.61 (m, 3H, H-Ar), 7.85-7.89 (m, 2H, H-
Ar). 13C NMR (62.9 MHz, CDCl3): δ = 24.7 (CH3), 25.6 (CH3), 33.3 (C-2), 42.1 (C-7), 77.2 
(C-3), 79.3 (C-6), 80.8, 81.1 (C-4, C-5), 112.9 (C(CH3)2), 127.0 (2 C-Ar), 129.1 (2 C-Ar), 132.7 
(C-Ar), 139.9 (C-Ar), 175.7 (C=O). IR (film) : 3270, 2985, 2928, 2857, 1716. ESI-HRMS: 
m/z calcd for C16H21NO7SNa [M+Na]+ 394.0931; found 394.0953. 
 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-benzosulfonylamino--D-
galactofuranosyl]carbonymethyl)]-L-nitro-arginine methyl ester 49 
Prepared starting from 48 (400 mg, 1.08 mmol) following procedure described for 39. Yield: 
84% (531 mg). White foam. Rf; 0.4 (EA/MeOH: 9/1). [α]D= +5.1° (c = 0.4, CHCl3). 1H NMR 
(400 MHz, CDCl3): δ = 1.25 (s, 3H, C(CH3)2), 1.38 (s, 3H, C(CH3)2), 1.65-1.76 (m, 3H, CH2 
arg), 1.93 (m, 1H, CH2 arg), 2.54 (dd, 1H, Jgem = 15.0, J2,3 = 3.5 Hz, H-2), 2.71 (dd, 1H, J2’,3 = 
9.0 Hz, H-2’), 3.22 (dd, 1H, Jgem = 13.0, J6,7 = 8.0 Hz, H-7), 3.30-3.37 (m, 2H, H-7ʼ, CH2 arg), 
3.56 (m, 1H, CH2 arg), 3.68 (m, 1H, H-6), 3.79-3.92 (m, 4H, H-3, OCH3), 4.56-4.65 (m, 3H, 
H-α, H-4, H-5), 5.77 (br s, 1H, NH), 7.13 (d, 1H, J = 7.0 Hz, NH), 7.52-7.62 (m, 5H, 3 H-Ar, 
2 NH), 7.90 (d, 2H, J = 7.5 Hz, H-Ar), 8.66 (br s, 1H, NH). 13C NMR (100 MHz, CDCl3): δ = 
24.5 (CH2 arg, CH3), 25.7 (CH3), 30.5 (CH2 arg), 36.1 (C-2), 40.5 (CH2 arg), 42.3 (C-7), 51.1 
(C-α), 53.1 (OCH3), 77.7 (C-3), 79.9 (C-6), 80.8, 81.6 (C-4, C-5), 112.9 (C(CH3)2), 127.0 (2 C-
Ar), 129.2 (2 C-Ar), 132.7 (C-Ar), 139.9 (C-Ar), 159.3 (C=N), 172.1 (C=O), 173.0 (C=O). IR 
(film) : 3360, 2933, 2867, 1735, 1633, 1539. ESI-HRMS: m/z calcd for C23H34N6O10SNa 
[M+Na]+ 609.1949; found 609.1969. 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-benzosulfonylamino--D-
galactofuranosyl]carbonymethyl)]-L-arginine methyl ester 50 
Prepared starting from 49 (500 mg, 0.85 mmol) following procedure described for 40. Yield: 
82% (367 mg). White solid. Rf; 0.24 (H2O/MeOH: 1/1). HPLC (70/30): tR = 6.049 min. [α]D= 
+15.0° (c = 0.2, H2O). 1H NMR (400 MHz, D2O): δ = 1.22 (s, 3H, C(CH3)2), 1.33 (s, 3H, 
C(CH3)2), 1.49-1.56 (m, 2H, CH2 arg), 1.64 (m, 1H, CH2 arg), 1.77 (m, 1H, CH2 arg), 2.53-
2.63 (m, 2H, H-2), 3.07-3.11 (m, 3H, H-7, 2 CH2 arg), 3.18 (dd, 1H, Jgem = 13.5, J6,7’ = 4.5 Hz, 
H-7’), 3.60 (m, 1H, H-6), 3.85 (td, 1H, J3,4 = 2.5 Hz, H-3), 4.12 (dd, 1H, JH-α,A1 = 8.0 Hz, JH-
α,A1’ = 5.0 Hz, H-α), 4.67-4.69 (m, 2H, H-4, H-5), 7.53-7.57 (m, 2H, H-Ar), 7.64 (m, 1H, H-
Ar), 7.79-7.82 (m, 2H, H-Ar). 13C NMR (100 MHz, D2O): δ = 23.6 (CH3), 24.4 (CH2 arg), 24.7 
(CH3), 28.8 (CH2 arg), 34.7 (C-2), 40.6 (CH2 arg), 41.3 (C-7), 54.8 (C-α), 77.7 (C-3), 79.1 (C-
6), 80.3 (C-5), 81.1 (C-4), 112.8 (C(CH3)2), 126.7 (2 C-Ar), 129.5 (2 C-Ar), 133.6 (C-Ar), 137.9 
(C-Ar), 156.7 (C=N), 171.9 (C=O), 178.4 (C=O). IR (pellets) : 3360, 3180, 2990, 2943, 2876, 
1645, 1586. ESI-HRMS: m/z calcd for C22H33N5O8SNa [M+Na]+ 550.1942; found 550.1956. 
 
3,6-Anhydro-2-deoxy-4,5-O-(1-methylethylidene)-7-(4-methylbenzenesulfonate)-D-
altro-heptonic acid methyl ester 51 
Prepared starting from 19 (1.0 g, 4.07 mmol) following procedure described for 8. Yield: 
98% (1.59 g). Colorless oil. Rf; 0.71 (cH/EA: 1/1). [α]D= +11.0° (c = 0.1, CHCl3). 1H NMR 
(250 MHz, CDCl3): δ = 1.31 (s, 3H, C(CH3)2), 1.45 (s, 3H, C(CH3)2), 2.46 (s, 3H, Ph-CH3), 
2.63 (dd, 1H, Jgem = 16.5, J2,3 = 7.0 Hz, H-2), 2.74 (dd, 1H, J2’,3 = 7.0 Hz, H-2’), 3.70 (s, 3H, 
OCH3), 4.00 (dd, 1H, Jgem = 10.5, J6,7 = 5.0 Hz, H-7), 4.08 (dd, 1H, J6,7’ = 4.5 Hz, H-7’), 4.18 
(m, 1H, H-6), 4.29 (td, 1H, J3,4 = 4.0 Hz, H-3), 4.71 (dd, 1H, J4,5 = 6.0, J5,6 = 0.5 Hz, H-5), 4.77 
(dd, 1H, H-4), 7.36 (d, 2H, J = 8.0 Hz, H-Ar), 7.80 (d, 2H, H-Ar). 13C NMR (62.9 MHz, CDCl3): 
δ = 21.8 (Ph-CH3), 25.0 (CH3), 26.3 (CH3), 34.5 (C-2), 51.9 (OCH3), 69.6 (C-7), 78.4, 81.4, 
82.7 (C-3, C-4, C-5, C-6), 113.1 (C(CH3)2), 128.2 (2 C-Ar), 130.2 (2 C-Ar), 132.6 (C-Ar), 145.3 
(C-Ar), 171.4 (C=O). IR (film) : 2985, 2943, 1737, 1596. ESI-HRMS: m/z calcd for 
C18H24O8SNa [M+Na]+ 423.1084; found 423.1087. 
 
3,6-anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-azido-D-altro-heptonic acid 
methyl ester 52 
Prepared starting from 51 (1.4 g, 3.5 mmol) following procedure described for 30. Yield: 
97% (920 mg). Colorless oil. Rf; 0.50 (cH/EA: 2/1). [α]D= +18.5° (c = 0.2, CHCl3). 1H NMR 
(250 MHz, CDCl3): δ = 1.33 (s, 3H, C(CH3)2), 1.49 (s, 3H, C(CH3)2), 2.73 (dd, 1H, Jgem = 17.0, 
J2,3 = 7.0 Hz, H-2), 2.81 (dd, 1H, J2’,3 = 7.0 Hz, H-2’), 3.28 (dd, 1H, Jgem = 13.0, J6,7 = 5.0 Hz, 
H-7), 3.43 (dd, 1H, J6,7’ = 6.5 Hz, H-7’), 3.71 (s, 3H, OCH3), 4.21 (m, 1H, H-6), 4.41 (td, 1H, 
J3,4 = 4.0 Hz, H-3), 4.64 (dd, 1H, J4,5 = 6.0, J5,6 = 0.5 Hz, H-5), 4.80 (dd, 1H, H-4). 13C NMR 
(62.9 MHz, CDCl3): δ = 25.2 (CH3), 26.4 (CH3), 34.5 (C-2), 51.8, 52.0 (C-7, OCH3), 77.6 (C-
3), 81.5, 82.9, 83.4 (C-4, C-5, C-6), 113.2 (C(CH3)2), 171.5 (C=O). IR (film) : 2990, 2938, 
2099, 1737. ESI-HRMS: m/z calcd for C11H17N3O5Na [M+Na]+ 294.1060; found 294.1073. 
 
3,6-anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-benzosulfonylamino-D-altro-
heptonic acid methyl ester 53 
Prepared starting from 52 (200 mg, 0.74 mmol) following procedure described for 47. Yield: 
83% (235 mg). Colorless oil. Rf; 0.29 (cH/EA: 7/3). [α]D= +26.2° (c = 0.14, CHCl3). 1H NMR 
(250 MHz, CDCl3): δ = 1.29 (s, 3H, C(CH3)2), 1.44 (s, 3H, C(CH3)2), 2.64 (dd, 1H, Jgem = 16.0, 
J2,3 = 7.0 Hz, H-2), 2.74 (dd, 1H, J2’,3 = 7.0 Hz, H-2’), 2.89 (ddd, 1H, Jgem = 13.0, J6,7 = 8.5, 
J7,NH = 4.0 Hz, H-7), 3.07 (ddd, 1H, J6,7’ = 5.0, J7’,NH = 8.0 Hz, H-7’), 3.71 (s, 3H, OCH3), 4.05 
(ddd, 1H, J5,6 = 1.0 Hz, H-6), 4.12 (td, 1H, J3,4 = 4.0 Hz, H-3), 4.53 (dd, 1H, J4,5 = 6.0 Hz, H-
5), 4.69 (dd, 1H, H-4), 4.78 (dd, 1H, NH), 7.49-7.63 (m, 3H, H-Ar), 7.85-7.89 (m, 2H, H-Ar). 
13C NMR (62.9 MHz, CDCl3): δ = 25.1 (CH3), 26.3 (CH3), 34.1 (C-2), 42.8 (C-7), 52.0 (OCH3), 
76.5 (C-3), 81.1, 81.9, 83.1 (C-4, C-5, C-6), 113.3 (C(CH3)2), 127.2 (2 C-Ar), 129.4 (2 C-Ar), 
133.0 (C-Ar), 139.7 (C-Ar), 171.5 (C=O). IR (film) : 3279, 2990, 2933, 1735. ESI-HRMS: 
m/z calcd for C17H23NO7SNa [M+Na]+ 408.1087; found 408.1090. 
 
3,6-anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-benzosulfonylamino-D-altro-
heptonic acid 54 
Prepared starting from 53 (200 mg, 0.52 mmol) following procedure described for 21. Yield: 
96% (185 mg). Colorless oil. Rf; 0.09 (cH/EA: 1/2). [α]D= +23.7° (c = 0.2, CHCl3). 1H NMR 
(250 MHz, CDCl3): δ = 1.30 (s, 3H, C(CH3)2), 1.45 (s, 3H, C(CH3)2), 2.69 (dd, 1H, Jgem = 17.0, 
J2,3 = 6.0 Hz, H-2), 2.78 (dd, 1H, J2’,3 = 6.0 Hz, H-2’), 2.91 (ddd, 1H, Jgem = 13.0, J6,7 = 8.0, 
J7,NH = 4.0 Hz, H-7), 3.08 (ddd, 1H, J6,7’ = 5.0, J7’,NH = 8.0 Hz, H-7’), 4.09 (ddd, 1H, J5,6 = 1.0 
Hz, H-6), 4.14 (td, 1H, J3,4 = 4.0 Hz, H-3), 4.56 (dd, 1H, J4,5 = 6.0 Hz, H-5), 4.71 (dd, 1H, H-
4), 5.12 (dd, 1H, NH), 7.48-7.62 (m, 3H, H-Ar), 7.84-7.89 (m, 2H, H-Ar). 13C NMR (62.9 MHz, 
CDCl3): δ = 25.1 (CH3), 26.3 (CH3), 34.1 (C-2), 42.8 (C-7), 76.5 (C-3), 81.1, 82.1, 83.1 (C-4, 
C-5, C-6), 113.4 (C(CH3)2), 127.2 (2 C-Ar), 129.4 (2 C-Ar), 133.0 (C-Ar), 139.6 (C-Ar), 175.4 
(C=O). IR (film) : 3265, 2985, 2928, 1716. ESI-HRMS: m/z calcd for C16H21NO7SNa 
[M+Na]+ 394.0931; found 394.0929. 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-benzosulfonylamino--D-
ribofuranosyl]carbonymethyl]-L-nitro-arginine methyl ester 55 
Prepared starting from 54 (170 mg, 0.46 mmol) following procedure described for 39. Yield: 
71% (191 mg). White solid. Rf; 0.37 (EA/MeOH: 9/1). [α]D= +7.0° (c = 0.5, CHCl3). 1H NMR 
(250 MHz, CDCl3): δ = 1.27 (s, 3H, C(CH3)2), 1.44 (s, 3H, C(CH3)2), 1.63-1.83 (m, 3H, CH2 
arg), 1.93 (m, 1H, CH2 arg), 2.54 (dd, 1H, Jgem = 15.5, J2,3 = 3.0 Hz, H-2), 2.75 (dd, 1H, J2’,3 = 
9.5 Hz, H-2’), 2.89 (m, 1H, H-7), 3.06 (ddd, 1H, Jgem = 13.5, J = 8.0, J = 4.5 Hz, H-7’), 3.31 
(m, 1H, CH2 arg), 3.47 (m, 1H, CH2 arg), 3.78 (s, 3H, OCH3), 4.12 (m, 1H, H-6), 4.19 (m, 1H, 
H-3), 4.49 (d, 1H, J4,5 = 6.0 Hz, H-5), 4.57-4.65 (m, 2H, H-α, H-4), 6.17 (br s, 1H, NH), 7.26 
(m, 1H, NH), 7.47-7.62 (m, 5H, 3 H-Ar, 2 NH), 7.83-7.88 (m, 2H, H-Ar), 8.59 (br s, 1H, NH). 
13C NMR (62.9 MHz, CDCl3): δ = 25.0 (CH2 arg , CH3), 26.4 (CH3), 30.2 (CH2 arg), 36.8 (C-
2), 40.8 (CH2 arg), 42.8 (C-7), 51.5 (C-α), 53.2 (OCH3), 76.6 (C-3), 81.6, 83.1, 83.3 (C-4, C-
5, C-6), 113.3 (C(CH3)2), 127.1 (2 C-Ar), 129.5 (2 C-Ar), 133.0 (C-Ar), 140.1 (C-Ar), 159.6 
(C=N), 172.2 (C=O), 173.5 (C=O). IR (film) : 3303, 2990, 2933, 2876, 1737, 1636, 1598, 
1537. ESI-HRMS: m/z calcd for C23H34N6O10SNa [M+Na]+ 609.1949; found 609.1940. 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-benzosulfonylamino--D-
ribofuranosyl]carbonylmethyl)]-L-arginine methyl ester 56 
Prepared starting from 55 (150 mg, 0.26 mmol) following procedure described for 40. Yield: 
70% (94 mg). White solid. Rf; 0.22 (H2O/MeOH: 1/1). HPLC (70/30): tR = 5.526 min. [α]D= 
+17.1° (c = 0.1, H2O). 1H NMR (250 MHz, D2O): δ = 1.37 (s, 3H, C(CH3)2), 1.52 (s, 3H, 
C(CH3)2), 1.59-1.95 (m, 4H, CH2 arg), 2.63 (dd, 1H, Jgem = 14.5, J2,3 = 7.5 Hz, H-2), 2.72 (dd, 
1H, J2,3’ = 6.5 Hz, H-2’), 3.06 (dd, 1H, Jgem = 14.0, J6,7 = 8.0 Hz, H-7), 3.14 (dd, 1H, J6,7’ = 6.0 
Hz, H-7’), 3.23 (t, 2H, J = 7.0 Hz, CH2 arg), 4.12 (dd, 1H, H-6), 4.20-4.27 (m, 2H, H-3, H-α), 
4.74 (d, 1H, J4,5 = 6.0 Hz, H-5), 4.84 (dd, 1H, J3,4 = 4.0 Hz, H-4), 7.66-7.80 (m, 3H, H-Ar), 
7.91-7.95 (m, 2H, H-Ar). 13C NMR (62.9 MHz, D2O): δ = 23.6, 24.4, 25.0 (2 CH3, CH2 arg), 
28.8 (CH2 arg), 35.2 (C-2), 40.7 (CH2 arg), 41.8 (C-7), 54.6 (C-α), 76.6 (C-3), 80.7, 82.1, 82.4 
(C-4, C-5, C-6), 113.1 (C(CH3)2), 126.6 (2 C-Ar), 129.6 (2 C-Ar), 133.6 (C-Ar), 138.3 (C-Ar), 
156.7 (C=N), 171.7 (C=O), 178.5 (C=O). IR (pellets) : 3331, 3134, 2988, 2928, 2860, 1632, 
1575, 1446. ESI-HRMS: m/z calcd for C22H33N5O8SNa [M+Na]+ 550.1942; found 550.1957. 
 
3,6-Anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-[[(4-
bromomethyl)benzo]sulfonylamino]-D-altro-heptonic acid methyl ester 57 
To a solution of 52 (165 mg, 0.6 mmol, 1.0 eq.) in MeOH (10 mL) was added Pd/C (10%) 
(17 mg, 10% w/w). After stirring under H2 atmosphere (15 psi) until completion of the reaction, 
the mixture was filtered through a pad of celite and the filtrate was concentrated in vacuo. The 
crude amine was solubilized in CH2Cl2 (1.5 mL) under argon and pyridine (165 µL, 2.1 mmol, 
3.5 eq.) and (4-bromomethylbenzyl)sulfonyl chloride (178 mg, 0.66 mmol, 1.1 eq.) were added 
dropwise. After stirring at room temperature for 30 min, the mixture was diluted with CH2Cl2 
(10 mL) and washed with 1N HCl (2x5 mL). The organic layer was dried over MgSO4, filtered 
and the solvent was evaporated under reduced pressure. The compound was purified by flash 
chromatography (silica gel, cyH/EA) to provide 57 (174 mg, 61%). Colorless oil. Rf; 0.43 
(cH/EA: 1/1). [α]D= +18.5° (c = 0.2, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 1.29 (s, 3H, 
C(CH3)2), 1.45 (s, 3H, C(CH3)2), 2.64 (dd, 1H, Jgem = 15.5, J2,3 = 6.5 Hz, H-2), 2.74 (dd, 1H, 
J2’,3 = 6.5 Hz, H-2’), 2.90 (ddd, 1H, Jgem = 13.0, J6,7 = 8.5, J7,NH = 4.0 Hz, H-7), 3.08 (ddd, 1H, 
J6,7’ = 5.0, J7’,NH = 8.0 Hz, H-7’), 3.71 (s, 3H, OCH3), 4.06 (ddd, 1H, J5,6 = 1.0 Hz, H-6), 4.12 
(td, 1H, J3,4 = 4.0 Hz, H-3), 4.53 (dd, 1H, J4,5 = 6.0 Hz, H-5), 4.62 (s, 2H, CH2-Br), 4.70 (dd, 
1H, H-4), 4.81 (dd, 1H, NH), 7.52-7.58 (m, 2H, H-Ar), 7.84-7.89 (m, 2H, H-Ar). 13C NMR 
(62.9 MHz, CDCl3): δ = 24.9 (CH3), 26.1 (CH3), 33.9 (C-2), 42.6 (C-7), 44.8 (CH2-Br), 51.8 
(OCH3), 76.3 (C-3), 80.9, 81.7, 82.9 (C-4, C-5, C-6), 113.2 (C(CH3)2), 127.5 (2 C-Ar), 129.2 
(2 C-Ar), 139.5 (C-Ar), 142.4 (C-Ar), 171.3 (C=O). IR (film) : 3274, 2985, 2924, 2848, 1735, 
1440. ESI-HRMS: m/z calcd for C18H24BrNO7SNa [M+Na]+ 500.0349; found 500.0317. 
 
3,6-Anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-[[(4-
azidomethyl)benzo]sulfonylamino]-D-altro-heptonic acid methyl ester 58 
To a stirred solution of compound 57 (120 mg, 0.25 mmol, 1 eq.) in DMF (2 mL) was added 
sodium azide (97 mg, 1.5 mmol, 6 eq.) and the mixture was stirred for 15 hours at 60°C. The 
solvent was removed in vacuo and the residue was diluted with CH2Cl2 (10 mL), washed with 
H2O (5 mL) and brine (5 mL). The organic layer was dried over MgSO4, filtered and the solvent 
was evaporated under reduced pressure. The compound was purified by flash chromatography 
(silica gel, cyH/EA) to provide 58 (110 mg, quantitative yield). White solid. Rf; 0.21 (cH/EA: 
7/3). [α]D= +21.7° (c = 0.25, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 1.29 (s, 3H, C(CH3)2), 
1.45 (s, 3H, C(CH3)2), 2.65 (dd, 1H, Jgem = 16.5, J2,3 = 7.0 Hz, H-2), 2.73 (dd, 1H, J2’,3 = 6.5 
Hz, H-2’), 2.88 (ddd, 1H, Jgem = 13.0, J6,7 = 9.0, J7,NH = 3.5 Hz, H-7), 3.08 (ddd, 1H, J6,7’ = 5.0, 
J7’,NH = 8.0 Hz, H-7’), 3.71 (s, 3H, OCH3), 4.03-4.14 (m, 2H, H-6, H-3), 4.46 (s, 2H, CH2-N3), 
4.53 (dd, 1H, J4,5 = 6.0, J5,6 = 1.5 Hz, H-5), 4.69 (dd, 1H, J3,4 = 4.0 Hz, H-4), 4.84 (dd, 1H, NH), 
7.49 (d, 2H, J = 8.0 Hz, 2 H-Ar), 7.89 (d, 2H, 2 H-Ar). 13C NMR (62.9 MHz, CDCl3): δ = 25.1 
(CH3), 26.3 (CH3), 34.0 (C-2), 42.7 (C-7), 52.0 (OCH3), 54.1 (CH2-N3), 76.5 (C-3), 81.1, 81.9, 
83.1 (C-4, C-5, C-6), 113.4 (C(CH3)2), 127.8 (2 C-Ar), 128.8 (2 C-Ar), 139.5 (C-Ar), 140.9 (C-
Ar), 171.5 (C=O). IR (pellets) : 3274, 2990, 2933, 2104, 1735. ESI-HRMS: m/z calcd for 
C18H24N4O7SNa [M+Na]+ 463.1258; found 463.1207. 
 
3,6-Anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-[[(4-
azidomethyl)benzo]sulfonylamino]-D-altro-heptonic acid 59 
Prepared starting from 58 (100 mg, 0.23 mmol) following procedure described for 30. Yield: 
quantitative yield (98 mg). Colorless oil. Rf; 0.21 (cH/EA: 1/3). [α]D= +15.7° (c = 0.3, CHCl3). 
1H NMR (250 MHz, CDCl3): δ = 1.29 (s, 3H, C(CH3)2), 1.45 (s, 3H, C(CH3)2), 2.63-2.80 (m, 
2H, 2 H-2), 2.91 (m, 1H, H-7), 3.07 (m, 1H, H-7’), 4.04-4.17 (m, 2H, H-6, H-3), 4.45 (s, 2H, 
CH2-N3), 4.56 (d, 1H, J4,5 = 6.0 Hz, H-5), 4.70 (dd, 1H, J3,4 = 4.0 Hz, H-4), 5.39 (dd, 1H, NH), 
7.47 (d, 2H, J = 8.0 Hz, 2 H-Ar), 7.87 (d, 2H, 2 H-Ar). 13C NMR (62.9 MHz, CDCl3): δ = 24.9 
(CH3), 26.1 (CH3), 34.1 (C-2), 42.6 (C-7), 53.9 (CH2-Br), 76.4 (C-3), 81.0, 82.0, 82.9 (C-4, C-
5, C-6), 113.2 (C(CH3)2), 127.6 (2 C-Ar), 128.6 (2 C-Ar), 139.3 (C-Ar), 140.7 (C-Ar), 175.6 
(C=O). IR (pellets) : 3265, 2985, 2924, 2857, 2104, 1716. ESI-HRMS: m/z calcd for 
C17H22N4O7SNa [M+Na]+ 449.1101; found 449.1130. 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-[[(4-azidomethyl)benzo]sulfonylamino]--D-
ribofuranosyl]carbonymethyl)]]-L-arginine methyl ester 60  
To a solution of H-L-Arg-OMe.2HCl (55 mg, 0.21 mmol, 1.1 eq.) and 59 (80 mg, 0.19 mmol, 
1 eq.) in DMF (10 mL) were added HATU (108 mg, 0.29 mmol, 1.5 eq.) and DIEA (105 µL, 
0.61 mmol, 3.2 eq.) at 0°C under argon atmosphere. The reaction mixture was stirred overnight 
at room temperature and the solvent was evaporated. This crude product was solubilized in THF 
(3 mL) and water (1 mL) and LiOH (30 mg, 0.57 mmol, 3 eq.) was added. The mixture was 
stirred until completion of the reaction monitored by tlc. Amberlite® IR-120 was added until 
pH = 3-4 and the mixture was filtered off. The solvent were evaporated and the product was 
purified by column chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to provide 
60 (95 mg, 86%). White solid. Rf; 0.18 (H2O/MeOH: 1/1). [α]D= +31.0° (c = 0.1, MeOH). 1H 
NMR (250 MHz, MeOH-d4): δ = 1.29 (s, 3H, C(CH3)2), 1.43 (s, 3H, C(CH3)2), 1.57-1.70 (m, 
2H, CH2 arg), 1.75 (m, 1H, CH2 arg), 1.87 (m, 1H, CH2 arg), 2.53 (dd, 1H, Jgem = 15.5, J2,3 = 
5.5 Hz, H-2), 2.63 (dd, 1H, J2’,3 = 8.0 Hz, H-2’), 2.87-3.04 (m, 2H, 2 H-7), 3.17-3.23 (m, 2H, 
CH2 arg), 4.02 (dd, 1H, J6,7 = 8.0, J6,7’ = 6.0 Hz, H-6), 4.17 (m, 1H, H-3), 4.28 (dd, 1H, J = 7.5, 
J = 5.5 Hz, H-α), 4.50 (s, 2H, CH2-N3), 4.62-4.69 (m, 2H, H-4, H-5), 7.55 (d app., 2H, J = 8.5 
Hz, 2 H-Ar), 7.90 (d app., 2H, 2 H-Ar). 13C NMR (62.9 MHz, MeOH-d4): δ = 23.9 (CH3), 24.8 
(CH2 arg), 25.4 (CH3), 30.0 (CH2 arg), 36.1 (C-2), 41.0 (CH2 arg), 42.6 (C-7), 53.6, 54.2 (CH2-
N3, C-α), 77.0 (C-3), 81.6, 83.2, 83.4 (C-4, C-5, C-6), 112.5 (C(CH3)2), 127.3 (2 C-Ar), 128.7 
(2 C-Ar), 140.5 (C-Ar), 141.1 (C-Ar), 157.4 (C=N), 171.3 (C=O), 177.2 (C=O). IR (pellets) : 
3364, 3184, 2981, 2938, 2104, 1648, 1598. ESI-HRMS: m/z calcd for C23H34N8O8SNa 
[M+Na]+ 605.2113; found 605.2118. 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-[((4-aminomethyl)benzo)sulfonylamino]--D-
ribofuranosyl]carbonymethyl)]]-L-arginine methyl ester 61 
To a solution of 60 (80 mg, 0.14 mmol) in MeOH (5 mL), was added Pd/C (10%) (8 mg, 10% 
w/w). After stirring under H2 atmosphere (15 psi) until completion of the reaction, the mixture 
was filtered through a pad of celite and the filtrate was concentrated in vacuo. The crude was 
purified by column chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to provide 
61 (65 mg, 87%). White solid. Rf; 0.38 (H2O/CH3CN/TFA: 7/3/0.1%). HPLC (70/30): tR = 
3.681 min. [α]D= +6.9° (c = 0.1, H2O). 1H NMR (400 MHz, DMSO-d6): δ = 1.25 (s, 3H, 
C(CH3)2), 1.38 (s, 3H, C(CH3)2), 1.45-1.61 (m, 3H, CH2 arg), 1.73 (m, 1H, CH2 arg), 2.47-2.53 
(m, 2H, 2 H-2), 2.68 (m, 1H, H-7), 2.82 (m, 1H, H-7’), 3.07-3.11 (m, 2H, CH2 arg), 3.87 (t, 
1H, J6,7 = 7.0 Hz, H-6), 4.10-4.17 (m, 3H, H-3, CH2-NH2), 4.20 (td, 1H, J = 8.0, J = 5.0 Hz, H-
α), 4.63 (d, 1H, J4,5 = 6.0 Hz, H-5), 4.66 (dd, 1H, J3,4 = 3.5 Hz, H-4), 6.99 & 7.20 (br s, 4H, 4 
NH), 7.59 (t, 1H, J = 5.5 Hz, NH), 7.67 (d, 2H, J = 8.0 Hz, 2 H-Ar), 7.84-7.90 (m, 3H, 2 H-Ar, 
NH), 8.18 (d, 1H, JNH, = 8.0 Hz, NH), 8.28 (br s, 3H, CH2-NH3+). 13C NMR (100 MHz, DMSO-
d6): δ = 25.2 (CH3), 25.5 (CH2 arg), 26.6 (CH3), 28.8 (CH2 arg), 35.3 (C-2), 40.7 (CH2 arg), 
42.2 (C-7), 42.9 (CH2-NH2), 51.8 (C-α), 77.0 (C-3), 81.3 (C-4), 82.1 (C-6), 83.0 (C-5), 111.8 
(C(CH3)2), 127.3 (2 C-Ar), 130.1 (2 C-Ar), 139.0 (C-Ar), 140.7 (C-Ar), 157.1 (C=N), 158.5 
(TFA), 170.0 (C=O amide), 173.9 (C=O acid). IR (pellets) : 3393, 3189, 2990, 2928, 1676, 
1546. ESI-HRMS: m/z calcd for C23H37N6O8S [M+Na]+ 557.2388; found 557.2399. 
 
3,6-Anhydro-2,7-dideoxy-4,5-O-(1-methylethylidene)-7-[((4-
methoxycarbonylmethyl)benzo)sulfonylamino]-D-altro-heptonic acid 62 
To a solution of 52 (192 mg, 0.71 mmol) in THF (5 mL) and water (2 mL) was added LiOH 
(51 mg, 2.13 mmol, 3 eq.) and the mixture was stirred until completion of the reaction 
monitored by tlc. THF was removed under reduced pressure, CH2Cl2 (20 mL) was added and 
the pH was adjusted to 2-3 with aqueous 1N HCl. The organic layer was washed with brine and 
dried over MgSO4, filtered and concentrated under reduced pressure. This carboxylic acid was 
solubilized in MeOH (10 mL) and Pd/C (10%) (20 mg, 10% w/w) was added. After stirring 
under H2 atmosphere (15 psi) until completion of the reaction, the mixture was filtered through 
a pad of celite and the filtrate was concentrated in vacuo. The crude amine was solubilized in 
pyridine (1 mL) and this solution was added dropwise under argon atmosphere to a stirred 
solution of methyl 2-[4-(chlorosulfonyl)phenyl]acetate (212 mg, 0.85 mmol, 1.2 eq.) in 
pyridine (2 mL). After stirring at room temperature until completion of the reaction, the solvent 
was removed under reduced pressure. The residue was diluted with CH2Cl2 (15 mL) and the 
pH was adjusted to 3-4 with 1N HCl. The layers were separated and the organic layer was 
washed with H2O (2x5 mL). The organic layer was dried over MgSO4, filtered and the solvent 
was evaporated under reduced pressure. The compound was purified by flash chromatography 
(silica gel, cyH/EA) to provide 62 (95 mg, 30%). Colorless oil. Rf; 0.48 (EA). [α]D= +13.1° (c 
= 0.1, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 1.30 (s, 3H, C(CH3)2), 1.45 (s, 3H, C(CH3)2), 
2.67 (dd, 1H, Jgem = 17.0, J2,3 = 7.0 Hz, H-2), 2.77 (dd, 1H, J2’,3 = 6.0 Hz, H-2’), 2.91 (m, 1H, 
H-7), 3.09 (m, 1H, H-7’), 3.70 (s, 2H, CH2-CO2CH3), 3.71 (s, 3H, CO2CH3), 4.01-4.18 (m, 2H, 
H-6, H-3), 4.57 (dd, 1H, J4,5 = 6.0, J5,6 = 1.0 Hz, H-5), 4.71 (dd, 1H, J3,4 = 4.0 Hz, H-4), 5.25 
(dd, 1H, NH), 7.43 (d, 2H, J = 8.0 Hz, H-Ar), 7.81 (d, 2H, H-Ar) , 9.53 (br s, 1H, COOH). 13C 
NMR (62.9 MHz, CDCl3): δ = 24.9 (CH3), 26.1 (CH3), 34.0 (C-2), 40.8 (CH2-CO2CH3), 42.7 
(C-7), 52.3 (CO2CH3), 76.4 (C-3), 80.9, 82.0, 83.0 (C-4, C-5, C-6), 113.2 (C(CH3)2), 127.3 (2 
C-Ar), 130.2 (2 C-Ar), 138.4 (C-Ar), 139.1 (C-Ar), 171.1 (C=O), 175.3 (C=O). IR (film) : 
3270, 2985, 2938, 1730, 1714. ESI-HRMS: m/z calcd for C19H25NO9SNa [M+Na]+ 466.1142; 
found 466.1190. 
 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-[((4-carboxymethyl)benzo)sulfonylamino]--D-
ribofuranosyl]carbonylmethyl)]]-L-arginine methyl ester 63 
Prepared starting from 62 (71mg, 0.16 mmol) following procedure described for 60. Yield: 
54% (50 mg). Colorless oil. Rf; 0.75 (H2O/CH3CN/TFA: 7/3/0.1%). HPLC (70/30): tR = 4.383 
min. [α]D= +5.0° (c = 0.2, H2O). 1H NMR (250 MHz, DMSO-d6): δ = 1.22 (s, 3H, C(CH3)2), 
1.36 (s, 3H, C(CH3)2), 1.43-1.62 (m, 3H, CH2 arg), 1.70 (m, 1H, CH2 arg), 2.64-2.93 (m, 4H, 
2 H-2, 2 H-7), 3.03-3.12 (m, 2H, CH2 arg), 3.68 (s, 2H, CH2-COOH), 3.84 (t, 1H, J6,7 = 7.0, 
J6,7’ = 7.0 Hz, H-6), 4.08-4.22 (m, 2H, H-3, H-α), 4.56-4.64 (m, 2H, H-4, H-5), 7.08 (br s, 2H, 
NH), 7.46 (d, 2H, J = 8.0 Hz, 2 H-Ar), 7.73 (d, 2H, J = 8.0 Hz, 2 H-Ar), 8.12 (m, 1H, NH), 
12.52 (br s, 2H, 2 COOH). 13C NMR (62.9 MHz, DMSO-d6): δ = 25.5 (CH3), 25.7 (CH2 arg), 
26.8 (CH3), 29.1 (CH2 arg), 35.6 (C-2), 40.8 (CH2 arg), 41.2 (C-7), 43.2 (CH2-COOH), 52.0 
(C-α), 77.2 (C-3), 81.5, 82.3, 83.3 (C-4, C-5, C-6), 112.0 (C(CH3)2), 127.1 (2 C-Ar), 131.0 (2 
C-Ar), 139.4 (C-Ar), 140.6 (C-Ar), 157.4 (C=N), 159.1 (TFA), 170.2, 172.8, 174.1 (3 C=O). 
IR (pellets) : 3374, 3213, 2985, 2938, 1718, 1664, 1648, 1544. ESI-HRMS: m/z calcd for 
C24H35N5O10SNa [M+Na]+ 608.2026; found 608.1997. 
 
3,6-Anhydro-2,7-deoxy-4,5-O-(1-methylethylidene)-7-[((4-iodo)benzo)sulfonylamino]-
D-altro-heptonic acid 64 
Prepared starting from 52 (100 mg, 0.37 mmol) and (4-iodo-benzo)sulfonyl chloride (135 
mg, 0.44 mmol, 1.2 eq.) following procedure described for 47. Yield: 82% (155 mg). Colorless 
oil. Rf; 0.25 (cH/EA: 7/3). [α]D= +18.5° (c = 0.8, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 
1.32 (s, 3H, C(CH3)2), 1.47 (s, 3H, C(CH3)2), 2.67 (dd, 1H, Jgem = 16.0, J2,3 = 7.0 Hz, H-2), 2.76 
(dd, 1H, J2’,3 = 7.0 Hz, H-2’), 2.91 (ddd, 1H, Jgem = 13.0, J6,7 = 9.0, J7,NH = 4.0 Hz, H-7), 3.09 
(ddd, 1H, J6,7’ = 5.0, J7’,NH = 8.0 Hz, H-7’), 3.73 (s, 3H, OCH3), 4.08 (ddd, 1H, J5,6 = 1.0 Hz, 
H-6), 4.15 (td, 1H, J3,4 = 4.0 Hz, H-3), 4.55 (dd, 1H, J4,5 = 6.0 Hz, H-5), 4.72 (dd, 1H, H-4), 
5.01 (dd, 1H, NH), 7.58-7.63 (m, 3H, H-Ar), 7.88-7.93 (m, 2H, H-Ar). 13C NMR (62.9 MHz, 
CDCl3): δ = 25.1 (CH3), 26.3 (CH3), 34.0 (C-2), 42.7 (C-7), 52.0 (OCH3), 76.5 (C-3), 81.1, 
81.9, 83.1 (C-4, C-5, C-6), 100.3 (C-Ar-I), 113.3 (C(CH3)2), 128.6 (2 C-Ar), 138.6 (2 C-Ar), 
139.4 (C-Ar), 171.5 (C=O). IR (film) : 3279, 2985, 2938, 1735, 1572. ESI-HRMS: m/z calcd 
for C17H22NO7SINa [M+Na]+ 534.0054; found 534.0056. 
 
3,6-Anhydro-2,7-deoxy-4,5-O-(1-methylethylidene)-7-[[4-(1-
trimethylsilylacetylenyl)benzo]sulfonylamino]-D-altro-heptonic acid 65 
To a stirred solution of 64 (137 mg, 0.25 mmol, 1 eq.), PdCl2(PPh3)2 (18 mg, 0.025 mmol, 
0.1 eq.) and CuI (3 mg, 0.015 mmol, 0.06 eq.) in Et3N (1 mL) was added ethynyltrimethylsilane 
(42 µL, 0.3 mmol, 1.2 eq.). The mixture was stirred at 80 °C until completion of the reaction. 
The solvent was removed under reduced pressure and the crude was purified by flash 
chromatography (silica gel, cyH/EA) to provide 65 (96 mg, 80%).Colorless oil. Rf; 0.32 
(cH/EA: 7/3). [α]D= +20.2° (c = 0.2, CHCl3). 1H NMR (250 MHz, CDCl3): δ = 0.29 (s, 9H, 
C(CH3)3), 1.32 (s, 3H, C(CH3)2), 1.47 (s, 3H, C(CH3)2), 2.67 (dd, 1H, Jgem = 17.0, J2,3 = 7.0 Hz, 
H-2), 2.76 (dd, 1H, J2’,3 = 7.0 Hz, H-2’), 2.89 (ddd, 1H, Jgem = 12.0, J6,7 = 9.0, J7,NH = 3.5 Hz, 
H-7), 3.08 (ddd, 1H, J6,7’ = 5.0, J7’,NH = 8.0 Hz, H-7’), 3.74 (s, 3H, OCH3), 4.07 (ddd, 1H, J5,6 
= 1.0 Hz, H-6), 4.13 (td, 1H, J3,4 = 4.0 Hz, H-3), 4.54 (dd, 1H, J4,5 = 6.0 Hz, H-5), 4.72 (dd, 1H, 
H-4), 4.87 (dd, 1H, NH), 7.61 (d app, 2H, J = 8.5 Hz, H-Ar), 7.82 (d app, 2H, H-Ar). 13C NMR 
(62.9 MHz, CDCl3): δ = 0.0 (C(CH3)3), 25.2 (CH3), 26.4 (CH3), 34.1 (C-2), 42.8 (C-7), 52.1 
(OCH3), 76.6 (C-3), 81.2, 82.0, 83.2 (C-4, C-5, C-6), 98.9, 103.3 (C≡C), 113.4 (C(CH3)2), 127.1 
(C-Ar), 127.2 (C-Ar), 128.3 (C-Ar), 132.7 (C-Ar), 132.8 (C-Ar), 139.1 (C-Ar), 171.5 (C=O). 
IR (film) : 3279, 2995, 2957, 2900, 2156, 1735, 1588. ESI-HRMS: m/z calcd for 
C22H31NO7SSiNa [M+Na]+ 504.1483; found 504.1479. 
 
3,6-Anhydro-2,7-deoxy-4,5-O-(1-methylethylidene)-7-[[(4-
acetylenyl)benzo]sulfonylamino]-D-altro-heptonic acid 66 
Prepared starting from 65 (80 mg, 0.17 mmol) following procedure described for 21. Yield: 
82% (55 mg). White foam. Rf; 0.48 (EA). [α]D= +27.5° (c = 0.1, CHCl3). 1H NMR (250 MHz, 
CDCl3): δ = 1.30 (s, 3H, C(CH3)2), 1.46 (s, 3H, C(CH3)2), 2.70 (dd, 1H, Jgem = 17.0, J2,3 = 7.0 
Hz, H-2), 2.78 (dd, 1H, J2’,3 = 6.0 Hz, H-2’), 2.90 (ddd, 1H, Jgem = 13.0, J6,7 = 8.5, J7,NH = 4.0 
Hz, H-7), 3.08 (ddd, 1H, J6,7’ = 5.0, J7’,NH = 8.0 Hz, H-7’), 3.26 (s, 1H, H-C≡C), 4.09 (m, 1H, 
H-6), 4.15 (m, 1H, H-3), 4.55 (dd, 1H, J4,5 = 6.0, J5,6 = 1.0 Hz, H-5), 4.71 (dd, 1H, J3,4 = 4.0 Hz, 
H-4), 5.20 (dd, 1H, NH), 7.59-7.63 (m, 2H, H-Ar), 7.79-7.83 (m, 2H, H-Ar). 13C NMR (62.9 
MHz, CDCl3): δ = 24.9 (CH3), 26.1 (CH3), 34.0 (C-2), 42.6 (C-7), 76.3 (C-3), 80.8, 80.9, 81.9, 
83.0 (C-4, C-5, C-6, C≡C), 113.3 (C(CH3)2), 127.0 (3 C-Ar), 132.8 (2 C-Ar), 139.5 (C-Ar), 
175.4 (C=O). IR (film) : 3270, 2990, 2928, 1711. ESI-HRMS: m/z calcd for C18H21NO7SNa 
[M+Na]+ 418.0931; found 418.0941. 
 
N-[2-C-[2,3-O-(1-methylethylidene)-5-[((4-acetylenyl)benzo)sulfonylamino]--D-
ribofuranosyl]carbonylmethyl)]]-L-arginine methyl ester 67 
Prepared starting from 66 (45 mg, 0.11 mmol) following procedure described for 60. Yield: 
67% (42 mg). White solid. Rf; 0.12 (H2O/MeOH: 1/1). [α]D= +10.6° (c = 0.3, H2O). 1H NMR 
(400 MHz, D2O): δ = 1.23 (s, 3H, C(CH3)2), 1.39 (s, 3H, C(CH3)2), 1.46-1.54 (m, 2H, CH2 arg), 
1.62 (m, 1H, CH2 arg), 1.77 (m, 1H, CH2 arg), 2.49 (dd, 1H, Jgem = 15.0, J2,3 = 7.0 Hz, H-2), 
2.58 (dd, 1H, J2’,3 = 7.0 Hz, H-2’), 2.86 (dd, 1H, Jgem = 13.5, J6,7 = 7.0 Hz, H-7), 2.91 (dd, 1H, 
J6,7’ = 7.0 Hz, H-7’), 3.07 (t, 2H, J = 7.0 Hz, CH2 arg), 3.95 (t, 1H, H-6), 4.07 (td, 1H, J3,4 = 4.0 
Hz, H-3), 4.11 (dd, 1H, JH-α,A1 = 8.0, JH-α,A1’ = 4.5 Hz, H-α), 4.57 (d, 1H, J4,5 = 6.0 Hz, H-5), 
4.67 (dd, 1H, H-4), 7.62 (d app., 2H, J = 8.0 Hz, H-Ar), 7.72 (d app., 2H, H-Ar). 13C NMR (100 
MHz, D2O): δ = 23.5 (CH3), 24.4 (CH2 arg), 24.9 (CH3), 28.8 (CH2 arg), 35.3 (C-2), 40.6 (CH2 
arg), 42.7 (C-7), 54.5 (C-α), 76.7 (C-3), 80.6 (C-4), 81.9 (C≡C), 82.6, 82.7 (C-5, C-6), 112.9 
(C(CH3)2), 125.8 (C-Ar), 126.6 (2 C-Ar), 132.8 (2 C-Ar), 140.4 (C-Ar), 156.6 (C=N), 171.7 
(C=O), 178.5 (C=O). IR (pellets) : 3350, 3289, 3184, 2990, 2938, 2872, 1648, 1593. ESI-
HRMS: m/z calcd for C24H33N5O8SNa [M+Na]+ 574.1942; found 574.1960. 
 
Compound 69 
To a solution of alcyne 67 (33 mg, 0.04 mmol, 1 eq.) and azido sugar 68 (15 mg, 0.04 mmol, 
1 eq.) in a water/tBuOH mixture (0.5 mL/0.5 mL) were added sodium ascorbate (2.4 mg, 0.008 
mmol, 0.2 eq.) and Cu(OAc)2 (1.2 mg, 0.004 mmol, 0.1 eq.). The solution turned progressively 
pale green and the mixture was stirred at room temperature until completion of the reaction (the 
blue color reappeared). Chelex® resin (100 mg) was then added to the solution and the 
suspension was stirred until the solution became colorless. The resin was filtered off and the 
solvent were removed under reduced pressure. The crude was purified by column 
chromatography (C-18 silica gel, H2O/MeOH) and lyophilized to provide 69 (37 mg, 
77%).White solid. Rf; 0.29 (H2O/MeOH: 1/1). HPLC (70/30): tR = 4.180 min. [α]D= -6.7° (c = 
0.1, H2O). 1H NMR (400 MHz, D2O): δ = 1.31 (s, 3H, C(CH3)2), 1.46 (s, 3H, C(CH3)2), 1.53-
1.61 (m, 2H, CH2 arg), 1.69 (m, 1H, CH2 arg), 1.84 (m, 1H, CH2 arg), 2.59 (dd, 1H, Jgem = 
15.0, J2,3 = 8.0 Hz, H-2), 2.66 (dd, 1H, J2’,3 = 6.5 Hz, H-2’), 3.04 (dd, 1H, Jgem = 13.5, J6,7 = 8.5 
Hz, H-7), 3.08-3.17 (m, 3H, CH2 arg, H-7’), 3.26 (m, 1H, H-11), 3.42- 3.59 (m, 3H, H-12, H-
13, H-14), 4.08 (dd, 1H, J6,7 = 8.5, J6,7’ = 6.5 Hz, H-6), 4.14-4.25 (m, 3H, H-3, H-α, H-9), 4.33 
(m, 1H, H-9’), 4.47 (d, 1H, J10,11 = 8.0 Hz, H-10), 4.61 (dd, 2H, JH,F = 47.5, J14,15 = 2.0 Hz, H-
15), 4.68 (d, 1H, J4,5 = 6.0 Hz, H-5), 4.73-4.77 (m, 3H, H-4, 2 H-8), 7.94 (d app., 2H, J = 8.0 
Hz, H-Ar), 7.99 (d app., 2H, H-Ar), 8.49 (H-triazole). 13C NMR (62.9 MHz, D2O): δ = 23.9 
(CH3), 24.6 (CH2 arg), 25.3 (CH3), 29.1 (CH2 arg), 35.6 (C-2), 40.9 (CH2 arg), 42.2 (C-7), 50.9 
(C-8), 54.8 (C-α), 68.5 (d, JC,F = 7.0 Hz, C-13), 68.7 (C-9), 73.1 (C-11), 74.5 (d, JC,F = 18.0 Hz, 
C-14), 75.7 (C-12), 77.0 (C-3), 81.0, 82.4, 82.7 (C-4, C-5, C-6), 82.1 (d, JC,F = 168.0 Hz, C-
15), 102.9 (C-10), 113.3 (C(CH3)2), 124.4 (C-Ar), 126.7 (2 C-Ar), 127.8 (2 C-Ar), 134.7 (C-
triazole), 138.5 (C-Ar), 146.0 (C-triazole), 156.9 (C=N), 172.0 (C=O), 178.7 (C=O) 19F NMR 
(235.2 MHz, D2O): δ = -235.16 (td, JH,F = 47.0, JH,F = 27.0 Hz). IR (ATR) : 3346, 3236, 1655, 
1505, 1150. ESI-HRMS: m/z calcd for C32H47FN8O13SNa [M+Na]+ 825.2860; found 825.2845. 
 
   
Molecular modeling 
 
The structures of the investigated compounds were prepared according to the CORINA1 (for 
the 3D conformers) and MOPAC2 softwares (for the atomic charges). The chemicals were 
firstly docked using the GOLD software.3 The protein target was the 3D structure of the b1 
domain of NRP-1 as solved by X-ray when bound with the small molecule EG002294 (pdb code 
3I97). Previous to the docking process, all hydrogen atoms were added to the PDB protein chain 
A considered at pH 7. In the GOLD settings, the protein binding site was defined according to 
the position of the EG00229 ligand within the complex providing a list of interacting amino 
acid residues with an extra range of 10 Å from each ligand atom. For each docking run, 50 
different ligand starting poses were used and optimized according to the Goldscore docking 
function. Molecular dynamics simulations were performed using the NAMD software.5 All 
protein/ligand complexes resulting from the best GOLD docking poses were checked for their 
stability using short 10 ns molecular dynamics. For this purpose, each protein 3D model was 
first solvated with an 80 Å3 box of TIP3P explicit water molecules. Next, ions were added for 
ensuring the electrostatic neutrality of the whole protein+solvent systems. The initial states for 
dynamics were generated from the GOLD models after 64,000 steps of conjugate gradients 
minimization followed by an equilibration stage of 1 ns. The simulations were carried out in 
the isobaric-isothermal ensemble, maintaining the pressure and the temperature at 1 atm and 
300 K respectively by using Langevin dynamics and the Langevin piston approaches. The 
equations of motion were integrated with a 1fs time step. Long-range interactions were treated 
using the particle-mesh Ewald approach with an 11 Å cut-off (switching distance 9 Å) for the 
real space calculation. The calculation of forces and motion equations was repeated to generate 
the trajectories corresponding to the requested simulation times. A conformation of the whole 
molecular system was recorded every 10ps, generating for each 10 ns runs a conformational 
sample of 1,000 frames which were analyzed using the VMD graphic software.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Protein production, purification and biocrystallogrphy  
Recombinant pET-15b (Novagen) vector producing the human NRP-1-b1 domain protein were 
previously constructed using the NdeI and BamHI restriction sites. The recombinant N-terminal 
His-fusion protein containing a bovine thrombin protease site were produced in E. coli cells 
strain BL21 (DE3) Rosetta 2 (Novagen). Growth was performed in 2 L of Luria Broth medium 
under agitation at 37°C and induced to an OD of 0.8 by addition of 0.2 mM Isopropyl--D-
Thiogalactopyranoside (Euromedex) and shifted at 20°C under the night. Cell harvesting was 
carried out by centrifugation (4 000 g, 30 min, 4°C). For purification, the frozen pellet was 
resuspended in 30 ml of lysis buffer (TrisHCl 50 mM pH 8, NaCl 300 mM, Imidazole 20 mM, 
β-Mercaptoethanol 5 mM) for sonication. After a centrifugation of 30 min at 4°C, 37 000 g, the 
supernatant was injected on a HiTrap TALON crude 5 ml column (GE Healthcare) and eluted 
by an imidazole gradient. The eluate was injected on a Hiload 16/60 Superdex 75 prep grade 
column (GE Healthcare) in GF buffer (TrisHCl 20 mM pH 8, NaCl 50 mM, Tris 2-
CarboxylEthyl Phosphine 0.5 mM) and the adequate fractions were pooled and concentrated 
using an Amicon Ultra-15 (Merck Millipore, 10 kDa cut-off) to a concentration of about 40 
mg/ml. 
A crystallization screening ofNRP-1-b1 fragment including a 6-His tag at the N-terminus was 
carried out in presence of compounds 27, 40, 50 and 56. The protein was diluted to a 
concentration of 7mg/ml and 10mM ligand prior to crystallization with the hanging drop 
method at 20°C. Crystals were obtained by mixing 2µl of protein solution with 1.5 µl of 
precipitating solution from the well: 25% PEG 550 mme, 5% PEG 20 000, 60mM MgCl2, Na-
Bicine 100mM pH 8.5. Diffraction data were collected at BM30A beamline at ESRF (Grenoble, 
France) at a wavelength of 0.97967 Å using a ADSC Quantum 315r detector. The diffraction 
intensities were indexed, integrated, scaled and merged with XDS and XSCALE.7 The 
structure, including modelled protein atoms, was refined with PHENIX8 starting from the 
coordinates of the 1KEX PDB entry.9 The crystal structure has been deposited at the Protein 
Data Bank10 with code 5C7G. 
 
 
 
 
 
 
 
 
   
Biological Assay 
 
General procedure for receptor binding assays: NRP-1 and KDR were obtained from R&D 
Systems (Lille, France), as recombinant chimeric proteins. The binding of new derivatives to 
recombinant NRP-1 protein was determined using a competition assay initially described by 
Tirand et al. (see details in SI).11The surface of microplates (Dutscher) was coated with either 
NRP-1 (2 mg/mL) or KDR (2 mg/mL) in PBS, overnight at room temperature. The plates were 
blocked with PBS containing 0.5% bovine serum albumin (blocking buffer) during 1 h at 37°C, 
to prevent non-specific interactions. Binding of compounds to NRP-1 was assessed using 5 
ng/mL of biotinylated VEGF-A165 (R&D Systems) in blocking buffer containing 2 mg/mL 
heparin. Biotinylated VEGF-A165 was added to the coated wells, in competition, or not, with an 
excess of compounds or non labelled VEGF-A165 (R&D Systems), as a positive control. After 
a 2-h incubation at room temperature, the plates were washed and the amount of bound 
biotinylated VEGF-A165 stained with streptavidin horseradish peroxidase conjugate (R&D 
Systems). After 20 min at room temperature, reaction was stopped by the addition of Stop 
Solution (R&D Systems). Optical densities were measured at 450 nm. Results were expressed 
as relative absorbance to wells containing only blocking buffer. Three wells per condition were 
used. 
 
General procedure for HUVECs culture and treatments: Briefly, HUVECs were collected 
from umbilical cords as previously described by Jaffe et al (see details in SI).12 HUVECs were 
cultured and used until passage 3 in EndoGro medium (Merck-Millipore, France) supplemented 
with 10% calf serum, 2 mM l-glutamine (GibcoBRL), 100 U/ml penicillin (GibcoBRL, France), 
100 μg/ml streptomycin (GibcoBRL, France), 2.5 μg/ml amphothericin B (GibcoBRL, France). 
For all experiments, tuftsin (Bachem, Switzerland), (TKPR) the natural ligand of NRP-1, was 
used as reference control. For angiogenesis and migration assays, bevacizumab (Roche, France) 
was used as positive control at the concentration of 200 µg/mL. 
 
General procedure for NRP1 signaling pathways: For analysis of pAKT and pERK1/2 
expression, western blotting was realized as previously described (see details in SI).13 Briefly, 
protein aliquots (40 μg) were denatured in the Laemmli buffer, containing ß-mercaptoethanol 
and before to be resolved in SDS-polyacrylamide gel electrophoresis. The separated proteins 
were transferred onto PVDF membranes (Amersham Biosciences, Orsay, France). After 
blocking the PVDF membrane with Tris base-buffered saline prepared with 0.1% (v/v) Tween-
20 containing 5% (w/v) bovine serum albumin, the following primary antibodies against human 
AKT (#9272, Cell Signaling, 1:1000 dilution), phosphorylated AKT at ser473 (pAKT) (#9271, 
Cell Signaling, 1:1000 dilution), ERK1/2 (#9102, Cell Signaling, 1:1000 dilution), 
phosphorylated ERK1/2 at Thr202/Tyr204 (pERK1/2) (#9106, Cell Signaling, 1:1000 dilution) 
were incubated overnight at 4˚C. Subsequently, immuno-reactive proteins were visualized 
using the enhanced chemiluminescence procedure (Pierce, USA). Quantification of relative 
band densities was performed using densitometer (LAS Imager FujiFilm) and AKT and ERK 
were used as control.  
 
General procedure for cell viability assays: Roche’s WST-1 cell proliferation reagent is a 
simple, colorimetric assay designed to measure the relative proliferation rates of cells in culture 
(see details in SI). The assay principle is based on the conversion of the tetrazolium salt WST-
1 into a colored dye by mitochondrial dehydrogenase enzymes. The soluble salt is released into 
the media. Within a given time period, the reaction produces a color change which is directly 
proportional to the amount of mitochondrial dehydrogenase in a given culture. As a result, the 
assay actually measures the net metabolic activity of cells. To perform the assay, the ready-to-
use WST-1 reagent is simply added directly into the media of cells cultured in 96 well plates. 
The cultures are then given 30 minutes to reduce the reagent into the dye form. At the set time, 
0.5 μmol/L WST-1 were added into each well. WST-1 reagent was used according to 
manufacturer instructions. The absorbance of the resulting solution was measured at 450 nm 
using wells without cells as blank (Multiskan Ascent microplate photometer, Thermo Scientific, 
France).  
 
Angiogenesis assay: HUVECs were plated (90,000 cells/cm2) onto 24-well plate ibidi 
precoated with Matrigel™ Basement Membrane Matrix (BD Biosciences, France, see details 
in SI). After 1 h, compounds were added on HUVECs which were cultured during overnight 
before being fixed with 4% paraformaldehyde. Photomicrographs of whole culture surface were 
taken (Nikon AZ100, Digital Sight DS-Qi1Mc camera, Nikon, France). The number of 
junctions and segments as well as the network length was quantified with Angiogenesis 
Analyzer for ImageJ.14  
 
Invasion assay: The invasion ability of cells was analyzed using culture permeable support 
(8 µm pore size, Falcon) coated with 100 µL Matrigel™ (BD Biosciences). HUVECs were 
pretreated with the different compounds during 24h and plated at a density of 4.105 cells in 500 
µL serum free medium, inoculated in the upper chamber; while 700 µL of medium containing 
10% FBS was used as the chemoattractant was placed in the lower chamber. After incubating 
the cells for 24h à 37°C, the non-invading cells remaining on the upper side of the filter were 
gently removed with cotton swab. The invading cells on the lower chamber were fixed with 4% 
paraformaldehyde (PFA) for 10 min and stained with crystal violet for 30 min. Crystal violet 
was solubilized with 4% acetic acid and absorbance at 540 nm was measured. All results were 
given as mean ± standard error of the mean (SEM) was used. Unpaired t test was employed to 
determine the statistical significance with a limit set to p<0.05 using GraphPad Prism 5 
(GraphPad Software, US) versus non treated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1. Crystallographic summary 
Diffraction data   
Space group P 41 21 2 
Unit cell a, c (Å) 62.280    85.960* 
Wavelength (Å) 0.97967  
Resolution (Å) 1.45  
Unique reflections 30 507 
Average redundacy 12.2 
Rmeas(%) 5.1  
Completeness (%) 99.5  
Refinement  
R-factor (%) 14.1  
R-free (%)  17.2 
# Protein atoms  2431 
# water atoms   294 
Wilson B-factor (Å2)   26.4  
RMSD from target     
Bond lengths (Å)  0008 
Bond angles (deg)    1.26 
* The c unit cell axis is significantly shorter (85.96 vs. 88.375 Å) compared to the published 
free protein fragment structure9 
   
 
 
 
 
 
Figure S1.  
Ribbon view of the NRP-
1 b1 dimer in the 
tetragonal crystal, where 
bicine interacts with 
residues of a symmetry 
related protein molecule. 
Symmetry code: -X+½, Y-
½, -Z+¼. Some residues 
interacting with bicine 
and the Na+ ion are 
shown.  
The bicine molecule 
forms short H...H van der 
Waals contacts (d = 2.23 
Å) with the symmetry 
related Gln218 side chain. 
The bicine carboxylate 
group is also making a salt 
bridge with the symmetry 
related Arg402.  
 
The binding of bulky ligands in the cleft is not compatible with the formation of the present 
tetragonal crystals. The binding cleft is located too close to a symmetry related protein. The b1 
domain of human NRP-1 bound with bulky molecule EG00229 crystallized actually in a 
different space group with two molecules in the asymmetric unit.4  
The bicine molecule was used as pH buffer at a concentration of 100mM in the conditions 
yielding crystals. The initial structure of the free protein9 which was crystallized at pH 6 using 
MES buffer has only water molecules in the binding site.  
   
a)    
 
 
 
 
 
 
b)  
Figure S2. a) Stereo view (wall eyes) of the electron density showing the bicine molecule in 
the binding site. The map shown is σA-weighted 2mFo-DFc map contoured at 1.2σ.  
b) Stereoview (wall eyes) of the bicine molecule within the binding site surface. The protein-
only surface is shown at an electron density level of 0.01 e/Å3 and colored according to atom 
types (oxygen: red, nitrogen: blue, carbon: grey, hydrogen: white). The water molecules are 
shown as red spheres and the Na+ ion as a purple sphere. The image was created with 
MoProViewer.15 The Na+ ion is also stabilized in this position distant from Asp320 due to a 
second electrostatic interaction with the symmetry related carboxylate of Asp289 (d = 4.1 Å) 
 
 
 
 
Figure S3: Effect of the different compounds (c = 50 µM) on HUVECs ability to migrate 
through a basement membrane matrix (invasion assay). The results are presented as mean ± 
standard error of the mean of the percentage of inviding cells with non treated cells used as 
reference, n=6 p<0.05 was considered to be statistically significant. tuf, tuftsin; beva, 
bevacizumab. 
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